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Abstract 
Effective agitation management through sedative delivery is a fundamental ac-
tivity in the intensive care unit (ICU), and is the basis for providing comfort and 
relief to the critically ill. The primary goal of sedation management in the ICU 
is to manage patient agitation, the sometimes violent activity that creates a risk 
to both patients and clinical staff. Recent statistics show that 71% of critically 
ill patients experience agitation for 58% of their stay in ICU, so the problem is 
significant in size and patients affected. 
In clinical practice, a lack of understanding of the underlying dynamics, com-
bined with subjective agitation assessment tools, makes effective and consistent 
agitation management difficult. Quantitative models of agitation-sedation dy-
namics are developed to enhance understanding of the underlying system, and 
to create a platform enabling the development of sedative control protocols for 
improved agitation management. Compaitmental pharmacokinetic models are 
employed to model the transport and elimination of drugs, and response surface 
modelling is used to represent the pharmacodynamic effect of the drugs on pa-
tient agitation. These physiologically-based models incorporate observations of 
critically ill patients, and are evaluated against recorded infusion data. 
The models are then used to evaluate different methods of sedation and pa-
tient agitation management. Constant infusion protocols, derivative-focused agi-
tation feedback control protocols, and non-linear agitation feedback protocols are 
specifically investigated. The results identify physiological effect saturation as a 
severe limitation on the capacity of sedative control protocols to reduce agitation. 
In spite of this restriction, significant improvements over current clinical practice 
are achieved through the use of very simple control protocols. These improve-
ments represent significant benefits for patients and medical staff alike. However, 
the fundamental outcome of this thesis is that improved agitation management 
is not determined so much by the class of drug or drug dose, as by the specific 
drug administration strategy employed. 

,/ 
Chapter 1 
Introd uction 
1.1 Motivation 
Critically ill patients are typically admitted to the Intensive Care Unit (ICU) 
for life support and specialised treatment. Patients commonly experience pain 
and/or discomfort as a result of the life support systems, combined with their dis-
ease, injury, and environment. This pain and discomfort can invoke anxiety and 
confusion, which may lead to patient agitation, including excessive potentially 
harmful motion, and increased heart rate and blood pressure. Such agitation 
reduces the ability of the patient to recover, and if not appropriately managed, 
>u",>"uo"o the length of stay and other potential risks. 
To provide comfort and relief, patients are typically given hypnotic drug 
therapy in the form of intravenous (IV) sedatives and analgesics. Sedative agents 
induce amnesia and a lowered state of consciousness, while analgesics primarily 
relieve pain. During surgical operations, sedative and analgesic drugs are used in 
anaesthesia to induce very deep sedation and remove any appreciation of pain. 
The goal of sedation in the ICU is to reduce anxiety, control agitation, and 
produce a patient who is calm, cooperative, and able to communicate [Fragen, 
1997]. (short-term) surgical anaesthesia and r CU (Iong-term) sedation 
have very different goals and target outcomes. 
Therefore, in the ICU, these drugs are used at different doses than in anaes-
thesia to induce a state known as ICU sedation. During ideal rcu sedation 
patients are thus not fully anaesthetised. Instead, they aFe administered only 
enough sedative and analgesic agents to adequately relieve their pain, provide 
2 CHAPTER 1 INTRODUCTION 
comfort, and ease anxiety enough to prevent agitation. 
Effective delivery of sedation is a fundamental activity in the ICU, and is the 
basis for providing comfort and relief to the critically ill. Insufficient sedation 
exacerbates anxiety and agitation, and increases the risk of complications such 
as self-extubation. Over-sedation, on the other hand, is damaging to patient 
health and increases the length of stay and healthcare costs [Kress et al., 2000]. 
Altered consciousness is one of the most common side-effects of continuous infu-
sion of sedatives and analgesics and may lead to delayed weaning and prolonged 
mechanical ventilation [De Jonghe et al., 2005]. For these reasons, it is impor-
tant that the appropriate dose of sedative and analgesic drugs is delivered at the 
appropriate time to ensure the best care for the patient. 
A Midazolam and Morphine combination, given by intermittent bolus or con-
tinuous infusion, is the mainstay of many ICU regimens [Burns et al., 1992]. 
Midazolam is a sedative agent used to induce amnesia and a lowered state of 
consciousness, and Morphine is a powerful opioid analgesic with mild sedative 
effects. While several drug delivery techniques exist, the typical drug therapy 
approach is for bedside medical staff to adjust the IV infusion rate based upon 
their observations of the patient. Accordingly, most sedative drugs administered 
in the Intensive Care Unit are given in respons,e to patient agitation [Fraser and 
Riker, 2001a], which contributes significantly to the US$0.8-1.2B spent on seda-
tion every year in the United States alone [Kress et al., 2000]. Hence, the target, 
or control, metric for regulating sedation in critical care is minimal patient agi-
tation utilising minimal drug dose, rather than a given level of consciousness. 
Although ICU sedation utilises hypnotic drugs similar to those used in Total 
IntraVenous Anaesthesia (TIVA), the drug dose and consciousness levels are dis-
tinctly different, as are the patients and the environment. More importantly, the 
overall goal of the therapy is significantly different with anaesthesia applications 
aiming to induce reduced consciousness for short periods and ICU sedation want-
ing to simultaneously minimise agitation and over-sedation over extended periods 
of time. Hence, critical care sedation management is a very different problem that 
seeks the best trade-off between sedative dose and patient agitation. Therefore, 
while similarities between the two fields may provide some insight, the differences 
prevent simple application of anaesthesia delivery methods, measurements and 
protocols to long-term ICU sedation administration. 
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The underlying non-linear dynamics of the agitation-sedation system are not 
well understood, and many complex interactions contribute to observed patient 
behaviour. Traditional therapeutic treatment methods rely heavily upon the 
knowledge, experience and intuition of the medical staff, the 'art of medicine', 
introducing variability and inconsistency [Kress et al., 2000]. While some studies 
report little benefit in the use of protocols [MacLarcn ct al., 2000; Devlin et al., 
1997], several recent studies have highlighted the cost and healthcare benefits of 
drug delivery protocols based upon agitation-sedation &')sessment scales [Brattebo 
et al., 2002; Smyrnios et al., 2002; Szokol and Vender, 2001; Barr and Donner, 
1995]. Very simple protocols minimising over-sedation have reduced the length of 
stay 28~35%, as well as reducing total drug requirements 46-57% and testing for 
altered mental status 67% [Kress et al., 2000; Brattebo et al., 2002]. The primary 
outcome of the studies is that it is not so important which drug is used, or the 
exact dose delivered, but rather how the drug is employed [De Jonghe et al., 2005; 
Kress et al., 2002]. In spite of these results, many intensive care units apply no 
specific, quantified protocol to sedative infusion, relying upon the judgement and 
experience of the intensive care unit staff [Cohen, 2002J. 
Computerised sedative infusion protocols that enable consistency of care and 
minimise fluctuations in treatment could therefore improve patient care, simplify 
administration, minimise drug consumptiQn and staff effort, and reduce costs. 
In spite of these significant potential advantages, current computer-assisted infu-
sion feedback control systems in the ICU are still in their infancy [Shaw et al., 
2003b; Smith and Reves, 1995]. One major drawback is the lack of a quantified, 
consistent means of measuring agitation, as current protocols rely on subjective 
assessment and dosing. 
Currently, subjective agitation assessment scoring systems are used to help 
guide sedation management. Several studies have been conducted to analyse 
the effect of scoring systems and agitation-sedation scales on patient outcome, 
length of stay, cost, and healthcare benefits [Smyrnios et al., 2002; Szokol and 
Vender, 2001; Barr and Donner, 1995J. However, in each case the studies have 
required large-scale, double-blind clinical trials involving many patients and staff, 
significant time, and careful ethical consideration. It is clearly not ethical to test 
the effectiveness of a proposed sedative infusion protocol on critically ill patients if 
there is a chance that the protocol may hamper recovery. Thus, the development 
of quantitative models to enhance understanding of the system and provide a 
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platform for the development and evaluation of control protocols is important. 
'rhe primary limitations to the development of automated sedative infusion 
protocols include the lack of an objective, physiologically-based, quantified agi-
tation scale and limited understanding of the underlying system dynamics. The 
subjective measures of agitation assessment currently employed introduce signif-
icant variability between assessors and inconsistency of care [Szokol and Vender, 
2001; Weinert et aL, 2001]. While no gold-standard agitation-sedation scale ex-
ists, the Riker Sedation Agitation Scale (SAS) is widely accepted [Fraser and 
Riker, 20mb]. Quantitative agitation sensors being developed [Lam et al., 2003; 
Lam, 2003; Starfinger et ai., 2003; Starfinger, 2003; Shaw et al., 2003b; Chase 
et al., 2004a], potential to significantly improve agitation management 
when coupled with dynamic models and control protocols [Chase et al., 2004a]. 
Recent has shown that consistent, quantifiable measures of patient 
agitation can be developed [Chase et al., 2004c,a; Lam et ai., 2003; Starfinger 
et al., 2003; Agogue, 2005; Lam, 2003; Starfinger, 2003], creating the potential for 
automated, or semi-automated, feedback control approaches to sedation manage-
ment with patient agitation as the control metric. Automated sedative delivery 
systems would thus offer the potential to optimally control patient agitation. It 
would also potentially improve patient care, simplify administration, minimise 
drug consumption and effort, and reduce costs. 
In spite of these advantages, there are no known computer assisted infusion 
utilising feedback control in the ICU [Smith and Reves, 1995; Shaw 
et al., 2003a,b]. Target Controlled Infusion (TCI) systems aim to deliver drugs 
at a rate that maintain target plasma concentrations, using a pharmacokinetic 
(PK) model. This approach is well suited to anaesthesia where short periods 
of reduced consciousness and well-known pharmacology are common. However, 
infusion systems that regulate the infusion rate to maintain target agitation levels, 
and therefore control the primary metric for long-term sedation, are the goal for 
improving care in the ICU. 
This research therefore has two primary aims: 
1. To develop physiologically-based models of the agitation-sedation system 
to enhance understanding of the system and create a platform enabling the 
development of agitation feedback protocols. 
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2. To utilise agitation-sedation models as a platform for the design and evalu-
ation of sedative administration control protocols using agitation feedback, 
for use in medical decision support systems and automated sedation ad-
ministration. 
1.2 Background and Literature Review 
While there are many pharmacological models of Morphine and Midazolam, no 
known models of the interaction of these drugs with patient agitation dynamics 
exist. However, related studies have investigated the PK and pharmacodynamics 
(PD) of Morphine [Meineke et al., 2002; Latsch et al., 2002; Anderson and Kenny, 
2003; Faura et al., 1998; Milne et al., 1996] and Midazolam [Platten et al., 1998; 
Persson et al., 1987; Bolon et al., 2003; Burns et al., 1992; Shafer, 1998; Tuk et al., 
1999], and related models have been developed for use in anaesthesia [Kenny and 
Mantzaridis, 1999; Schwilden et al., 1989; Gentilini et aL, 2001]. However, none 
of these studies attempt to model the effect of sedative and analgesic drugs on 
agitation in ICU patients. 
1.2.1 Agitation Management 
Previous attempts to improve agitation management in the ICU have been limited 
to clinical trials employing constant sedative infusion protocols and subjective 
agitation assessments [Kress et al., 2000; Smyrnios et al., 2002; Brattebo et al., 
2002; Brook et al., 1999]. The use of quantitative modelling to enhance under-
standing of the system and provide a simulation platform is a recently developed 
tool in this area [Shaw et al., 2003b; Rudge et al., 2003a,b]. Hence, there is no 
significant, relevant body of prior art in this field. In particular, the linking of a 
physical patient symptom, like agitation, to a therapeutic pharmacodynamic, is 
not common in any area. 
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1.2.2 General Pharmacology 
The study of pharmacology has developed methods for modelling the PKs and 
PDs of drugs in the body. Pharmacokinetics describes the distribution of drugs 
throughout the body, and their subsequent elimination from the body, while phar-
macodynamics describes the effect drugs have on the body. Hence, pharmacology 
represents the physics of transport once delivered, and the physics of utilisation 
and effect in the body. 
Medical experience and empirical studies have shown that the rate of elim-
ination of drugs from the body is proportional to the concentration of the drug 
itself. Consequently, common PK approaches include the use of rate equations to 
model the distribution of drugs throughout the body, and their elimination from 
the body. Differential equations therefore form the backbone of PK studies. 
Observations of delayed drug distribution gave rise to the method of compart-
mental modelling, which represents the body as several vessels in which different 
drug concentrations can exist. This approach is popular because it is capable of 
capturing observed drug dynamics, is flexible in terms of complexity and struc-
ture, is well-suited to differential equations, and is easily visualised. For example, 
Figure 1.1 shows a 2-compartment model [Wood and Wood, 1990]. The linear 
equations describing the drug distribution in Figure 1.1 are defined: 
(1.1 ) 
(1.2) 
where VI and 112 are the volumes of the compartments, C1 and C2 are the drug 
concentrations in the compartments, K12 is the transfer rate from compartment 1 
to compartment 2, K21 is the transfer rate from compartment 2 to compartment 
1, K EZ is the rate of drug elimination from compartment 1 and Dose is the rate 
of infusion of drug into C1 • 
Experimental research has shown that the typical effect of a drug on the body 
is not linearly proportional to its concentration. Rather, there is a non-linear PD 
relationship between concentration and effect. The Hill equation is a common 
representation of the generalised relationship between drug concentration and 
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Figure 1.1 Schematic of a basic 2-compartment PK model. 
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effect, and forms the basis for many PD models. One form of the generalised Hill 
equation is displayed in Figure 1.2 and defined: 
E = Eo + (Emax - Eo) (..pC'" ) 
. 0 50 + O..p (1.3) 
where E represents the pharmacodynamic drug effect, Eo is the minimum 
feet, Emax is the maximum possible effect, 0 is the drug concentration, 'IjJ is the 
steepness coefficient) and 0 50 is the concentration corresponding to 50% drug 
effect. 
Figure 1.2 shows the non-linear sigmoidal relationship between drug concen-
tration and PD effect per Equation (1.3). As concentration reaches higher levels 
past point A, the increase in effect gained from increased concentration dimin-
ishes. p&st point B there is effectively no additional effect for additional drug, 
indicating a saturation of effect. 
In sedation management, saturation past point B means excess drug exists 
in the system and may be stored in fatty tissue. This stored drug will be re-
leased later when the plasma concentrations fall, typically during weaning from 
sedation [Wagner and O'Hara, 1997]. The result is increased length of effect, 
and as a result length of stay (LOS) and cost and increase. Thus, saturation 
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Figure 1.2 Representation of the non-linear PD concentration-effect relationship described 
by the Hill Equation. 
is an important patient-specific parameter to be accounted for in any effective 
sedation management protocol. Simply identifying and avoiding saturation may 
significantly reduce the incidence and effect of over-sedation. 
Similarly, observations of the effects of interactions between several drugs 
simultaneously present in the body have shown that the combined effect is not 
always linear. In particular, it has been shown that different drug combinations 
interact differently to produce either additive, synergistic (super-additive), or 
antagonistic (sub-additive) effects. Several techniques have been developed to 
model the effects of these drug interactions, many of them using response surfaces 
[Fidler et aI., 2003; Minto et aI., 2000; Rudge et aI., 2005bj. The main goal of 
all these approaches is a better, more accurate description of saturation that is 
applicable to common clinical practice of using multiple drugs in combination. 
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1.2.3 PK and PD Studies 
While there have been many pharmacological studies on Morphine and Midazo-
lam, very few, if any, investigate the effect of these drugs on patient agitation in 
the critically ilL In particular, there have been many PK studies investigating 
the distribution of Morphine and Midazolam throughout the human body. How-
ever, they focus primarily on animal or healthy human subjects. Although there 
have been fewer studies on the PD of Morphine and Midazolam, they too focus 
primarily on healthy subjects. 
A review of the pharmacology of Morphine and its metabolites in both hu-
mans and animals was conducted by Milne et aL [1996]. Further, studies have 
investigated the PK of Morphine in patients with Acute Renal Failure (ARF) 
[Bion et aL, 1986], Renal Failure (RF) [Osborne et aL, 1993], Chronic Renal 
Failure (CRF) [Aitkenhead et aL, 1984], and neurosurgical and neurological ICU 
patients [Meineke et aL, 2002]. A few PK studies employing compartmental 
modelling to investigate the PK of Morphine for healthy [Latsch et aL, 2002] and 
ICU patients [Meineke et al., 2002] are also available. There are fewer studies 
investigating the PD of Morphine, however Barr and Donner [1995] and Levine 
[1994] present qualitative information regarding the PD effects of Morphine. In 
particular, the results published by Berger and Waldhorn [1995], Schmidt et al. 
[2004], and Tverskoy et aL [1989] point to the potent analgesic and mild sedative 
properties of Morphine. 
Studies have investigated the PK of Midazolam in patients with ARF [Driessen 
et aL, 1991], CRF [Vinik et aL, 1983], elderly patients [Fragen, 1997], and gen-
eral ICU patients [Driessen et aL, 1991; Malacrida et al., 1992; Oldenhof et al., 
1988; Shafer, 1998; Bolon et aL, 2003]. A few PK studies employing compart-
mental modelling to investigate the PK of Midazolam for healthy [Persson et aL, 
1987] and ICU patients [Bolon et aL, 2003] are also available. are fewer 
studies investigating the PD of Midazolam, however Fragen [1997] and Platten 
et al. [1998] present information regarding the PD effects of Midazolam. Perhaps 
more importantly, several reviews and studies discuss the combined PD effects 
of Morphine and 11idazolam [Tverskoy et al., 1989; Wagner and O'Hara, 1997; 
Barr and Donner, 1995; Fragen, 1997; Gilliland et al., 1996]. 
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1.2.4 Anaesthesia Models 
In general, the body of knowledge of short term anaesthesia is much more ad-
vanced than that of ICU sedation and provides a useful clinical and theoretical 
backdrop. However, its direct application to work with ICU sedation is lim-
ited due to distinctly different drug doses, target metrics, end-points, and goals. 
Specifically, anaesthesia uses volatile, very short acting agents in large doses to 
induce a deeply anaesthetised state of unconsciousness. However, many of these 
volatile agents, such as Propofol, are toxic in the long time-frames and doses 
encountered in ICU sedation management [ADRAC, 2004; Kang, 2002; McKeage 
and Perry, 2003]. In contrast to anaesthesia, sedation uses longer acting agents 
in much lower doses to slightly lower the level of consciousness, 
and manage agitation. 
anxiety, 
Pharmacological models of the opioid Alfentanil have been developed and 
ll-sed in closed-loop feedback control of analgesia [Gentilini et aL, 2002]. Similarly, 
attempts have been made using various anaesthetic drugs to create models for 
closed-loop control of anaesthesia [Kenny and Mantzaridis, 1999; Schwilden et aL, 
1989; Gentilini et aL, 2001]. However, in most cases, the models focus on the 
PKs rather than the PDs, and use blood pressure or the Bispectral Index (BIS) 
as a feedback quantity. One reason for the lack of PD focus is the difficulty of 
objectively quantifying the resulting level of sedation in a consistent repeatable 
fashion- very similar to the difficulty in measuring agitation. In addition, while 
there is some debate in the literature over the clinical usefulness of BIS in the 
ICU environment, most studies conclude that more trials are required to prove 
the clinical effectiveness of BIS in the ICU [De Deyne et al., 1998; Simmons et al., 
1999; Gilbert et al., 2001; Nasraway et aL, 2002; Tonner et al., 2005; Nasraway, 
2005; Kress et aL, 2002]. 
While the models and systems developed for anaesthetic applications cannot 
be directly applied to ICU sedation, they certainly contribute to the methodol-
ogy and considerations used in developing models and controllers for agitation 
management. In particular, a focused design approach based upon specific target 
metrics, similar to current anaesthesia approaches, would provide significant ad-
vantages over current approaches to sedation management in the ICU that lack 
quantified feedback control metrics. 
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1.2.5 Summary and Preface 
Quantitative models of the agitation-sedation dynamics are developed to enhance 
understanding of the agitation-sedation system and create a platform enabling 
the development of agitation feedback protocols. The developed models are then 
used as a platform for the UC;,;:UF;U and evaluation of sedative administration control 
protocols using agitation feedback, for use in medical decision support systems 
and automated sedation administration. 
Part I of this thesis focuses on the physiology and modelling of the agitation-
sedation system. The first chapter covers the construction of the proposed 
agitation-sedation model, starting with an initial model consisting of two com-
partments. The next chapter develops the initial model into a more physiologically-
representative model by adding separate PKs, a non-linear PD concentration-
effect relationship, synergism, endogenous agitation reduction, and 
tion. 
satura-
Part II develops the model evaluation metrics and procedures for use with 
recorded infusion data. The model evaluation technique is explained, followed by 
the development of several model evaluation metrics. The initial model is eval-
uated and its capabilities and limitations ·identified. The more physiologically-
based model of Chapter 3 is then evaluated, including the identification of system 
parameters and analysis of their sensitivities. 
Part III develops and evaluates control protocols for use in semi-automated 
sedative control systems. Control protocol specifications are developed based 
upon physiological limits and goals of ICU sedation. Simple controllers are used 
in conjunction with the developed models to assess the of the sim-
ple control protocols, before developing more advanced controllers. Finally, the 
robustness of the developed control protocols is assessed. 
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Part I 
Modelling and Physiology 

Chapter 2 
Physiology and Current Treatment Methods 
2.1 Physiology 
Critically ill patients are typically admitted to the Intensive Care Unit for critical 
treatment and life support. As a result of the life support systems, combined 
with their critical condition, and environment, patients commonly experience 
pain and/or discomfort during their stay in ICU. This pain and discomfort can 
invoke anxiety and confusion, which can lead to patient agitation. 
Agitation affects 71% of critically ill patients for 58% of their stay in ICU 
[Fraser and Riker, 2001bj. Anxious and agitated patients may groan and grimace, 
and in some circumstances attempt to remove the endotracheal tube and other 
catheters, as well as resist staff [Agogue, 2005; Kress et al., 2000j. This phys-
iological stress on the body increases the chance of complications and prevents 
speedy recovery. 
While many drug administration routes exist, such as the subcutaneous, 
intra-muscular, and intravenous routes, sedative and analgesic drugs in the ICU 
are typically administered intravenously into the blood stream. Intravenous ad-
ministration is selected because the delay between drug delivery and effect is 
small, and because of the ease of administration through current drug delivery 
systems. 
Although the use of the opioid drug Morphine has a history dating back to 
the early 19th century [Milne et al., 1996], its pharmacology and the mechanism 
of action is still not fully understood [Faura et al., 1998; Meineke et al., 2002; 
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Milne et al., 1996]. Midazolam is part of the benzodiazepine family of sedative 
drugs, whose popularity has recently increased [Wagner and O'Hara, 1997] due 
to their application for long-term sedation, consistency of action, and relatively 
less significant side-effects. While there have been many studies investigating the 
pharmacology and mechanism of action of benzodiazepines, their exact mode of 
action is also not fully understood [Crippen, 1990]. Drugs delivered intravenously 
enter the venous blood stream returning to the heart. After passing through the 
heart and lungs, the drug is then distributed in the blood throughout the different 
parts of the body, including the brain and central nervous system, where sedative 
action occurs. 
For hypnotic drugs, the site of action is commonly considered to be the re-
ceptors in the brain and the spinal column in the cerebro-spinal fluid (CSF). 
Studies have detected Morphine and Midazolam in the CSF, although the entry 
mechanism is still unclear [Faura et al., 1998; Arendt et al., 1983]. Morphine and 
Midazolam then bind with their respective receptors and assert their PD effects 
[Milne et al., 1996; Arendt et al., 1983]. 
The half-life of Morphine and Midazolam is approximately 2.5-8.5 hours 
[Bion et al., 1986; Aitkenhead et al., 1984; Volles and McGory, 1999] and 3-7 
hours [Fragen, 1997; Malacrida et al., 1992; 'Vagner and O'Hara, 1997]' respec-
tively. Morphine is primarily metabolised in the liver and kidneys, and only a 
small portion is excreted in the urine [Crippen, 1990]. In contrast, Midazolam 
is metabolised extensively in the liver and conjugated and excreted exclusively 
in the [Crippen, 1990]. During metabolism, Morphine is converted into its 
major metabolites Morphine-3-glucuronide (M3G) and Morphine-6-g1ucuronide 
(M6G) [Milne et al., 1996]. Midazolam is also converted into its major metabo-
lites a-hydroxy-Midazolam and 4-hydroxy-Midazolam [Mandemaet al., 1992; Thk 
et al., 1999]. While some studies have shown that these Morphine and Midazo-
lam metabolites are pharmacologically active, the extent of their activity and 
mechanism of action is still under debate [Knoester et al., 2002; Mandema et al., 
1992; Milne et al., 1996; Meineke et aL, 2002]. 
The half-life, clearance and PK parameters of Morphine and Midazolam are 
known to vary between patients, and are particularly influenced by renal and 
hepatic failure [Knoester et al., 2002; Mandema et al., 1992; Platten et al., 1998; 
Fragen, 1997; Vinik et al., 1983; Milne et al., 1996; Aitkenhead et al., 1984]. 
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Drug storage in the fatty tissues can result in delayed release of drugs, causing 
prolonged effect [Crippen, 1990], and effectively increasing the half-life during 
periods of low infusion, like weaning. Combinations of sedatives and analgesics 
are synergistic in producing sedation [Wagner and O'Hara, 1997], potentially 
leading to an unintendedly higher total level of sedation. 
Delirium occurs in 20.7-36.8% of ICU patients [Szokol and Vender, 2001], 
and is defined as "a reversible, global impairment of cognitive processes, usu-
ally of sudden onset, coupled with disorientation, impaired short-term memory, 
altered sensory perceptions (hallucinations), abnormal thought processes, and in-
appropriate behaviour". Delirium can go unrecognised in more than two-thirds 
of patients in clinical practice, and may be confused for agitation [Ely et al., 
2004], leading to mistreatment in both cases. Delirium is commonly treated with 
haloperidol, and can be antagonised by Morphine and Midazolam [Crippen, 1994] 
or similar sedatives. As a result, over-sedation leads to time-consuming and ex-
pensive testing for altered mental status, to ensure the appropriate treatment is 
being given [Kress et al., 2000; Ely et al., 2004]. 
Finally, the natural response of the body to induced pain or stress is the 
release of endorphins. Abbreviated from "endogenous Morphine", endorphins 
are a form of natural analgesic produced i9 response to pain and physical stress 
[Kreek, 2002]. Although endorphins form an important part of the physiological 
system and their qualitative effect can be described, their impact is difficult to 
quantify. This dynamic, along with the previously mentioned dynamics, may be 
important in the agitation-sedation system and are significant considerations for 
the development of a quantitative model of the agitation-sedation system. 
2.2 Current 'freatment Methods 
In the hospitalised adult, agitation is defined as an excessive motor or verbal 
behavior that interferes with patient care, patient or staff safety, and medical 
therapies. Current agitation management methods rely on subjective agitation 
assessment, and an appropriate sedation input response, from bedside medical 
staff. Bedside medical staff assess patient agitation using subjective agitation 
scales [Ramsayet al., 1974; Riker et al., 1999; Fraser and Riker, 2001b; Jaarsma 
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et al., 2001; Sessler et al., 2002]' and then select an appropriate infusion rate based 
upon their evaluation, experience, and intuition [Kress et al., 2002]. This process 
is depicted in Figure 2.1. Figure 2.2 shows the same situation schematically in 
block diagram form where bedside medical assess agitation and choose the 
drug infusion rate. Subjectivity, and more particularly subjective a..'Ssessment, 
is introduced in this section. The most current subjective agitation scales are 
presented and discussed to delineate the current state of the art in agitation 
assessment, and thus sedation management. 
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Figure 2.1 Diagram of typical sedative administration method. 
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Several recent studies have highlighted the cost and healthcare benefits of 
drug delivery protocols based upon agitation-sedation assessment scales [Brattebo 
et al., 2002; Smyrnios et al., 2002; Szokol and Vender, 2001; Barr and Donner, 
1995]. Very simple protocols minimising over-sedation have reduced the length 
of stay 28-35%, as well as reducing total drug requirements 46-57%. However, 
a daily interruption of sedative drug infusion can lead to under-sedation, which 
results in sudden changes in the level of consciousness due to mental and physical 
stress. In spite of the obvious benefits of formal sedation protocols, many intensive 
care units apply no specific, quantified protocol to sedative infusion, relying upon 
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Figure 2.2 Block diagram schematic of typical sedative administration. 
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the judgement and experience ofthe intensive care unit staff [Cohen, 2002]. Note 
that the use of sedative infusion protocols assumes that everything has been done 
to remove or reduce all obvious sources of stimulus that may lead to agitation 
[Kress et al., 2002]. Further, it is acknowledged that the removal of all obvious 
sources of stimulus may be sufficient for some patients, inferring that not all 
patients require sedation [Kress et al., 2002]. 
There are many subjective agitation scales available to bedside medical staff 
for assessing patient agitation. However, their subjectivity means that the result-
ing assessment, and hence resulting treatment, relies heavily on the experience 
and intuition of the staff. Further, once bedside staff have assessed the patient 
agitation, their response also depends upon their experience and intuition. This 
reliance creates variability and inconsistency in treatment, as ability and experi-
ence can vary greatly between staff, and over time for any given clinician. These 
factors make it difficult to implement a pre-defined agitation management proto-
col, particularly one that is effective and patient-specific, given the variability also 
present in patients. A summary of some of the common agitation and sedation 
scales used in ICUs is presented below. 
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2.2.1 The Ramsay Scale 
The first scale developed to assess level of agitation and sedation of critically 
ill patients was the Ramsay scale developed in 1974 [Ramsay et al., 1974]. It 
consists of a 6-grade scale from 1 (agitated) to 6 (unarousable, over-
sedated). These different are detailed in Table 2.1. 
or 
2 Patient awake, cooperative, orientated and tranquil 
3 Patient drowsy, with response to commands 
4 Patient a.."lleep, brisk response to glabella tap or loud 
auditory stimulus 
5 Patient a.."lleep, sluggish response to stimulus 
6 Patient has no response to firm nail-bed pressure or 
other noxious stimuli 
The subjectivity of this scale was first estimated in 1999 [Riker et al., 1999], 
with an inter-rater agreement (K = 0.88). Unfortunately, the Ramsay scale classi-
fies all different levels of agitation into one single level including behaviours from 
mild anxiety to dangerous agitation [Ramsay et aL, 1974]. In spite of this limita-
tion, the Ramsay scale remains one of the most widely used scalesfor monitoring 
sedation in daily practice, as well as clinical research [Carrasco, 2000]. 
2.2.2 The Riker Sedation/Agitation Scale 
The Riker Sedationj Agitation Scale (SAS) was first developed in 1994, and sub-
sequently improved in 1999 [Riker et al., 1999]. It provides a symmetric approach 
of 3 grades each to assess the patient's levels of agitation and sedation, and a mid-
dle grade for calm and co-operative patients - a total of 7 possible levels. The 
Riker SAS has an inter-rater agreement of K = 0.92. The intra-rater agreement 
has not been evaluated. The validity of this scale has also been assessed through 
agreement with other subjective scales [Riker et al., 1999]. However, there is a 
key limitation in the Riker SAS, since the patient is classified as either agitated, 
or sedated, but not both. 
Recent research by Shaw et aL [2005] ha.."l shown that a patient can be simul-
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taneously agitated and sedated. Therefore, it is more consistent to assign the 
patient with both an agitation index and a sedation index. A modified version 
of the original Riker SAS, to as the modified SAS, is shown in Table 
2.2. This scale has been developed and used in the Christchurch Hospital ICU 
to assess agitation and sedation levels separately, creating two concurrent and 
independent indices, around the "0" score. 
Table 2.2 Modified version of the SAS Scale 
Score Term Description 
Agitation score 
3 Dangerous Agitation Pulling at Endotracheal Tube (ETT), trying 
to remove catheters, climbing over bed rail, 
striking at staff, thrashing side-to-side 
2 Very Agitated Requiring restraint and frequent verbal re-
minding of limits, biting ETT 
1 Agitated Anxious or physically agitated, calms to ver-
bal instructions 
o Calm Calm 
Sedation score 
o Cooperative 
-1 Sedated 
-2 Very Sedated 
-3 Unarousable 
Easily arousable, follows commands 
Difficult to arouse but awakens to verbal 
stimuli or gentle shaking, follows simple com-
mands but drifts off again 
Arouses to physical stimuli but does not com-
municate or follow commands, may move 
spontaneously 
Minimal or no response to noxious stimuli, 
does not communicate or follow commands 
Guidelines for applying the modified SAS assessment [Riker et al., 1999] help 
differentiate different levels of sedation and agitation. First, agitated patients are 
scored by their most severe degree of agitation in the 0~3 range. Then, sedated 
patients are scored similarly for level of sedation on the -3-0 range. Finally, both 
scores are reported as concurrent, independent indices. 
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2.2.3 The Motor Activity Assessment Scale 
The Motor Activity Assessment Scale (MAAS) has been developed from the 
Riker SAS and is also a 7 -level scale with three categories for both agitation and 
sedation, as well as a middle level for calm patients [Fraser and Riker, 2001bj. 
Behavioural descriptors are provided to assist clinicians in patient assessment, as 
defined in Table 2.3. The MAAS has an inter-rater agreement of K, = 0.83, and 
has been confirmed through comparisons with other subjective scales and clinical 
parameters, such as changes in vital signs [Fraser and Riker, 2001bj. However, 
the validity of the MAAS has only been assessed in surgical lCU patients, and 
further study should be carried out on critically ill patients [Carrasco, 2000j. 
Table 2.3 The Motor Activity Assessment Scale 
Score Term Description 
6 Dangerously agitated, No external stimulus is required to elicit 
5 
4 
3 
2 
1 
uncooperative movement, and patient pulls at tubes or 
catheters or thrashes side-to-side or strikes 
at staff or tries to climb out of bed and does 
not calm down when asked 
Agitated 
Restless and coopera-
tive 
Calm and cooperative 
Responsive to touch 
or name 
Responsive only to 
noxious stimuli 
No external stimulus is required to elicit 
movement, and attempts to sit up or moves 
limbs out of bed and does not consistently 
follow commands (e.g., will lie down when 
asked but soon reverts to attempts to sit up 
or move limbs out of bed) 
No external stimulus is required to elicit 
movement and patient picks at sheets or 
tubes or uncovers self and follow commands 
No external stimulus is required to elicit 
movement and patient adjusts sheets or 
clothes purposefully and follow commands 
Opens eyes or raises eyebrows or turns 
head toward stimulus OR moves limbs when 
touched or name is loudly spoken 
Opens eyes or raises eyebrows or turns head 
toward stimulus or moves limbs with noxious 
stimulus 
o Unresponsive Does not move with noxious stimulus 
There are additional subjective assessment tools available to evaluate the 
level of sedation and agitation of a patient. Among those are the Harris scale, the 
Sheffield scale, the Vancouver interaction and calmness scale, the visual analogue 
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scale [Fraser and Riker, 2001b], the Observer's Assessment of Alertness/Sedation 
(OAA/S), the CO::VIFORT [Jaarsma et al., 2001], and the Richmond Ag-
itation Sedation Scale (RASS)[Sessler et al., 2002]. They all provide a reliable 
assessment tool with advantages and disadvantages, and they may focus more or 
less on different aspects. However, these scales are more subjective and they are 
not presented in more detail in this thesis. 
2.2.4 Summary of Subjective Scales 
Among the literature concerning agitation and sedation assessment methods, 
Fraser and Riker [2001 b] recommend that each intensive care unit select one 
scale proven to be valid and reliable, and include that scale in their agitation and 
sedation protocols. Because of the ease of use, proven reliability and validity, 
behavioural descriptors to guide patient classification, and the capability of mon-
itoring both agitation and sedation, Christchurch Hospital leU uses the modified 
Riker SAS [Shaw et al., 2005, 2003bj. However, no data confirms that this scale 
is superior to others. 
More importantly, all the scales described share the requirement of subjective 
assessment with relatively limited (3-5) levels of resolution for agitation. In 
addition, all scales currently available describe agitation and sedation as two 
ends of a single spectrum, rather than two independent spectrums. The scales 
therefore fail to separate agitation and sedation, even though the application of 
sedative agents is the treatment for patient agitation. If sedatives are used to 
treat agitation, and the sedation and agitation levels are related, then the 
measure a balance of treatment and behaviour. However, the subjective 
previously mentioned are not utilised in this way. Furthermore, social, personal, 
and professional factors have been shown to influence sedative therapy [Weinert 
et al., 2001], and intra- and inter-rater scales reported from controlled studies with 
well trained staff can differ significantly in every day practice [Agogue, 2005]. 
Given the variation in assessment as well as sedation, implementation of 
closed-loop feedback control of sedation with agitation as the feedback quantity 
could well improve patient healthcare and cost. To enable the development of 
semi-automated systems, quantitative models of the agitation-sedation dynam-
ics are required to gain insight and understanding of the system, and develop 
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suitable sedative administration controllers. This thesis develops models of the 
agitation-sedation system and employs the models for the development of sedative 
controllers to provide improved agitation management through feedback control 
of patient agitation. 
Chapter 3 
Agitation-Sedation Modelling 
Several quantitative models of the agitation-sedation system have been developed 
throughout the course of this research, each model building upon the previous 
model's strengths and improving the weaknesses. The first models developed cap-
ture the fundamental dynamics of the agitation-sedation system, but lack physio-
logical resemblance and more advanced dynamics. These first models established 
a platform from which more physiological models were developed, incorporating 
more advanced dynamics. The model development process, beginning with the 
creation of the initial model, and consisting of improvement building on previous 
models is portrayed in Figure 3.1. The three models presented in this section are: 
Initial Model This model was developed to capture the fundamental dynamics 
of the agitation-sedation system, and employs simple PK relationships and 
linear PDs. The model is used to establish a fundamental platform for 
further model development. 
Predator-Prey Model This model is a development of the initial model in-
corporating non-linear PDs. This model is used to investigate the impact 
of non-linear PDs on the ability of the model to capture the fundamental 
dynamics. 
Physiologically-based Model This model builds upon the understanding gained 
from the previous models and adds more complex dynamics to the model, 
capturing synergism, saturation, and a non-linear concentration-effect dy-
namic. This model captures both the fundamental dynamics of the agi-
tation system captured in the Initial mode, while at the same time being 
more representative of the physiology. 
26 
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Figure 3.1 Schematic of the model development process. 
This chapter presents each of the models and explains the important aspects 
of each model and their physiological resemblance. Part II of this thesis then pro-
ceeds to evaluate the models consecutively. Rather than present only the final 
physiological model, this thesis presents the three separate models as a progres-
sion of the development process to convey the development and improvement of 
the models, and to help compare and contrast the various aspects of the mod-
els. Through explicit comparison between models, the important features within 
each model can be identified thereby enhancing understanding of the underlying 
system dynamics. 
3.1 Initial Model 
An initial model of the agitation-sedation system is presented as a platform from 
which to develop the agitation-sedation model. The models developed are in-
tended to be the simplest required to capture the fundamental patient dynamics 
common to leU patients, rather than represent the detailed and complex mech-
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anisms underlying all of the pharmacology. macroscopic approach to mod-
elling arises out of the overall goal of this research to enhance understanding of 
the system dynamics and create a platform for controller development. 
The initial model presented in this section builds upon a well-known general 
two-compartment PK model [Wood and Wood, 1990], adding patient agitation 
as a third state variable. As a simplification, the model treats Morphine and 
Midazolam as one fixed-ratio drug. Equations (3.1)-(3.3) define the agitation-
sedation system model: 
(3.1) 
(3.2) 
dA it () -K (t-T) 
- = wls - W2KT O2 T e T dT dt 0 
(3.3) 
where 0 1 is the drug concentration in compartment 1 (mg/L), O2 is the drug 
concentration in compartment 2 (mg/L), U is the IV infusion rate (mL/min), 
R is the concentration of the drug in the infusion solution (mg/mL), Vd is the 
volume of distribution (L), A is an agitation index, S is the stimulus invoking 
agitation, K l - 3 are parameters related to drug elimination and transport (min-I), 
and KT is the effect time constant (min-I): Time is represented by t in min, T 
the variable of integration, and the terms WI and W2 are the stimulus and sedative 
sensitivities, respectively. A and S are assumed unitless. 
This initial model is intended to be the simplest necessary to capture the 
essential dynamics of the agitation-sedation system. Therefore, K l - 3 are assumed 
constant over time, although they can be treated as slow moving functions of time 
to model more complicated, very long-term phenomena such as tachyphylaxis or 
fatty tissue distribution [Hughes et aL, 1992]. Hence, it also considers Morphine 
and Midazolam administered concomitantly as a single drug. 
Equation (3.1) represents the kinetics of drug infusion and distribution, while 
Equation (3.2) represents the transport of sedative from the infusion site to the 
site, which for sedative and analgesic drugs is the central nervous system. 
acceptable approximation for this effect site concentration is considered by 
some authors to be the drug concentration in the CSF [Meineke et aL, 2002; 
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Cousins and Mather, 1984J. These kinetics are shown schematically in Figure 3.2 
for Equations (3.1)-(3.3). 
Figure 3.2 Schematic representation of the PK of the initial model. 
The non-linear pharmacodynamic Equation (3.3) was developed based upon 
physiological observations of ICU patient behaviour. Specifically, it states that 
the rate of change of agitation depends upon the magnitude of the stimulus 
relative to the cumulative effect of the sedative agent. Stimulus this context 
refers to the combined effect of inherent pain, distress, or loss of inhibition caused 
by the diseased/injured state of the patient, and the therapeutic and diagnostic 
procedures performed by medical staff [Kress et aL, 2002J. 
Equations (3.1)-(3.3) represent a model of the fundamental dynamics of the 
ICU patient. In particular, the PD Equation (3.3) is developed to capture the 
agitation response of the patient to external stimuli and drug delivered to the 
patient. The model, and PD equation in particular, should be independent the 
nursing response and stimulus inputs. More specifically, the patient PDs are not 
a function of the nurse or stimulus, but a response to inputs. Hence, the 
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models should be patient specific but independent of these external inputs that 
are administered to the patient. 
Under constant stimulus levels, observed agitation typically falls or remains 
unchanged upon increased infusion of sedative agents. Similarly, patients become 
more agitated by increased stimulus, due to procedures or condition, if infusion 
rates are not increased. Patient agitation is therefore modelled as being primarily 
reduced by the cumulative effect of current and prior sedation administration, as 
modelled by the convolution term in Equation (3.3). Finally, the KT term in 
front of the integral term in Equation (3.3) exists to scale the integral term back 
to a magnitude of similar order to the terms within the integral. 
The introduction of the convolution term in Equation (3.3) creates a simple 
method of capturing the cumulative effect of Morphine and Midazolam on pa-
tient agitation. It represents a novel method of capturing the cumulative effect 
over time of current and prior sedative administration. While the model is not 
completely physiological, it creates a good base for the further development of 
the agitation-sedation model. 
Equation (3.3) emphasises the pharmacological effect of the drugs on agi-
tation over time. Specifically, it captures the observed time-lag between drug 
concentration and drug effect, which may represent the crossing of drugs across 
the blood brain barrier, or the uptake of drug by receptors. While other forms 
of Equation (3.3) are explored in Chapter 13, the form presented in this section 
is physiologically intuitive because of its explicit representation of the effect of 
pharmacological action over time. Specifically, it emphasises the relatively high 
impact of recent drug delivery compared to the reduced impact of prior drug de-
livery, recognising rates of transport and utilisation of drug. The form of Equa-
tion (3.3) also has particular advantages in controller formulation, particularly 
techniques employing the Laplace transform. The presence of the convolution 
integral in Equation (3.3) simplifies the evaluation of its Laplace transform and 
thus enables the use of other well known control development and analysis tools. 
This initial drug model incorporates the fundamental PK principles, and in-
troduces a simple relationship between drug concentration, stimulus, and patient 
agitation. However, it lacks the separate PK profiles of Morphine and Midazolam, 
and assumes a linear relationship between drug concentration and effect. This 
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model is therefore incapable of capturing saturation or drug interaction dynam-
ics. The model also lacks complete physiological resemblance and is not easily 
visualised because of the uni-directional transfer and losses, as seen in Figure 3.2. 
However, it does capture the essential PK transfer of drug and its utilisation to 
reduce agitation. Hence, it creates a fundamental platform from which to develop 
more advanced physiologically-based models of the agitation-sedation system. 
3.2 Predator-Prey Model 
The model presented in this section is identical to the initial model in all re-
spects except for the integral term in Equation (3.3). The predator-prey model 
incorporates a non-linear dynamic commonly observed in species competing for 
existence, and often used in pharmacodynamic models, such as for the insulin-
glucose system [Lam et al., 2002; Bergman et al., 1985]. 
Equations (3.4)-(3.6) define the Predator-Prey version of the initial agitation-
sedation system model of Equations (3.1)-(3.3): 
(3.4) 
(3.5) 
T7 A it C ( ) -KcC(t-T)d W2I\.T 2 T e T 
o 
(3.6) 
where CI is the drug concentration in compartment 1 (mg/L), C2 is the drug 
concentration in compartment 2 (mg/L), U is the IV infusion rate (mL/min), 
R is the concentration of the drug in the infusion solution (mg/mL), Vd is the 
volume of distribution (L), A is an agitation index, S is the stimulus invoking 
agitation, are parameters related to drug elimination and transport (min-I), 
and KT is the effect time constant (min-I). Time is represented by t in min, T is 
the variable of integration, and the terms WI and W2 are the stimulus and sedative 
sensitivities, respectively. A and S are assumed unitless. 
The distinction between the initial model and the predator-prey model is in 
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the inclusion of agitation in the integral term in the final pharmacodynamic, third 
equation. By adding agitation as a factor in the term responsible for reducing 
patient agitation, the predator-prey framework suggests that the level of agitation 
affects the ability of the therapeutic drugs to reduce patient agitation. More 
specifically, it defines a multiplications relationship so that very low agitation 
limits the drug effect and very high agitation magnifies it. 
Observations of agitation in critically ill patients reveal no direct suggestion 
of the existence of this type of predator-prey dynamic. There is also no known 
mention of its effects in the published literature. However, the predator-prey 
model is regularly used to model other drug pharmacodynamics such as those of 
the insulin-glucose system [Lam et al., 2002]. Hence, it may yet represent a valid 
(and accepted) modelling framework that at 'central' levels of agitation and drug 
effect is similar to a calibration constant in W2. 
Therefore, the predator-prey model of agitation-sedation dynamics is retained 
for further investigation. Its independent representation of patient specific PDs 
is also used later in the independent selection of the nurse control parameters in 
Section 6.1. Hence, it provides a second, independent dynamic model of patient 
agitation-sedation response using a well-known PD modelling structure. 
3.3 Physiologically-based Model 
Using the initial model as a platform for further development, additional dynam-
ics are added to the model to create a more physiologically representative model. 
This improved model utilises separate PK models for Midazolam and Morphine, 
and incorporates a non-linear PD relationship. Displayed schematically in Fig-
ure 3.3, the model is a closer representation of the actual physiological system 
than the initial model and includes delayed distribution, drug synergism, effect 
saturation and endogenous agitation reduction (EAR). The model is defined in 
three main portions: 
I. Pharmacokinetics of Morphine: 
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(3.8) 
V a dC~ K a C a K a Ca e dt = - ee e + ee e (3.9) 
II. Pharmacokinetics of Midazolam: 
(3.10) 
(3.11) 
III. Pharmacodynamics of Morphine and Midazolam: 
(3.12) 
where Ce , Cp and Ce are the drug concentrations (mg/L) in the central, peripheral 
and effect compartments, Vc" v;, and Ve are the distribution volumes (L) of the 
central, peripheral and effect compartments, U is the IV infusion rate (mL/min), 
A is an agitation index, S is the stimulus invo.king agitation, Kij is the transfer 
rate (L/min) from compartment i to compartment j, KCL is the drug clearance 
(L/min), KT is the effect time constant (min-I), and Ra and R8 are the concen-
trations of analgesic ('a') Morphine and sedative ('s') Midazolam in the infusion 
solution respectively (mg/mL). A and S are assumed unitless. Time is repre-
sented by t (min), T is the variable of integration, and the terms WI and W2(t) are 
the stimulus and sedative sensitivities respectively. Similarly, W3 is the sensitivity 
associated with the endogenous reduction of patient agitation. Finally, EComb is 
the combined PD effect of the individual effect site drug concentrations of Mor-
phine and Midazolam, determined using response surface modelling as defined by 
Minto et al. [2000]. The PD response surface is displayed in the lower portion of 
Figure 3.3. 
To define the PD response surface, the effect concentrations of Morphine and 
Midazolam are first normalised and expressed in units of potency: 
ca 
e 
Ua = ca ' 
50 
CS 
e 
Us = CS 
50 
(3.13) 
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Figure 3.3 Schematic representation of the physiologically-based model, including the com-
partmental PKs (upper portion) and the PD response surface (lower portion). 
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where G50 (mg/L) represents the concentration that results in 50% of maximal 
drug effect if administered alone. Hence, Ua and Us represent the concentrations, 
which are functions of time, relative to the midpoint of the sigmoidal curves in 
Figure 3.3. 
The PD response surface function, EComb , can then be defined as a dual-drug 
version of the Hill equation presented in Section 1.2: 
where 0 = 
(Ua + Us) ",(B) U50 (O) EComb = Eo + [Emax(O) - Eo]--'---'---'-'----
(Ua + Us) "'(B) 1 + U50 (O) 
(3.14) 
~ is the ratio of the two drugs, 'lj;(O) is the steepness of the 
Ua+Us 
concentration-response relation at ratio 0, U50 (O) is the number of units (U) 
associated with 50% of maximum effect at ratio 0, and Emax(O) is the maximum 
possible drug effect at ratio O. The terms 'lj;(O) , U50 (O), and Emax(O) simply 
express how the terms they represent change with varying drug ratios, and are 
each defined in terms of a fourth order polynomial: 
Emax(O) = (3E,o + (3E,l ·0 + (3E,2 .02 + (3E,3 .03 + (3E,4 .04 (3.15) 
U50 (O) = (3u,o + (3U,l ·0 + (3U,2 .02 + (3U,3 .03 + (3U,4 .04 (3.16) 
(3.17) 
where (3E,0-(3E,4 are the coefficients of the polynomial defining Emax over 0, (3u,o-
(3U,4 are the coefficients ofthe polynomial defining U50 over 0, and (3""0-(3,,,,4 are the 
coefficients of the polynomial defining 'lj; over 0, as defined by Minto et al. [2000]. 
The values for these parameters are selected to create the general shape of the 
desired response surface, and depend on the relative PD effects of the drugs and 
whether the drug interaction is synergistic or antagonistic [Minto et al., 2000]. 
As per the initial model of Section 3.1, Equations (3.7)-(3.12) represent a 
model of the fundamental dynamics of the leU patient. The physiological model 
is more detailed in its representation of the PK and PD response of the patient. 
The model, and PD equation in particular, are also designed to be independent 
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of the nursing response and stimulus inputs. Hence, the models are capable of 
being patient specific but independent of these external inputs administered to 
the patient. 
3.3.1 Physiology 
This physiologically-based model in Equations (3.7)-(3.12) incorporates some of 
the major dynamics lacking in the initial model. The model is still intended to be 
the simplest necessary to capture the essential dynamics of the agitation-sedation 
system, matching patient observations and published literature with a physiologi-
cally representative model. Equations (3.7)-(3.8) represent the pharmacokinetics 
(PK) of the infusion and distribution of ::Vlorphine, and Equation (3.9) represents 
transport of Morphine to and from the effect site. Similarly, Equation (3.10) 
represents the PKs of the infusion and distribution of Midazolam, and Equation 
(3.11) represents transport of Midazolam to and from the effect site. 
Although the model compartments are hypothetical, the model is a repre-
sentation of the physiological system, as presented in Figure 3.4. The central 
compartment represents the infusion site and local blood vessels such as the 
heart and lungs. peripheral compartment can be thought of as the other 
peripheral parts of the body to which blood flows, such as the legs and arms. 
The effect site is that region in which the drug exerts its primary effect, which 
can be considered to be the CSF, or the brain. Finally, the delay induced by 
can be thought of as crossing of the blood brain barrier, or uptake by receptors 
in the brain. 
The non-linear PD Equation (3.12) is based on physiological observations 
of patient behaviour, and simply states that the rate of change of agitation 
pends upon the relative magnitude of the stimulus to the cumulative sedative 
effect and EAR. Stimulus in this context refers to the combined effect of inherent 
pain, distress, or loss of inhibition caused by the diseased/injured state of the pa-
tient, and the therapeutic and diagnostic procedures performed by medical staff. 
Observed agitation typically falls upon increased infusion of sedative un-
der (apparently) constant stimulus. Similarly, patients become more agitated by 
increased stimulus if infusion rates are not increased. Patient agitation is there-
fore primarily reduced by the cumulative impact of current and prior sedation 
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Figure 3.4 Schematic outlining the physiological representation of the hypothetical compart-
ments. 
administration, as modelled by the convolution integl;al in Equation (3.12). 
The major development from the initial model is that the combined PD 
effect of the drugs is captured in Equation (3.12) using a response surface for 
drug interactions [Minto et al., 2000]. This surface incorporates synergism and 
effect saturation in its shape, as shown in Figure 3.3. Hence, where the initial 
model was linear in its drug effect at all levels, this model allows more realistic, 
saturable behaviours. The ability of this model to capture saturation is essential 
for capturing over-sedation. 
3.3.1.1 Pharmacokinetic (PK) Modelling 
The PK compartments in this model, shown in the upper portion Figure 3.3, 
are hypothetical, but can be thought of as different regions of the body. The 
central compartment represents the infusion site and local blood such as 
the heart and lungs. The peripheral compartment can be thought of as the other 
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peripheral parts of the body to which blood flows, such as the legs and arms, 
and incorporating the fatty tissues into which these drugs and/or metabolites 
can be deposited. The effect site is that region in which the drug exerts its 
primary effect. For drugs affecting the central nervous system, such as Morphine 
and Midazolam, an acceptable representation of the effect site can be considered 
to be the CSF [Meineke et al., 2002; Cousins and Mather, 1984]' or the brain 
[Anderson and Kenny, 2003; Bates et al., 2004]. 
Clinical trials investigating the PK of Morphine show that concentration pro-
files in healthy and ICU subjects are best approximated by a 3-compartment 
model [Meineke et al., 2002; Latsch et al., 2002]. These studies attempt to model 
the PK of IV Morphine incorporating the effect of metabolites such as M3G and 
M6G by employing additional compartments. However, the analgesic and seda-
tive effects of these metabolites are not easily quantified and the details of their 
pharmacological effect are not yet fully understood [Anderson and Kenny, 2003; 
Faura et al., 1998; Milne et al., 1996]. Further, metabolite concentrations have 
been shown to be small when administration techniques bypassing the first-pass 
effect are used, such as IV administration [Faura et al., 1998]. Therefore, the 
model employed in this research uses three compartments for Morphine kinetics, 
as shown in the upper portion of Figure 3.3. In addition, it does not attempt to 
model the formation, distribution or secondary effects of Morphine metabolites. 
Clinical trials investigating the PK of IV Midazolam show that concentration 
profiles in healthy and ICU subjects are best approximated by a 2-compartment 
model [Platten et al., 1998; Persson et al., 1987; Bolon et al., 2003]. While the 
activity of the major metabolite of Midazolam, a-OH Midazolam, has been the 
subject of much research, its activity has not yet been fully defined [Burns et al., 
1992; Shafer, 1998; Tuk et al., 1999]. Therefore, the model employed in this 
research uses two compartments, as shown in Figure 3.3, and does not model the 
formation, distribution or secondary effects of metabolites for Midazolam. 
3.3.1.2 Pharmacodynamic (PD) Modelling 
Many pharmacological models exist for the individual delivery of Morphine or 
Midazolam. However, in this application Morphine and Midazolam are admin-
istered concomitantly. This model therefore utilises separate compartmental PK 
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equations for each drug, so the combined drug infusion rate results in individual 
effect site concentrations, In addition, this research seeks to capture their impact 
on agitation, not sedation, which is the focus of all prior PD studies, Hence, it 
is important to capture the appropriate effect site concentrations. 
Midazolam is a commonly used sedative agent that can be used to induce 
anaesthesia or induce sedation, depending on dose [Persson et aL, 1987; Young 
et al., 2000]. Morphine, while primarily an analgesic, is also a mild sedative 
[Barr and Donner, 1995; Levine, 1994]. However, Morphine and Midazolam, 
when administered concomitantly act in a synergistic manner to have an overall 
combined effect greater than the simple sum of the two individual effects [Wagner 
and O'Hara, 1997; De et aL, 2003; Kress et aL, 2002], Furthermore, the 
effects of Morphine and Midazolam are typically not linearly proportional to drug 
concentrations, and instead behave like the well-known sigmoid concentration-
effect relationship [Minto et al., 2000; Romberg et al., 2004; Koopmans et al., 
1988]. 
A mathematical representation of the combined PD effect of these drugs is 
created using a response surface for drug interactions [Minto et al., 2000]' incor-
porating synergism and effect saturation, as shown in Figure 3.3. The sedative 
effect on the vertical lowers awareness, relieving anxiety and reducing agita-
tion. Finally, Equation (3,12) captures the cumulative sedative effect of the drugs 
on the brain over and provides the relationship between stimulus invoking 
agitation and the sedative agents employed to manage agitation. 
The non-linear PD Equation (3,12) is based on physiological observations of 
patient behaviour. It states that the rate of change of agitation depends upon the 
relative magnitude of the stimulus to the cumulative sedative effect and EAR. Ob-
served agitation typically falls upon increased infusion of sedative agents, under 
constant stimulus. Similarly, patients become more agitated by increased 
ulus if infusion rates are not increased, Patient agitation is therefore primarily 
reduced by the cumulative impact of current and prior sedation administration, 
as modelled by the convolution integral in Equation (3,12). 
Note that these PD effects are limited by the response surface, Ecombl defined 
in Equation (3.14), at very high and very low concentrations. In between such 
levels the model behaves somewhat linearly. The major difference is that the 
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initial model treats the drugs as a single drug, whereas this model treats the 
drugs separately for PK modelling, and combines them using the PD response 
surface in Figure 3.3. 
The final term in Equation (3.12) represents the effect of the endogenous 
opioid biochemical compounds endorphins. Abbreviated from "endogenous Mor-
phine", endorphins are a form of natural analgesic produced is response to pain 
and physical stress [Kreek, 2002; Guyton and Hall, 1996]. An agitated patient 
may therefore experience a reduction in agitation due to the natural sedative 
effect of endorphins produced as result of agitation itself, modelled by the EAR 
term, -W3A, in Equation (3.12). This term is not present in the initial model, 
and is a further example of additional dynamics added to make the model more 
physiologically representative. 
This physiologically representative model has the capacity to model many 
dynamics existing in the agitation-sedation system such &'3 saturation, syner-
gism, concomitant administration, and endogenous agitation reduction. However, 
in general terms the model, or portions of it, creates a platform for modelling 
the general effects of concomitant administration of combinations of a variety of 
drugs. In particular, the model may be used to model the of different seda-
tives and analgesics in the ICU. Different drug interactions, such as antagonism 
and simple addition, may be modelled through different definitions of the shape 
of the response surface. Different drug profiles can be implemented by changing 
the drug transfer parameters K ij , and varying numbers of compartments can be 
used to model different drug types. In this thesis, however, the model will be 
applied only to the concomitant administration of Morphine and Midazolam to 
ICU patients. 
3.4 Model Summary 
The initial model and the Predator-Prey model represent two approaches to cap-
ture the same observed fundamental dynamics, and are later used to analyse the 
appropriateness of the initial models drug/stimulus balance equation. "While the 
initial model employs a simple drug effect as the agitation reduction mechanism, 
the predator-prey model employs a well-known and non-linear species-competitive 
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mechanism of agitation reduction. Both models are assumed to capture the fun-
damental dynamics of the agitation-sedation system and will be employed later 
for further analysis. 
This physiologically-based model builds on the initial model by incorporating 
some of the major dynamics not present in the initial model. The two major 
developments from the initial model are the EAR dynamic and the combined PD 
effect of the drugs captured in the response surface [Minto et al., 2000]. This 
surface incorporates synergism and effect saturation in its shape, as shown in 
Figure 3.3. Hence, where the initial model was linear in its drug effect at all 
levels, this model allows more realistic, saturable behaviours. The ability of this 
model to capture saturation is essential for capturing over-sedation. 
Part II 
Model Evaluation and System 
Identification 
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Chapter 4 
Recorded Data and Model Evaluation Technique 
To verify the models presented in Chapter 3, three ingredients are required: 
CD Recorded patient infusion data 
CD A model of the fundamental clinical sedation management response to ag-
itation 
CD A robust simulation platform 
These elements enable modelled inputs and outputs to be compared to recorded 
data. From this comparison a variety of graphical, numerical and statistical 
conclusions can be drawn. 
4.1 Recorded Data and Patient Cohort 
The Christchurch Hospital lCU employs a semi-automatic sedative and anal-
gesic adminstration protocol designed to minimise over-sedation. The protocol, 
administered electronically, delivers a fixed ratio Morphine (lmg/mL) and Mida-
zolam (0.5mg/mL) solution based upon bedside medical staff (subjective) assess-
ment of patient agitation. The fixed ratio sedative/analgesic solution is delivered 
intravenously using Graseby 3500 electronic infusion pumps (Graseby Medical 
Limited, Herts, U.K.). 
The device, known as the InfuseRite infusion system, facilitates the simple 
administration of Morphine and Midazolam. It also records all infusion data 
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[Greenfield et aL, 2001]. Figure 4.1 displays the current sedation administration 
situation in the Christchurch ICU. Note that InfuseRite is the new element 
in an otherwise typical sedation management situation, as seen by the difference 
between Figure 2.1 and Figure 4.1. 
Bedside Staff 
Device 
..... ~ 
: ... 
~. ...+ 
Figure 4.1 Schematic of the infusion protocol employed in the Christchurch ICU. 
semi-automated infusion protocol employed in the ICU at Christchurch 
Hospital utilises bedside nursing staff as a form of patient agitation sensor and 
feedback controller. Under this system, bedside medical staff observe the patient 
and deliver a fixed-dose bolus infusion in response to observed agitation, by press-
the 'bolus' button on the InfuseRite interface. An Infinite Impulse Response 
(lIR) filter [Rorabaugh, 1998] is employed to ensure the sedation infusion rate is 
minimised in the absence of agitation and reduce variability due to errors and 
inconsistencies in subjective clinical assessment of agitation. The lIR filter is 
defined: 
n-l 
DC(mt(n) ~ I: [Dcont(i) + DBolus(i)] 
i=n-4 
(4.1) 
where DCont(i) and DBolus(i) represent the dose of drug (mg) delivered per hour 
through continuous and bolus infusion respectively in the ith hour. The amount 
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delivered via continuous infusion, DCont(i), is the ongoing constant level of input. 
The amount delivered via bolus infusion, DBo!us(i), is the amount given beyond 
this input in response to observed patient agitation. Safety limits, determined by 
patient age and condition, are also placed on the range of allowable drug delivery 
rates, and the infusion rate is updated hourly. 
Equation (4.1) represents a low-pass filter and titrates sedation to the min-
imum required, thereby minimising over-sedation and reducing vulnerability to 
assessment variability and error response. If more than one-third of the hourly 
total is given as bolus, indicative of significant agitation, the amount delivered 
via continuous infusion, DContJ rises. Less, and the amount falls. Note that 
one-third limit is arbitrary and based on clinical experience [Shaw et al., 2003a]. 
It is important to know that with this definition oscillations below 1-2 times per 
day have a gain than OdB, increasing the mean infusion rate and reflecting 
a potential instability. 
Importantly, the protocol is effectively a closed-loop feedback controller, where 
nursing staff close the loop by providing agitation sensing and feedback via the 
electronic infusion controller, as shown in Figure 4.1. Staff assess the agitation 
levels using the modified Riker SAS in Table 2.2, and respond to agitation with 
additional bolus sedation. Boluses are provided in response to agitation and lead 
to modifications of the continuous infusion rate via Equation (4.1). The infusion 
rate is therefore representative of efforts to control agitation, and is not influenced 
by any efforts to induce sedation, which is in a minimal amount 
of the total sedation administered and required [Fraser and Riker, 200la]. 
Examples of sedation administration profiles in critically ill patients for whom 
the nurse control protocol has been employed are presented in Figure 4.2. Solid 
dark areas in Figure 4.2 represent bolus drug delivery, and lighter filled areas 
represent the resulting continuous infusion rate. Note that the continuous in-
fusion rate increases after large volumes of bolus delivery, and declines rapidly 
in the absence of boluses to minimise over-sedation due to unnecessary sedation 
administration. 
The presence of sudden spikes and apparent over-shoots are likely a result of 
the variability and subjectivity of nursing staff assessment of agitation [Agogue, 
2005]. Figure 4.2 shows that the infusion rate varies considerably for each of the 
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four patients. Further, it can be seen that boluses tend to occur in regular clusters. 
In this control system, intensive care staff respond to heightened or depressed 
levels of agitation with increased or reduced volumes of boluses respectively. 
-5lli ~U :5 4 ~ L~ ~~~~ 
o 50 100 150 200 250 300 350 
~ 10 
§15~ ~Time(HOUrs) 
J:~~ 
o 50 100 150 200 250 
_B 
:5 
~6 
~ 
~ 4 
Time (Hours) 
c -
o -
~ 2 __ _ __ ~ _ , _~_ _ -~~- __ 
EO· 
o 20 40 60 BO 100 120 140 
Time (Hours) 
~B~ -6 ~ 4 ~ . _ -= -_~ :~. 12 
-oo-.. LU----~ .. ~5~0~~BU~~BU1~00~LA~~~BU1W50KWBU~BU----~20~0--UBWL~ 
Time (Hours) 
Figure 4.2 Examples of sedative administration profiles recorded using the InfuseRite infu-
sion device. 
In addition to the standard boluses and continuous infusion delivered to the 
patients, independent procedural boluses are given to patients in anticipation 
of painful or uncomfortable procedures. Examples of typical procedures include 
bathing, turning, or changing the patient, inserting new feed or arterial lines, 
applying new dressings, suctioning, and diagnostic procedures such as x-rays, 
MRIs, and cognitive testing. The procedural boluses are intended to be delivered 
entirely independent of the standard boluses and continuous infusion, and are 
designed to be given in preparation for a painful or uncomfortable procedure. 
Procedural boluses are delivered approximately 10-30 minutes prior to the pro-
cedure, typically last for 10-30 minutes, and are electronically recorded by the 
infusion device [Shaw et al., 2003bj. 
Sedative drug infusion data was recorded using the InfuseRite infusion de-
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vice [Greenfield et al., 2001; Shaw et al., 2003a; Rudge et aL, 2003a; Shaw et al., 
2003b] for all ICU patients admitted to the ICU during a nine month observation 
period and requiring more than 24hrs of sedation. Over this period, infusion 
data equivalent to 377 days of continuous data was recorded from a total of 114 
patients. Infusion data containing less than 48hrs of continuous data, or data 
from patients with severe brain injuries, trauma or excessive sedation require-
ments were excluded from further analysis. The remaining patient cohort after 
exclusions therefore consists of 37 ICU patients. The results in this thesis, unless 
otherwise stated, are for this cohort of 37 ICU patients. Approval was obtained 
from the Canterbury Ethics Committee for this research. 
4.2 Nurse Control Model Capturing the Clinical 
Response 
Bedside intensive care staff rely on monitored autonomous parameters (e.g. blood 
pressure, heart rate etc) and physical indicators (e.g. sweat, rapid motion etc) 
to subjectively gauge agitation levels [Riker et al., 1999; Kress et aL, 2000; Co-
hen, 2002]. Many primary indicators of agitation are qualitative in nature, and 
sometimes contradictory, and therefore difficult to assess consistently over time 
and between assessors [Lam, 2003; Starfinger, 2003; Agogue, 2005]. 
As early as 1959 Helson showed perception to be relative to the mean or 
"adaptation level" in the whole environment [Helson, 1959]. The perception of 
many properties objects such as weight, colour and odour, accordingly, become 
subjective [Helson, 1959; Wallach, 1963; Pol et al., 1998]. For example, the evalu-
ation of pain level varies as a function of past pain levels experienced [Dar et al., 
1995]. This subjective adaptation level will lead to small changes in odour, colour, 
weight or pain having little impact on subjective experiences. Minor changes in 
agitation over long periods of time are therefore often overlooked, while more 
rapid changes, or derivatives, are more readily assessed. More specifically, the 
primary changes noticed are relative changes rather than absolute magnitudes. 
This form of observational sensing and feedback can be modelled as a propor-
tional-derivative feedback controller. Hence, the fundamental sedation manage-
ment response of bedside medical staff in the control loop of Figure 4.1 can 
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be simply modelled as a proportional-derivative controller with agitation as the 
feedback quantity. The output, U, can then be combined with the IIR filter in 
Equation (4.1). The infusion rate, U, in the form of a proportional-derivative 
controller using agitation, A, as the feedback quantity can be defined: 
(4.2) 
where U is the feedback-controlled infusion rate, A is the agitation level, A is the 
rate of change of agitation, and Kp and Kd are the proportional and derivative 
gains, respectively. the relative values of these gains are left to be identified via 
recorded infusion data. 
The feedback-controlled infusion, U, in Equation (4.2) represents the nursing 
response to agitation, and is updated once each hour, as per clinical practice in 
the Christchurch lCU, creating a piecewise constant infusion. The infusion rate, 
U, is then put through the filter in Equation (4.1) via DBolus(i), implementing 
the filtered protocol used in Christchurch Hospital to minimise over-sedation. 
The simulated nursing sedative administration input, U, with the IIR filter, is 
substituted into Equation (3.1) or Equations (3.7) and (3.10) to model the feed-
back loop created by their response to subjectively assessed patient agitation for 
model evaluation. Note that negative infusion rates are not allowed. 
4.3 Stimulus Input Generation 
The unknown nature of pain and anxiety, combined with disease state and painful 
diagnostic procedures makes the direct recording of stimulus profiles impossible. 
A surrogate is therefore required for simulations using Equations (3.1)-(3.3) and 
(3.7)-(3.12). The stimulus, S, invoking agitation in Equations (3.3) and (3.12) is 
an important term in the agitation-sedation system. As mentioned in Sections 3.1 
and 3.3.1, stimulus in this context refers to the combined effect of inherent pain, 
distress, or loss of inhibition caused by the diseased/injured state of the patient, 
and the therapeutic and diagnostic procedures performed by medical staff. 
The semi-automated sedation infusion system implemented in the lCU, and 
described in Section 4.1 has as its input the bedside medical staff's indications 
of observed agitation, via the demand for additional bolus sedation. These bolus 
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Figure 4.3 Example of the bolus and stimulus profiles for Patient 3. 
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recordings indicate periods where the patient's agitation levels increased enough 
to warrant additional sedative, implying the presence of stimulus. This bolus 
recording thus forms the basis for a surrogate measure of stimulus for the purpose 
of fundamental dynamic model evaluation. Obtaining the 4-hour moving average 
of this record retains the underlying structure of the recording, while creating a 
smooth stimulus profile with minimal subjective noise. All simulations in this 
thesis employ the 4-hour moving average of the recorded bolus profile as the 
stimulus profile. Figures 4.3-4.4 show examples of the recorded bolus profile, 
and resulting stimulus profile for Patients 3 and 37. 
Note that clinical implementation of agitation feedback control of sedation 
would not require this input profile, requiring only measured agitation to deter-
mine the infusion needed. Hence, this surrogate is used only for evaluation of the 
fundamental dynamics. While this approach is less than perfect, it is one of the 
best options available. 
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Figure 4.4 Example of the bolus and stimulus profiles for Patient 37. 
4.4 Model Simulation Methods 
Combining Equations (3.1)-(3.3), (3.4)-(3.6), or (3.7)-(3.12) with the nurse con-
trol model in Equation (4.2) creates a system for simulating the patient dynamics 
and nursing staff response, respectively. Figure 4.5 presents the block diagram in 
which the nursing response control model and the InfuseRite IIR filter close the 
loop by providing feedback control of sedation using agitation as the feedback 
quantity. 
Sedative drug infusion data, recorded through the electronic infusion system, 
provides a basis for comparison and model evaluation. Using the stimulus pro-
files developed in Section 4.3, a simulation is conducted for each patient using an 
identical procedure for all patients. Although quantitative agitation sensors are 
under development, they are not currently available. This limits the data avail-
able for model evaluation, and necessitates the use of these alternative methods. 
Numerical and graphical approaches are used to provide statistical measures of 
tracking to assess the model's ability to capture the fundamental dynamics of the 
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The systems of equations presented in Sections 3.1 and 3.3 represent differ-
ential equations that can be solved using an ODE solver. These equations are 
implemented and solved in MATLAB using f::,t = 1min. This implementation 
creates the platform for analysis of the physiological system, and is final 
ingredient required for model evaluation. 

Chapter 5 
Model Evaluation Metrics 
Quantitative research and problem-solving in any field of study invariably proceed 
with the aid of mathematical models. An important aspect of model development 
for practical applications is validating the proposed model against empirical data. 
A good model is usually the result of an arduous, iterative process involving 
incremental steps of improvement and refinement, guided by empirical data via 
goodness-of-fit diagnostics. Such diagnostic tools constitute an essential part 
of the model development process and good tools can go a long way toward 
shortening the process or improving the quality of the resulting model. 
Using the model equations in Sections 3.1 and 3.3 with the method described 
in Section 4.4 results in simulated total infusion profiles, generated from the 
nurse-control feedback model and IIR filter. These are compared to the recorded 
total infusion profiles. For each of the 37 patients, a comparison between the 
simulated and recorded infusion profile provides an indication of the model's 
ability to capture the fundamental observed dynamics. 
Overlaying the simulated and recorded infusion profiles allows a simple visual 
comparison between simulated and recorded infusion data. However, objective 
comparison methods are required for more rigorous model evaluation. To objec-
tively assess how well Equations (3.1)-(3.3) and (3.7)-(3.12) model the agitation-
sedation system, two general methods of comparing the recorded and simulated 
infusion profiles are utilised: a graphical approach and a numerical approach. 
Both methods, based on accepted statistical analyses, are developed to provide 
an objective, quantified understanding of the model's ability to capture essential 
dynamics present in the recorded infusion data. These approaches also examine 
both the local and global measures of model validity. 
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The approach to model assessment has two parts: 
Graphical Approach Use of local linear kernel regression and Chebyshev's in-
equality to construct a non-parametric probability band for qualitative vi-
sual assessment. This band can also be used to quantify the time in band. 
Numerical Approach Use of local linear kernel regression and weighted kernel 
density estimation to construct a density profile that provides quantitative 
statistical measures of compatibility between model output and empirical 
data. This approach more rigorously quantifies the likelihood of the model 
dynamics being the same as those observed clinically. 
The non-parametric character of the overall approach avoids making unnec-
essary simplifying assumptions about the data. In many applications, including 
the one in this research, it can be difficult to impose a parametric model on the 
data, or perhaps even undesirable to do so. Equally importantly, it overcomes the 
difficulty of comparing the outputs of a continuous model with discrete recorded 
data. 
5.1 Model Evaluation Metrics 
A simple indication of the similarity between the recorded and simulated infusion 
profiles is the total drug dose delivered. If two infusion profiles are similar, then 
the total drug dose is also similar. Therefore, the total drug dose of the simulated 
infusion profile, relative to the recorded total drug dose, represents the Relative 
Total Dose (RTD). 
RT D = Total Simulated Dose 
Total Recorded Dose 
(5.1) 
RTD is clearly a useful, but not sufficient, measure of similarity between the 
simulated and recorded profiles. For instance, a simulated infusion equal to a 
constant infusion at the rate equal to the average recorded infusion rate would 
result in a RTD=1.0, yet is not a good fit with the recorded data. However, it is 
a good overall measure of global matching of the model and recorded data. 
5.2 PROBABILITY BAND FORMULATION 55 
Deterministic dynamic models represented by differential equations are very 
popular in many areas of research for modelling all kinds of phenomena that vary 
over time or space. Empirical data for model evaluation, on the other hand, are 
almost inevitably discrete measurements of some kind, hence imperfect and noise-
corrupted. The goal is to develop a way to assess the models against empirical 
data, without introducing yet another (parametric) model for the data, so as to 
avoid imposing an inadequate model onto the data. One way to proceed is to 
consider non-parametric regression of the recorded data. 
Non-parametric regression has been suggested for assessing a parametric sta-
tistical model by constructing a confidence band for the proposed model and 
then checking whether the non-parametric regression curve lies within the band 
[Azzalini et al., 1989]. For instance, a confidence band may be created for a statis-
tical model of population growth or financial market fluctuations. The regression 
curve from the measured data can then be overlaid to see whether it falls within 
the confidence band. 
However, in the case of a deterministic model, there is no confidence band. 
Hence a reversal of roles is suggested - construct a probability band for the non-
parametric regression curve and check whether the proposed model lies within 
the band. This novel approach extends the utility of non-parametric regression 
for model assessment to deterministic models. 
5.2 Probability Band Formulation 
A graphical method of identifying instances in time where the model and nurse-
controller are less than adequate serves to identify regions of differing performance 
within a patient's simulated profile. The development of a probability band 
for the recorded infusion profile [Lee et al., 2005, 2003; Rudge et al., 2005b] 
enables a visual assessment of the performance of the simulation. The band is 
constructed using Chebychev's inequality, and represents the target region of the 
simulated infusion controller. A simulated infusion profile that lies entirely within 
the probability band represents good performance, while regular departures from 
the band illustrate where the model does not effectively capture behaviour. 
Let U1 , U2 , ... , Un be the observed time series of the infusion rate over the 
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time interval (0, T). Assuming the signal includes noise due to error in subjective 
assessment or response results in the following additive noise model: 
(5.2) 
where /-Lt is the underlying mean infusion rate and c is a zero-mean noise pro-
cess. For t E T, we wish to estimate /-Lt from the recorded data using local 
linear kernel regression with a compact kernel. Centering the kernel at t, let 
U[t-m], U[t-m+l] , U[t-m+2], ... , U[t+m-2], U[t+m-l], U[t+m] be the observations that are 
within the support of the (2m + 1) long kernel. 
An estimate of /-Lt, the regression function, obtained using local linear ker-
nel regression with a compactly supported kernel with bandwidth m, can be 
expressed in the form of a weighted average as [Wand and Jones, 1995]: 
m 
{it = L Wt,iUt+i (5.3) 
i=-rn 
where Wt,i are the normalised effective kernel weights such that, for each t 
m 
L Wt,i = 1 (5.4) 
i=-m 
and Wt,i = 0 if t + i < 1 or t + i > n. Note that Equations (5.3)-(5.4) are 
effectively a finite impulse response filter (FIR) reducing higher frequency content 
depending on the weights, Wt,i' The estimated regression function, (it, therefore 
forms a smoothed profile of the recorded data, representing the underlying mean 
recorded infusion rate. 
The recorded infusion data, U 1 , U2, ... , Un, are smoothed using local linear 
kernel regression with the Epanechnikov kernel, according to Equation (5.3), to 
give smoothed infusion rates, [ll:n. The Wi(t) values for the kernel regression are 
evaluated using: 
(5.5) 
where t[i] is the time index corresponding to U[i], kh (t[i] - t) is the kernel function 
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centered about point t with bandwidth h, and sr(t; h) is defined: 
m 
Sr(t; h) = L (tli] - ttkh(t[i] - t) (5.6) 
i=-m 
In this application the Epanechnikov kernel used is defined in Wand and 
Jones [1995]: 
k(t)={ 0.75(1-t2) if-1<t<1 
o otherwise 
(5.7) 
This kernel is selected because it has compact support, meaning that it has a finite 
number of points within its support, and enjoys certain asymptotic optimality 
properties [HardIe, 1990; Wand and Jones, 1995], which give it a theoretical 
edge over other kernel shapes. The amount of smoothing is controlled by the 
bandwidth of the kernel. The kernel including bandwidth h is defined by 
(5.8) 
Kernel smoothing refers to a general methodology for recovery of the under-
lying structure in data sets. Kernel smoothing offers a means of estimating the 
underlying function without the need to specify a parametric model, and has the 
advantage of mathematical and intuitive simplicity. This application of kernel 
smoothing utilises local linear kernel regression with a compactly supported ker-
nel. Local linear kernel regression is chosen for its balanced combination of good 
practical performance and theoretical properties. A compact, or finite, kernel is 
used to simplify computations and to facilitate the construction of probability 
bands for the smoothed estimates. 
Bandwidth selection is extremely important. An excessively narrow band-
width results in an under-smoothed estimate that removes little of the random 
fluctuations from the underlying data structure. An over-sized bandwidth on the 
other hand results in an over-smoothed estimate that removes part of the under-
lying structure within the data set. From an engineering perspective, this process 
is effectively a filtering process to remove noise and recover the underlying sys-
tematic dynamics in the data. A suitable bandwidth is one in which the kernel 
estimate is not overly noisy, yet the essential structure of the underlying function 
has been recovered. The bandwidth is therefore potentially partly subjective in 
choice. 
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A variety of methods exist to select an appropriate bandwidth based upon 
the properties of the data set. However, for this application in which a fixed 
bandwidth is used to smooth the infusion profiles for a variety of time series with 
different total lengths, no obvious objective method of selecting the bandwidth 
presents itself. 
There are many situations where it is satisfactory to choose the bandwidth 
subjectively by eye, especially when the user has reason to believe that there 
is certain underlying structure in the data [Wand and Jones, 1995; Silverman, 
1986]. The process used in this research involves looking at several estimates 
over a range of bandwidths and selecting the estimate that recovers the essential 
structure of the underlying function by removing unwanted noise, without losing 
important features. In this application, a 4-hour bandwidth was found to achieve 
these objectives. Moreover, it matches the rv4-hour half-life of the and the 
4-hour window in the IIR filter in Equation (4.1). 
Let EX(Pt) and V ar(Pt) denote the expectation (mean) and variance, respec-
tively, of the regression function estimate Pt. For 0 < p < 1 and by Chebyshev's 
inequality, a probability equation can be written: 
var(pt)] 
1 ~p 
-p 
(5.9) 
Thus, if Ex(Pd and Var(Pt) can be estimated, a 100p% probability band for Pt 
is defined: 
(5.10) 
:\10reover, since Chebyshev's inequality holds regardless of the underlying distri-
bution of (h:n, Equation (5.10) is a non-parametric probability band for the mean 
recorded infusion rate. 
The proof in Appendix A shows that EX(Jlt ) and Var(Pt) can be estimated 
as defined: 
m 
Ex(Pt) = L Wt,i/lt+i (5.11) 
i=-m 
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m m~l m~2 
Wt,iWt,i+l + 2a~ 2=: Wt,iW t,i+2 + ... 
i=~m i=-m i=-m 
(5.12) 
respectively, where a~ is defined: 
n~>' a~ = n ~ A 2=:(Uk iik)(Uk+>, flH>.) V A = 0,1, ... , 2m 
k=l 
(5.13) 
Note that the estimator for Ex(flt) in Equation (5.11) has the same form as 
the local linear kernel estimator for J-lt in Equation (5.3), except with smoothed 
values replacing recorded data values. Thus, the mean of the regression curve is 
estimated by the same local linear kernel regression on the regression curve itself. 
To summarise, a non-parametric probability band can be constructed using 
Equations (5.5)--(5.13). After determining fll:n through kernel smoothing, the 
means and variances of fll:n are computed using Equations (5.11) and (5.12). 
The probability band is then obtained using Equation (5.10). A 99% probability 
band constructed using this method implies that for at least 99% of the time, the 
estimated mean value of the recorded infusion rate lies within the band. 
Figure 5.1 contains three graphs showing the 99% probability bands for three 
patients. probability band is shown as the grey shaded region in each graph. 
Note that the bands widen automatically near the boundaries where the kernel 
is truncated and less data points are available to use. Each graph also contains 
the recorded infusion data (darker solid line). 
As a graphical assessment tool, the probability band is useful for model de-
velopment and refinement. In addition to providing an overall visual indication 
of model performance, it also draws attention to specific regions of good or poor 
performance, which is extremely useful for diagnosing model error. However, as 
yet, it does not provide a quantifiable metric. 
A useful numeric metric based upon the probability band is the amount of 
time that the simulated infusion profile lies within the band, relative to the total 
recorded time. This metric is denoted as the Time In Band (TIB): 
T I B = Time in Band 
Total Time of Series (5.14) 
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TIB quantifies a g10bal measure of model validity. However, the TIB does not 
provide any guidance locally as to where the model may not be valid, as the 
probability band does visually. Hence, numerically the TIB is a global evalu-
ation metric, while graphically the probability band is both a local and global 
evaluation metric. 
The probability band forms an excellent visual tool for testing and developing 
improved models. Inspection of a recorded profile and probability band Vlrith 
simulated infusion profile overlaid depicts, in a simple manner) the closeness of 
fit of the simulated and recorded profiles. Further, locations where the simulated 
profile departs from the probability band highlight instances where there is a poor 
fit. Globally, the TIB metric provides a numerical indication of the ability of the 
model to capture the dynamics present in the agitation-sedation system. Overall 
this information is extremely useful in identifying dynamics in the agitation-
sedation system that are not captured by the model, and provides an invaluable 
tool for model improvement. 
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5.3 RAND Metric for Model Evaluation 
The form of the mean estimator from Equation (5.3) is also used to define a 
weighted kernel density estimator that gives an estimate of the marginal density 
for each smoothed value. Taken together, the set of marginal densities defines 
a density profile from which numerical measures of compatibility between the 
proposed model and the empirical data can be defined and computed. Two such 
measures are presented in this section - average normalised density (AND) and 
relative average normalised density (RAND). 
Intuitively, the AND of the proposed model measures how close the simu-
lated output is to regions of high probability in the recorded infusion profile as 
determined by the recorded data. RAND calibrates the AND of the proposed 
model by the AND of the smoothed curve, allowing assessment of the closeness 
of the model relative to a typical realisation in the form of the smoothed curve. 
Plotting the density profile using constant density contours would also provide 
another visual assessment tool that could potentially be more informative than 
the original probability band. 
Let ftU},) be the marginal density of P at time t, which describes the density 
of the infusion rate at time t. Consider a weighted kernel estimator for ft(P), 
motivated by the form of Ex(Pt) in Equation (5.11), where each PHi is replaced 
by a normal kernel with variance s; and centered at PHi: 
m 
h(p) = L Wt,i¢(PIPHi, s;) (5.15) 
i=-m 
where ¢(·IJ.t, 0'2) denotes the normal density with mean J.t and variance 0'2. 
It is important to note that the estimated marginal density, h(p), should 
contain the same information expressed by the mean and variance, Ex(Pt) and 
V~r(Pt), in Equations (5.11) and (5.12). It is therefore important that the mean 
and variance of the marginal density are equivalent to the mean and variance, 
Ex(Pt) and V~r(Pt), in Equations (5.11) and (5.12). To ensure the estimated 
marginal density, h(p), has the same mean and variance as Ex(Pt) and V~r(Pt), 
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the following form of estimator is proposed: 
m 
h{p) = L Wt,d){Plati1Hi + (1 (5.16) 
i=-m 
Note that with at = 1, Equation (5.16) becomes Equation (5.15). More impor-
tantly, the presence of at gives added flexibility for matching the mean and 
variance to Ex{Pt) and Var(flt). 
There are two ways to see how at facilitates this matching. First, at may 
be thought of as a shrinkage factor on the locations of the normal kernels and a 
scale factor on their variance. More specifically, PHi is "shrunk" towards Ex(flt) 
when 0 < at < 1 and "stretched" away from Ex(Pt) when a> 1. Controlling the 
variance of a kernel density estimator by "shrinking" the kernel locations was first 
suggested by West [1993]. Here, the kernel locations may also be "stretched". 
Second, suppose that a random variable is generated from Equation (5.15), mul-
tiplied by at and then added to (1 ak)Ex(flt). The resulting random variable 
will have density it. 
It is shown in Appendix B at the end of this thesis that the following equalities 
are valid: 
(5.17) 
m 
Var{h) ailst + L Wt,iP;+i - EX{J'lt)2] (5.18) 
i=-m 
With the appropriate selection of at and St, Equation (5.18) yields: 
(5.19) 
Therefore, Equation (5.16) with the appropriate choice of at and St, represents 
an estimate of the marginal density of the estimated mean recorded infusion rate 
at time t, or Pt. 
It is observed that near a data boundary, where the regression kernel is trun-
cated, some of the effective kernel weights, Wt,i, can become negative [Wand and 
Jones, 1995]. These negative values can upset the definition of the weighted ker-
nel estimator in Equation (5.16). To remedy this problem, the following variables 
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can be defined: 
m 
(5.20) 
i=-'n" 
(5.21) 
so that 0 ::; Wt,i ::; 1 and 
m 
l...:: W;,i = 1 (5.22) 
i=-m 
Defining: 
(5.23) 
where sgn(x) denotes the sign of x, and using Wt,i = sgn(Wt,i) IWt,il and Equations 
(5.21) and (5.23) yields 
m m I I m 
'"""' * A * '"""' Wt,i ( ) A '"""' A ~ Wt,ilj,Hi = ~ --sgn Wt,i pt/-LHi = ~ Wt,i/-Lt+i 
i=-m i=-m Pt i=-m 
(5.24) 
h · h . 1 f ~m A d ~m * A* S owmg t e eqmva ence 0 ui=-m Wt,i/-LHi an ui=-m Wt,i/-LHi' Therefore, the 
modified weighted kernel estimator can be defined: 
m 
hUt) = l...:: w;'i¢(fi,IO:tfi,;+i + (1- O:t)Ex (fi,t) , o:;s;) (5.25) 
i=-m 
As a result, Jt(fi,) remains well-defined even when some of the effective kernel 
weights become negative. Moreover, Equation (5.25) is equivalent to Equation 
(5.16) when all of the effective kernel weights are non-negative. 
To summarise, the density profile is the collection of marginal densities com-
puted from Equation (5.25). It enables the definition of an objective, numerical 
measure of fit between the recorded and simulated infusion rates using the esti-
mated marginal density. These marginal densities can be thought of as the local 
density of the smoothed infusion profile at the point in time of interest. 
Let U1:n = {U1 , U2 , ... Un ,} be the sequence of output values produced by a 
proposed model. The average normalised density (AND) value for the data series 
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of UI :n is defined: 
(5.26) 
where AND(UI :n ) is an average of normalised densities, and each component in 
the sum is the value of it at Ut , normalised by the maximum value of!t. A 
normalised density value equals 1 when Ut occurs at a point where !t has a 
maximum value. Therefore, AND(UI :n ) equals 1 if and only if the simulated 
values coincide exactly with the maximum density at every time point. On the 
other hand, AND(UI :n ) approaches 0 if the simulated values are all far away from 
regions of high density. Hence it is a strict statistical representation of how well 
the model correlates globally, by examining the normalised density for each point 
in the data series. 
Clearly, the interpretation of the values AND(UI :n ) is easy for values near 0 or 
1, but less so for values in between. For example, how good is AND(U1:n ) = 0.7 
or how bad is AND(UI :n ) 0.2? To remedy this issue, a calibrated version of 
AND(UI:n) using {ll:n is defined: 
(5.27) 
Equation (5.27) defines RAND as the relative average normalised density (RAND) 
of (UI :n ). It tells us what A:'-JD(UI :n ) is, relative to a typical realization (in the 
form of {l1:n) from it. Intuitively, RAND=0.6 may be interpreted as being 60% 
similar (on average) to a typical realization from it, greater similarity 
means compatibility between the simulated values and the empirical ones. 
bottom panel in Figure 5.2 shows the marginal density estimate at t =55 
hours, for the density profile in the top panel. The simulated hourly infusion 
rates are indicated by the superimposed dots, and the dot on the x-axis indicates 
the value of the deterministic simulated infusion rate for t From this plot, it 
can be seen that for t =55, the value of the marginal density at the simulated in-
fusion rate is approximately 1.0 and the maximum density value is approximately 
2.5, giving a normalised density of approximately 0.4. 
The AND for the simulated infusion rates is the average of these normalised 
density values over all time points for a given patient. Similarly, the AND for the 
smoothed infusion rates is obtained by superimposing the smoothed values onto 
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Figure 5.2 Example of the density profile (upper portion) and the marginal density at time 
point 55 (lower portion). 
the same density profile, after which RAND can be computed. Recall that RAND 
measures how probabilistically similar the model outputs are to the smoothed 
data, and hence the of compatibility between the model and the recorded 
clinical data. RAND is a global measure of model performance as it does not 
indicate where (in time) any lack of compatibility may 
Since the models in Chapter 3 are deterministic, their outputs do not come 
from the same probabilistic mechanism that generated the data. As a result, 
RAND is an extremely stringent measure. Consequently, consistently high RAND 
values that are close to 1.0 are not expected, even for a good modeL A reasonable 
and practical threshold for adequate model performance is RAND> 0.5, which 
implies that the model outputs are more similar than not, to the smoothed data. 
If comparing two models then the higher valued model, assumed to be greater 
than 0.5 as well, would be selected. 
The statistical model evaluation metric, RAND, complements and completes 
the other statistical tools previously employed for model evaluation. The proba-
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bility band with hard boundaries developed previously allows visual assessment 
and numerical TIB evaluation, which is useful during model development and 
refinement. RAND provides an objective, calibrated measure of statistical com-
patibility between the simulated infusion profile and the recorded data. It thus 
provides a statistical measure of how well the model captures the essential dynam-
ics of the agitation-sedation system. Together, RAND, TIB and the RTD metrics 
presented in Sections (5.1)-(5.3) cover a range of model evaluation criteria. 
Chapter 6 
Model Evaluation: Initial Model 
This chapter presents the evaluation method, results and discussion for the initial 
model of Section 3.1. Section 6.1 outlines the procedure used in the simulations 
and presents the parameters employed in the model. Section 6.2 presents the 
results and discusses their implications with regard to model evaluation. The 
overall goal is to analyse the initial and predator-prey models and their parame-
ters. 
6.1 Model Evaluation Methods 
In this chapter, the initial and predator-prey basic model structures outlined in 
Chapter 3 are axiomatically assumed to be appropriate representations of ob-
served agitation-sedation dynamics. They are both used to evaluate the available 
data to provide additional insight in contrasting their results. Given their con-
trasting linear and non-linear pharmacodynamics the comparison also ensures 
that results of the linear model are not simply an artefact of loop gain, as dis-
cussed. This section introduces the known quantities and measurements for the 
initial and predator-prey models, and what variables yet remain to be identified. 
6.1.1 Elements for Model Analysis 
The information available to identify the system consists of two strings of recorded 
infusion data from 37 patients: 
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L Recorded infusion profiles consisting of standard boluses and continuous 
infusion related by the IIR filter of Equation (4.1). 
2. Procedural bolus data. 
The elements of the agitation-sedation system model that must be identified for 
patient specific simulation analysis are: 
L Stimulus profile, S(t), for input. 
2. PD model parameters (ratio WJ/W2) yielding W2 for a fixed WI)' 
3. Nurse control model parameters (Kp and Kd) for Equation (4.2), or specif-
ically their ratio for a fixed or calibrated Kp. 
Table 6.1 summarises this information. 
Table 6.1 Summary of information available and elements required for simulation 
Model Information Available Elements Required 
Initial Standard bolus data Stimulus 
Procedural bolus data PD parameters (WI and W2) 
Nurse control model (Kp and Kd) 
Predator-prey Standard bolus data Stimulus 
Procedural bolus data PD parameters (WI and W2) 
Nurse control model (Kp and Kd) 
Because only two independent strings of data are available for determining 
three elements of the system, a complete system identification is not possible using 
a single model without an added measurement, such as agitation, which does not 
fully exist yet [Agogue, 2005]. However using both the initial and predator-
prey models, a method is developed for independently determining the required 
elements of the system. 
The main idea of the construction is to show that for the given model struc-
ture, the agitation-sedation mechanism chosen is independent of the nurse model 
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and is fundamentally important for optimal model evaluation metrics. That is, a 
slightly inferior agitation mechanism cannot be compensated for by changing the 
nurse model parameters, and the nurse model is independent of the particular 
agitation mechanism chosen. The nurse model parameters can then be effectively 
separated from the agitation parameters. 
approach makes the agitation mechanism mathematically identifiable, 
as it consists of two unknown parameters Stimulus and PD parameters which 
can be identified from two pieces of recorded data: the standard bolus and in-
fusion data, and the procedural bolus data. The third unknown, parameters Kp 
and Kd , are accounted for and independently identified by requiring their invari-
ance with respect to two independent models containing two different agitation 
mechanisms. This invariance property across both models provides the third 
independent condition required to identify the three unknowns of stimulus, PD 
parameters and nurse model. 
Note that the initial and predator-prey models are expected to capture the 
same essential PK and PD of the patient, though one model may be slightly 
inferior to the other. Hence, the external stimulus, S, and nurse model gains, 
Kp and K d , must remain unaffected by the choice of model. Both models can 
therefore be expected to capture the patiynt dynamic the same stimulus 
input and nurse response model across both models. More specifiGally, given 
the same stimulus across both models, the identified nurse model gains over all 
patients and entire patient records should be the same for both models, and 
largely invariant between patients. Such a result would indicate that the nurse 
control model obtained is independent of the model and any linear loop gain. 
It is also important to note that if the identified nurse control model was 
different for each of the two patient models, it would indicate that the nurse gains 
are in fact model-dependant. A model-dependant nurse response would directly 
imply that one or both patient models did not accurately capture the dynamics 
in the data. Alternatively, it might equally well indicate an inaccurate model for 
nursing control response for that model, which implies a model-dependent nursing 
controller. Such a result would thus be a failure of the modelled patient dynamics 
to be independent of, and invariant to, the external stimulus and fundamental 
nursing agitation management response. This last case is not true clinically, 
where the patient experiences a stimulus and receives treatment independent of 
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how they might be modelled. 
Any model structure that fails to satisfy this requirement could not be con-
sidered adequate to model this system. Similarly, any model that did satisfy this 
requirement and showed improved performance in matching system responses 
would represent a superior model of the fundamental dynamics to those pre-
sented. 
The method is outlined as follows: 
• Assume the fundamental validity of the initial and predator-prey models as 
axIOms. 
• Generate the stimulus profile using the recorded standard bolus data as 
outlined in Section 4.3. 
CD Select basic PK parameters and KT for both models based on observed 
simulations and information from the literature. 
• Identify W2 for a fixed value of WI for both models using the procedural 
bolus data. Note that WI is fixed to calibrate agitation to a 0-100 scale. 
.. Identify the nurse control model gains i'ndependently for both the initial 
and predator-prey models using optimisation-based deconvolution across 
entire patient records. 
• Use the average nurse control gains across both models, if similar, to obtain 
a nurse control model that is independent of either model, yet fundamen-
tally valid for both. 
To summarize, in the method outlined the unknown elements, stimulus, S, 
PD parameters WdW2 and nurse model gains, Kp and K d, are identified using 
the recorded standard bolus and infusion data, the procedural bolus data, and 
the invariance condition of Kp and Kd with respect to the initial model and the 
predator-prey model. 
Importantly, if the initial model structure were a self-fulfilling prophesy, one 
should be able to get another model with a different agitation mechanism and 
tune the parameters to get precisely the same or a better match to the data. By 
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showing that another independent model with a different agitation mechanism 
gives statistically significant, inferior results after optimally tuning the parame-
ters, contradicts the self-fulfilling prophesy argument, and shows that the initial 
model structure, which provides the foundation for further improvements later in 
the thesis, is a real independent representation of agitation dynamics. 
Therefore until a superior model structure is found, which can be assessed 
using the mathematically well-defined method in this chapter, the essential model 
structure presented in this thesis will provide the foundation for future work in 
this area. Furthermore, the model structure will provide the basis for launching 
more clinical studies once further measuring systems like agitation are developed. 
6.1.2 Parameter Selection 
Although more advanced parameter selection methods are presented for the 
physiologically-based model in Chapter 8, many parameters for the initial model 
are manually selected based upon observed performance of the model in simula-
tions and information available in the literature. These parameters are selected 
to represent the long-term sedation dynamics in sedated ICU patients, and are 
more carefully evaluated for the physiological model in Chapter 7. Key compo-
nents of the model such as sedative sensitivity, W2, and the nurse model control 
gains, Kp and K d , are the subject of a more rigorous identification procedure 
outlined Sections 6.1.3 and 6.1.4. 
The value of KT is selected to give a drug effect decay rate approximately 
equivalent to the pharmacokinetic decay rates of Morphine and Midazolam. The 
relationship between half-life and rate constant KT can be defined by: 
(6.1) 
where t 1/ 2 is the desired half-life in minutes. Hence, KT requires a known t 1/ 2 
value. 
The PK half-life of Morphine and Midazolam in ICU patients is commonly 
accepted to be longer than that in healthy patients. The half-life of Midazolam 
is approximately 2-8 hours [Fragen, 1997; Driessen et aL, 1991; Malacrida et aL, 
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1992J, and can be as long as 13 hours [Fragen, 1997J. Similarly, the half-life for 
Morphine also lies in the range 2-8 hours [Bion et aL, 1986; Osborne et aL, 1993; 
Aitkenhead et al., 1984; Volles and McGory, 19991, and can be up to 10.5 hours 
[Bion et al., 1986J. For the initial and predator-prey models, a half-life of 7.5 
hours was chosen, corresponding to a KT value of 0.0015. This value is in the 
reported range, nearer some of the average reported values. Near the higher end 
of the range, it also helps account for potential drug accumulation in the system 
and delayed clearance, for example from fatty tissue [Wagner and O'Hara, 1997; 
Crippen, 1990; Hughes et aL, 1992; Arbour, 2000J. 
The remaining PK parameters are manually selected through observations of 
simulations and from data in the literature [Fragen, 1997; Driessen et al., 1991; 
Malacrida et al. , 1992; Bion et aL, 1986; Osborne et al., 1993; Aitkenhead et al., 
1984; Volles and McGory, 1999; Chase et al., 2004a]. Identical time-invariant 
parameters are used for all 37 patients, for both the initial and the predator-prey 
models, and are listed in Table 6.2. 
Table 6.2 Parameter values employed in the initial model 
Parameter Value Unit 
Kl 0.008 min 1 
K2 0.0046 min~l 
K3 0.005 min-1 
KT 0.0015 min- I 
R 1 mg/mL 
Vd 100 L 
6.1.3 Obtaining Sedative Sensitivity from Recorded Pro-
cedural Bolus Data 
The remaining parameters in the initial and predator-prey models, WI and W2, or 
more specifically their ratio for a fixed WI, are identified through observed sim-
ulation results and additional information contained in the recorded procedural 
bolus data described in Section 4.1. Selection of the values for parameters WI 
and W2 relies on two fundamental principles: 
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• The desired patient agitation is approximately 0-100, calibrating WI' 
Note that this range is in arbitrary units and 100 offers acceptable resolu-
tion . 
• Procedural boluses are delivered in advance of procedures with the intention 
to induce the same (mean agitation) state prior to, and in the long term 
steady state after, the procedure. 
The first principle determines the magnitude of 1111, while the second principle 
leads to the identification of the specific value of Wz. Having selected a value 
for WI, the sedative sensitivity, Wz, can then be identified, relative to that value, 
using the recorded procedural bolus data. In particular, the intent of the proce-
dural bolus combined with recorded dose of delivered procedural bolus provides 
a method of identifying sedative sensitivity, Wz. 
6.1.3.1 Selection of WI 
This section presents the method of identifying WI, for the initial and predator-
prey models, based on the principle tha~ the desired patient agitation range 
is 0-100. Observations of simulation results using the previously selected PK 
parameters and the recorded drug delivery rate show that WI ;::: 0.03 leads to 
agitation values commonly exceeding 100 for some patients, whereas WI ::;; 0.03 
leads to agitation values significantly lower than 100 for many patients. Therefore, 
as a compromise, patient agitation typically in the 0-100 is achieved using 
a value of WI 0.03. This value is used for both the initial and predator-prey 
models. 
6.1.3.2 Identification of Wz for the Initial Model 
This section presents the method for identifying sedative sensitivity, Wz, for the 
initial and predator-prey models. The approach is based on the principle that 
procedural boluses are delivered in advance of procedures to induce the same 
mean agitation state prior to the procedure and in the steady state (long term) 
after the procedure. More specifically, clinical instructions indicate that proce-
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dural boluses should be given 10~30 minutes prior to the procedure [Shawet al., 
2003bj. 
dA 
dt 
Integrating Equation (6.2) leads to: 
(6.2) 
(6.3) 
Assuming that patient agitation att2 = 00, a long time after the procedure, 
returns to the same level as at t1 0, prior to the procedure, leads to: 
(6.4) 
where t1 = 0 and A(t2) A(t1) A(o), which can be simplified to: 
(6.5) 
Equation (6.5) states that the weighted areas of the stimulus, S, !:l.nd net pharma-
cological drug effect, E, must be equal. This equation expresses mathematically 
the principle behind the procedural bolus as clinically defined. Solving Equation 
(6.5) for W2 gives: 
(6.6) 
In this case, Equation (6.6) is independent of the mean agitation. However, 
note that for a general agitation mechanism in which in Equation (6.2) is 
a function of agitation, like the predator-prey model, the analogous expression 
for Equation (6.6) will be dependent on the mean agitation, as will be shown in 
section 6.1.3.3. 
Assuming that a procedural bolus is delivered to a patient prior to a painful or 
uncomfortable procedure, it is possible to obtain the value on the right hand side 
of Equation (6.6). The recorded procedural bolus data provides the size of bolus 
delivered which, using the PK equations and previously selected parameters, leads 
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to E(t) and the evaluation of the denominator of Equation (6.6). Similarly, the 
numerator can be evaluated if the intensity and duration of the stimulus profile of 
the procedure is known. Therefore, the identification of sedative sensitivity, W2, 
uses the open-loop portion of the block diagram presented in Figure 4.5. Figure 
6.1 presents the open-loop block diagram for the method used to identify W2 using 
the procedural boluses. 
Sftmulus 
I: 
Patient Patient ~ Patient ~ Pharmacokinetics ~ Pharmacodynamics r---~ }-~-l Ag~ation Dynamics 
E, 
U, 
Procedural 
Bolus 
Drug Effect • 
r:,}---------
..................... A. 
Patient Agitation 
Figure 6.1 Block diagram for the identification of W2 using procedural bolus data. 
The intensity of the stimulus due to the procedure is assumed to be directly 
proportional to the dose of the stimulus in accordance with the stimulus genera-
tion method outlined in Section 4,3. Although the exact duration of the procedure 
is unknown, an estimate of 10-30 minutes is not unreasonable for the procedures 
outlined in Section 4.1. Therefore, by simulating the delivery of the procedural 
bolus and the presence of the stimulus during the painful procedure, all terms on 
the right hand side of Equation (6.6) can be evaluated. 
Figure 6.2 shows an example of a procedural bolus of size 0.8mL delivered 
at time t = 1 hour, followed by a painful/uncomfortable procedure 20 minutes 
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later, of duration 20 minutes. This was generated using Wz =0.4459. Note 
that although the procedural bolus causes an almost instantaneous rise in the 
drug concentration in compartment 1, the transport of the drug to compart-
ment 2 takes further time. Furthermore, while the stimulus, representing the 
painful/uncomfortable procedure, an immediate effect on patient agitation, 
the effect of the drugs is delayed and prolonged. This result occurs because the 
PK parameters in Section 6.1.2 were selected to represent the long-term sedation 
dynamics in sedated leU patients. Importantly, the agitation a long time after 
the procedure returns to the same value as that prior to the procedure, in ac-
cordance with method and principlc previously described. Although Figure 6.2 
shows the situation where agitation begins at zero, agitation still returns to the 
initial value even if a non-zero initial agitation value is used. Finally, note that it 
is assumed the nurse delivers the procedural bolus based on how much a patient 
should be sedated to negate the effect of the procedure. Thus, in simulations the 
procedural bolus and procedure are assumed to be separate from other stimuli 
and drugs, and the initial drug concentrations are set to zero. 
_ 0,8 
g 0,6 
.* OA jl 0.2 
!! 0.8 
"5 0.6 
,§ 0.4 
'" 0.2 
Time (Hours) 
Figure 6.2 Example of a procedural bolus of size 0.8mL delivered at time t = 1 hour, followed 
by a painful/uncomfortable procedure 20 minutes later, of duration 20 minutes. 
Note that identification of Wz using Equation (6.6) is essentially independent 
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of the order and separation between the procedural bolus and the painful pro-
cedure. This feature exists because the key aspect is that the areas under the 
stimulus and pharmacological drug effect profiles are equal, thereby ensuring that 
agitation is the same before and after. Using values of 10-30 minutes for stimulus 
duration in Equation (6.6) yields a range of W2 =0.23-0.67, and an average value 
of 20 minutes yields W2 -V.":l:CltVV. A value of W2 =0.4459 is therefore employed in 
the initial model across all patients. 
6.1.3.3 Identification of W2 for the Predator-Prey Model 
All the parameters previously identified are also applicable to the predator-prey 
model, with the exception of W2. The procedure for identifying W2 follows a 
similar methodology to section 6.1.3.2, but in this case the analogous form of 
Equation (6.6) for the predator-prey model cannot be written in closed form. 
However, the equation for W2 can be formulated implicitly and solved numerically. 
The final equation of the predator-prey model can be written: 
(6.7) 
where E KT J; G2(r)e- KT(t-r)dr. Equation (6.7) has the analytical solution: 
(6.8) 
where, J; E(r)dr,Ao = A(O). 
Assuming that the patient's agitation at t (Xl a long time after the proce-
dure, returns to the same level at t = 0, prior to the procedure, leads to: 
where Ao = Amean is the mean patient agitation. Assuming that the stimulus 
occurs 20 minutes after the bolus and has a duration of 20 minutes gives: 
s (t) S, 20 :::; t :::; 40 
0, otherwise (6.10) 
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Substituting Equation (6.10) into Equation (6.9) gives: 
(6.11) 
The solution to Equation (6.11) is defined: 
(6.12) 
where for a given stimulus magnitude, S, and mean agitation, Amean , F is eval-
uated by numerically solving Equation (6.11) for W2. Note that in this case the 
definition of W2 depends on the average agitation, thus unlike the initial model it 
may change significantly from patient to patient. Also, a degree of uncertainty or 
noise on the patient's average agitation should be accounted for, thus the formula 
for W2 is defined: 
W2,pred-prey F(S, Amean,pred-prey + <5Astd,pred-prey) (6.13) 
where Amean,pred-prey and Astd,pred-prey are the mean and standard deviation of 
the predator-prey model's simulated agitation and 1 ~ <5 ~ 1. 
The full rigorous implementation of requires that Equation (6.13) is coupled 
to the optimisation procedure for finding Kp 'and Kd described later in Section 
6.1.4. The goal can be achieved using the following procedure for each patient: 
1. Set i = a 
2. Choose <5i I + a.li 
3. Approximate Amean,pred-prey and Astd,pred-prey using Amean,initial and Asld,initial, 
which are the mean and standard deviation of the simulated agitation cal-
culated from the initial model. 
4. Calculate W2,pred-prey from Equation (6.13) 
5. Find Kp and Kd that give the best RAND for the patient 
6. Re-simulate predator-prey model and compute Amean,pred-prey and Astd,pred-prey 
7. Continue 
1%) 
( 4 )-( 6) until W2,pred-prey converges (changes by less than 
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8. The final value of W2,pred-prey satisfies Equation (6.13) 
9. Repeat steps (2)-(8) for i 1, ... ,20 and choose the 6i that gives the best 
RAND, therefore selecting the corresponding W2,pred-prey 
Although the above steps describe a general method that could be applied to 
any model, it was found that for simulations of the predator-prey model, steps 
(6)~(8) were not required, since convergence was achieved immediately. The 
reason for this is that the predator-prey model is itself a reasonable model for de-
scribing dynamics and as later sections show, gives results that are on average not 
too different from the initial modeL Thus, the following approximation to Equa-
tion (6.13) for the case of the predator-prey model was found to be sufficiently 
accurate: 
WZ,pred-prey = F(S, Amean,initial + 8Astd,initial) (6.14) 
However, note that for general models with a significantly poorer performance 
than the predator-prey and initial models this result may not hold. Thus, Equa-
tion (6.13) is a mathematically well-defined formula for Wz based on the recorded 
procedural bolus data. This definition can be applied to all potential models, 
and the definition of Wz is specific to each particular model and independent 
of all other models. In this case it is approximated by Equation 6.14 for the 
predator-prey model employed. 
This resulting calibration of Equation 6.14 effectively adjusts patient-specific 
sedative sensitivity, W2, in the predator-prey model to be essentially equivalent in 
the mid-range of the patient's agitation to the sedative sensitivity in the initial 
model, as might be expected. This is a reasonable approximation for the sedative 
sensitivity in the predator-prey model, and creates inherent equivalence between 
the initial and predator-prey models when patient agitation is close to the central 
value for each patient. 
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6.1.4 Identifying the Nurse Model 
6.1.4.1 Invariance Hypothesis 
Having selected the parameters for the initial model, the final component required 
for simulation is identification of the nurse control model parameters, Kp and 
K d , outlined in Section 4.2. However, as highlighted in Table 6.1 and section 
6.1.1, a third independent condition is required to identify the nurse control 
model. The nurse control Kp and Kd are identified in each of the initial 
and predator-prey models by requiring both high evaluation metrics and their 
invariance between the models with the same stimulus. This concept can be 
expressed in the general form: 
Invariance Hypothesis: Given two independent patient" models, axiomati-
cally assumed to capture the fundamental agitation-sedation dynamics, an inde-
pendent nurse control model will produce 'favourable' results in both models 
when implemented using an identical stimulus profile for both models. 
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Figure 6.3 Schematic of the invariance hypothesis. 
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This invariance condition ensures that the nurse control gains cannot be ad-
justed to make up for a potentially poor agitation model and provides the third 
property required to make the model mathematically identifiable. Applied to the 
current situation, the two models are the initial model and the predator-prey 
model of patient-specific agitation-sedation dynamics. Both models have similar 
mechanisms at central levels of agitation and drug effect. More importantly, both 
models have similar overall structure and are representative of typical methods 
of modelling PD effects for other therapeutics [Carson and Cobelli, 2001; Hann 
et al., 2005; Doran et al., 2004; Aitkenhead et al., 1984; Chase et al., 2004a; 
Hughes et al., 1992; Lee et al., 2003, 2005; Persson et al., 1987; Wagner and 
O'Hara, 1997]. 
Therefore, both models are assumed, axiomatically, capable of modelling the 
fundamental dynamics of the agitation-sedation system. However, the initial 
model is linear in agitation, A, whereas the predator-prey is clearly non-linear. 
Specifically, the models incorporate different mechanisms for reducing agitation 
and different assumptions of behaviour, particularly at the extremes of drug effect 
and/or agitation level. Therefore the two models are independent representations 
of the fundamental patient dynamics. 
The initial and predator-prey models ?-re expected to capture the same PK 
and PD of the patient. Hence, the external stimulus, S, and nurse model gains, 
Kp and Kd must remain unaffected by the choice of model. Both models should 
therefore be expected to capture the patient dynamics using the same stimulus 
input and nurse response model across both models. 
More specifically, given the same stimulus across both models, the identified 
nurse model gains over all patients and entire patient records should be the same 
for both models. They should also be largely invariant between patients. Such a 
result would indicate that the nurse control model is independent of the model 
any linear loop gain or other self-fulfilling argument. 
If the identified nurse control model were different for each patient model, 
it would indicate that the nurse gains are in fact model-dependant, implying 
that one or both patient models did not accurately capture the dynamics in the 
data. Alternatively, it might equally well indicate an inaccurate model for nursing 
control response for that model. The latter result implies a model-dependent 
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nursing controller, and thus a failure of the modelled patient to be independent 
of the fundamental nursing agitation management response. 
Any model structure that fails to satisfy this requirement could not be con-
sidered adequate to model this system. Similarly, any model that did satisfy this 
requirement and showed improved performance in matching system responses 
would represent a superior model of the fundamental dynamics to those pre-
sented, 
6.1.4.2 Method for Identification of the Nurse Model 
Identification of the nurse control parameters is achieved using optimisation-based 
deconvolution over entire patient records to achieve infusion profiles as close as 
possible to the average recorded infusion profiles, as indicated by the evaluation 
metrics TIB and RAND. In particular, a gradient descent search method, employ-
ing MATLAB's FMINSEARGH function, is used to optimise the nurse control 
gains for both models independently. 
The gains are optimised to provide a constant set of gains over the entire 
record, rather than obtaining gains that vary each hour as exact deconvolution 
would provide. Such time-varying gains would not be representative of the aver-
age nursing response seen in each record and across all records. More specifically, 
each patient is treated over their stay by several nurse from the 100 nurses in the 
Christchurch hospital. Hence, each record represents an overall average clinical 
central bahaviour. Extreme hour-to-hour variation obtained from exact decon-
volution would not accurately represent this situation. More importantly, it is 
important to discern whether this average response, while clinically accurate, can 
be effective for the two different axiomatically assumed model structures. 
Two primary evaluation metrics are used to identify the nurse proportional-
derivative control (PDC) gains for each model: 
,. Optimising the average RAND across all patients 
., Optimising the average TIB across all patients 
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The gains Equation (4.2) are optimised with no restriction placed on the 
possible gain values other than Kp 2:: 0 and Kd 2:: O. Optimising for each metric 
for each model over all patient records results in four sets of nurse control gains 
as given in Table 6.3. These gains are optimised over all 37 patients. 
Table 6.3 Optimised nurse control model gains 
Model Optimise RAND 
Initial K p=0.000326 
K d=0,423 
Gain Ratio=1297 
Median RAND=0.65 
Median TIB=0.79 
Predator-Prey K p=0,000413 
K d=0,409 
Gain Ratio=990 
Median RAND=0,51 
Median TIB=0.61 
Optimise TIB 
Kp=0.00033 
K d=0,425 
Gain Ratio=1287 
Median RAND=0.65 
Median TIB=0.79 
K p=0.000416 
Kd=0.388 
Gain Ratio=933 
Median RAND=0,48 
Median TIB=0.61 
Average Gains: [Kp K d]=[0.00037 0,41] 
The optimised gain values are largely similar in all four cases, with an aver-
age value of [Kp K d]=[0.00037 0.41], a Gain Ratio (~) of magnitude 1000 in p 
each case. These results indicate that a derivative-focused PDC nurse model is 
appropriate for both the initial and predator-prey models. The inherent nature 
of a derivative-focused PDC imitate the observational sensing and feedback per-
formed by bedside medical staff. Small changes over long periods (low derivative) 
have little effect on the control output, while large changes over shorter periods of 
time (large derivative) significantly affect the commanded sedation administra-
tion. Similarly, an absolute change in vital indications only invokes action once it 
reaches a threshold level. The nursing response equation is presented again here 
for clarity: 
(6.15) 
where U is the feedback-controlled infusion rate, A is the agitation level, A is the 
rate of change of agitation, and Kp and Kd are the proportional and derivative 
gains, respectively. 
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Table 6.3 also presents the median RAND and TIB values for of the 
optimised gain values for both models. The median RAND and TIB values for 
the initial model are 0.65 and 0.79 respectively for both optimisations. This 
indicates that optimising for TIB or RAND for the initial model makes very 
little difference in gain selection and evaluation metrics. The median RAND 
value for the predator-prey model is 0.51 and 0.48 for the RAND-optimised and 
TIB-optimised methods, and the median TIB is 0.61 for both optimisations. This 
indicates that optimising for TIB or RAND for the predator-prey model has only 
a small impact on gain selection and evaluation metrics. 
It is clear in Table 6.3 that while both models capture the fundamental dy-
namics of the agitation-sedation system, the predator-prey model does not cap-
ture the dynamics as well as the initial model. The initial model is therefore 
selected for further analysis of inter-patient variability in the nursing response 
gains. In particular, the gradient descent search method is used to select patient-
specific nurse gains, and observe the range and variability across the 37 patients. 
This scenario results in one specific PDC nurse model per patient record, re-
sulting in 37 distinct 'nurses'. Table 6.4 presents the statistical summary of the 
resulting patient-specific nurse gains. 
Table 6.4 Results summary for individual optimisation of nurse for the initial model 
RAND Optimised TIB Optimised 
Kp Kd Kp Kd 
Max 0.000400 0.475 0.000443 0.491 
UQ 0.000360 0.443 0.000354 0.441 
Mean 0.000328 0.427 0.000329 0.426 
LQ 0.000310 0.410 0.000300 0.415 
Min 0.000244 0.371 0.000243 0.331 
Table 6.4 shows that the variation of between patients of the optimal gains is 
small, and in all cases the Gain Ratio has a value in the order of 1000. Further, 
the average nurse control gains obtained by optimising for each patient are very 
close to the gains obtained by optimising across all patients. Finally, it can be 
seen that optimising RAND or TIB has very little effect on the selection of the 
nurse control gains. The mean gain values obtained using this method provide 
a 'constant average nurse across all patients' representing the average ICU nurse 
and are thus similar to those in Table 6.3 optimised over all patients, as expected. 
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The feedback-controlled infusion, U, in Equation (6.15) represents the nurs-
ing response to agitation. Setting control gains to the rounded average values 
over both models and objective functions in Table 6.3 of [Kp [0.0004 0.4] 
implements derivative-focused control. The derivative-focused approach to con-
trol focuses on controlling the shape of the agitation response rather than its 
magnitude, and in this case captures the fundamental nursing response to pa-
tient agitation. More importantly, these average nurse control gains represent an 
average of similar results across both models, are model-independent and thus 
implement the invariance hypothesis requirement in Section 6.1.4.1. 
Derivative-focused control is not uncommon, and can be seen in other phar-
maceutical PKjPD feedback controllers in systems similar to the agitation-sedation 
system [Lam et aL, 2002; Doran et aL, 2003; Chase et aL, 2005b; Hann et aL, 2005; 
Carson and Cobelli, 2001; 1991; Purler et al., 1985; Lehman and Deutsch, 
1996; Ollerton, 1989]. The controller described by Equation (6.15) with gains [Kp 
KdJ=[0.0004 0.4] is therefore selected as the candidate for the nursing response 
controller. Simulations using this nurse response model in conjunction with both 
the initial and predator-prey models are used to show the model-independence 
and of the nursing response. 
Table 6.5 summarises the results of simulations for all patients using the 
same stimulus and independent nurse modelled response across both models, thus 
matching the hypothesized requirements. The median RAND and TIB values for 
the initial model are 0.56 and 0.71 respectively, whereas the median RAND and 
TIB for the predator-prey model are 0.52 and 0.62 respectively. The TIB values 
are high for both the initial and predator-prey models, although slightly lower 
for the predator-prey model than for the initial modeL RAND values are lower 
than the TIB values, an indication of the stringency of the RAND values, but 
follow the same trend between models. 
The RAND and TIB values for the initial model, combined with the observed 
simulated infusion profiles, indicate a very good fit between the recorded and 
simulated infusion profiles. Although the median RAND value of 0.51 for the 
predator-prey model is lower than that of the initial model, it is still greater 
than the 0.5 threshold, indicating a good fit between the recorded and simulated 
infusion profiles. 
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Table 6.5 Summary results for initial and predator-prey models using [Kp Kd]=[0.0004 0.4] 
Initial Predator-Prey 
RAND TIB RAND TIB 
Max 0.78 0.94 0.71 0.93 
UQ 0.66 0.80 0.61 0.75 
Med 0.56 0.71 0.51 0.64 
LQ 0.51 0.64 0.43 0.52 
Min 0.38 0.54 0.25 0.33 
These results show that the nurse control model is effective in both the initial 
and the predator-prey models. Therefore, the nursing response model is shown 
to be model-independent and is supported by many other biological controllers 
in similar systems. The nursing response model defined in Equation (6.15) with 
gains [Kp K d ]=[0.0004 0.4] is therefore employed for all models throughout this 
thesis. 
The initial model has higher RAND and TIB than the predator-prey model 
using the independent nurse model and in general, indicating that the initial 
model captures the fundamental dynamics of the agitation system better than the 
predator-prey model. This result is supported by clinical observations of patient 
behaviour and understanding of the agitation-sedation system. In particular, 
it is not an observation that the ability of drug therapy to reduce agitation is 
diminished during low agitation, as the predator-prey model depicts. The model 
development in the following chapters will therefore proceed with the form and 
structure of the initial model, and the predator-prey model will not be further 
developed. 
In summary, identical time-invariant parameters are used across all 37 pa-
tients in the initial, and are summarised in Table 6.6. 
6.1.5 Model Evaluation Summary 
The initial model and the predator-prey model represent two independent mod-
els capturing the fundamental dynamics of the agitation-sedation system. The 
control gains of a PDC nursing response model were optimised for the initial and 
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Table 6.6 Parameter values employed in the initial model 
min-1 
min-1 
0.005 min-1 
0.0015 min-1 
1 mg/mL 
lid 100 L 
WI 0.03 
W2 0.4459 
Kp 0.0004 mL/min 
Kd 0.4 mL 
predator-prey models independently. These gains were then averaged to create a 
model-independent nursing response, which can be used across a wider variety of 
models. Simulations implementing the nursing response in both the initial and 
predator-prey models showed that while both models produce favourable results, 
the initial model is a slightly better representation of the agitation-sedation sys-
tem, particularly in the agitation troughs. The nursing response model is there-
fore selected for use throughout this thesis and across all patient models, and the 
initial model is selected for evaluation and further development. 
Equations (3.1)-(3.3) can now be implemented in conjunction with the nurse 
control model developed in Section 6.1.4, the IIR filter, and patient-specific stim-
ulus profile detailed in Chapter 4. This combination models the situation in the 
Christchurch ICU where the recorded infusion data used for model evaluation 
was obtained. More specifically, the IIR filter captures the InfuseRite device's 
impact on the 'raw' nursing sedation management response to patient agitation 
as captured by the nurse control model of Equation (4.2). 
Each patient is simulated by solving the differential equations throughout the 
length of the recorded infusion, yielding drug concentration profiles, an agitation 
profile, and a simulated infusion profile for each patient. The simulated and 
recorded infusion profiles are then compared using the probability band described 
in Section 5.2 and the numerical metrics RTD, TIB and RAND. 
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6.2 Simulation Results and Discussion 
Figure 6.4 illustrates how the three state variables for this model (Gl , G2 and 
A) change over time in response to the simulated nurse infusion, U, and the 
presence of the stimulus, S. Similarities between the simulated and recorded 
infusion profiles are clear. In this figure, the solid dark lines represent the model 
responses to the simulated infusion using nurse control model and IIR filter, while 
the lighter filled area represents the actual recorded infusion profile. 
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Figure 6.4 Example of modelled responses of recorded and simulated infusion profiles using 
the initial model for Patient 3. 
Figure 6.5 presents three examples of the 99% probability band, with the 
simulated infusion overlaid. The grey area represents the probability band, the 
thin line represents the recorded infusion profile, and the solid dark line represents 
the simulated infusion profile. Again, the similarities between the clinical and 
simulated data are clear. The graphical nature of these probability bands and 
their ability to show areas of poorer performance is also evident. 
The simulated infusion profiles are clearly smoother than the recorded infu-
sion profiles. This is due to the fact that the recorded infusion profiles are the 
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Figure 6.5 of probability bands with simulated infusion profile using the initial 
model for three patients (Patients 7, 18 and 22 from top to bottom). 
result of the response of bedside medical staff who periodically check on the pa-
tient, whereas the simulated infusion profile is the result of a consistent control 
protocol continuously observing patient agitation. In addition, the InfuseRite 
filter modifies the rate every hour yielding discrete clinical data. This discrete 
recording will also contribute to a small amount of poor correlation. 
Figure 6.5 shows that the simulated infusion profile lies predominantly within 
the grey 99% probability band and track" the mean recorded infusion rate closely, 
for these three patients. Similar graphs are observed for aU 37 patients, as demon-
strated by the median time within the band of 0.71 across all patients seen in 
Table 6.7. Due to size, Table 6.7 is located at the end ofthis Chapter for clarity 
and ease of use. The TIB has a median of 0.71 with a range of [0.54,0.94], show-
ing that while for most patients the simulated infusion rate lies predominantly 
within band, there are some patients where the simulated infusion rate leaves the 
probability band for approximately 30-40% of the time. 
Importantly, a common reason for reduced total time within the probability 
band is a single, but lengthy, departure from the probability band, rather than 
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a consistently poor performance throughout the length of the simulation. This 
feature is observed in the upper plot of Figure 6.5 for Patient 7 between t=7 and 
t=14 hours. This result implies that, while performing well much of the time, the 
simulated infusion rate deviates from the recorded infusion rate over some par-
ticular period, and takes some time before tending towards the recorded infusion 
rate again. Equally importantly, these deviations are not visually dramatic and 
the inherent trends remain similar in both the simulated and clinical profiles. 
The periods where the simulated infusion rate departs from the 99% proba-
bility band indicate the areas where the model may not capture certain dynamics. 
These periods may represent periods of particular distress or physiological change 
due to patient condition, or dynamics that are not captured by the model. In 
particular, a common reason for the departure of the simulated profile from the 
probability band is apparent time-delay, as observed in the upper plot of Figure 
6.5. 
Table 6.7 presents the evaluation metrics for the initial model. The RTD has 
a median value of 0.99 with a range of [0.92, 1.0l], indicating that the simulated 
infusion rates are very close to the recorded infusion rates over the entire patient 
record. Ideally, the RTD should approach 1.0, representing identical equivalent 
doses. The RAND has a median of 0.56, with a range of [0.38, 0.78]. The low 
values for RAND are a combined result of the stringent criteria imposed by the 
RAND metric and the actual, overall capability of the initial model to capture 
all the observed dynamics. Visually, the simulated infusion rate clearly captures 
all the overall trends of the recorded infusion rate, as indicated by the median 
TIB=O.71. However, the RAND metric remains relatively low for many patients, 
highlighting the stringency of the RAND criteria. 
Although there is a general correlation between the RAND, AND, TIB and 
RTD in Table 6.7, this is not always the case. Patient 21, for example, has a 
RTD of 0.98, which is close to the median RTD across all patients and very close 
to the ideal value of 1.0. However, the TIB and RAND for Patient 21 are 0.57 
and 0.52, both of which are well below the median of 0.71 and 0.56. This result 
indicates that while RTD provides important information, it is a global variable 
only, and can be misleading. In contrast, there appears to be relatively good 
correlation between the TIB and RAND metrics for most patients, although the 
RAND values are consistently lower. This result is a consequence of the related 
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formulations of the probability band and the RAND metric, and the stringency 
of RAND. The evaluation metrics in Table 6.7 are a good illustration that a 
metric alone is not a good indication of the model's ability to capture the 
observed dynamics. 
Of the 37 patients, 7 patients have a RAND<O.5, of which two have RAND<0.45 
and four 0.45<RAND<O.5. Inspection of the patients with low RAND values re-
veals that a common feature of these patients is an apparent time-delay between 
the recorded and simulated infusion rates. An example of this feature is shown 
in Figure 6.6 for Patient 21. Figure 6.6 shows the recorded and simulated infu-
sion rates for Patient 21 with the probability band overlaid. delay may be 
the result of excessive delayed drug distribution in the compartments. As the 
parameters for this model were manually selected, parameter selection is a likely 
cause of such differences between the recorded and simulated infusion rates. 
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Figure 6.6 of the delay between the recorded and simulated infusion profiles using 
the initial model for Patient 21. 
In addition to the apparent delay, there are examples of simulations where the 
simulated infusion rate lies well below the band at the peaks and troughs. This 
may be the result of the a..'3sumed linear PD relationship in the initial model. 
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The effect of the linear PD relationship has the most impact at high and low 
drug concentrations. The linear PD relationship typically over-estimates the PD 
effect, particularly at high concentrations. This effect may be a reason for the 
differences between the recorded and simulated infusion rates at the peaks and 
troughs, and may contribute to the low evaluation metrics. 
It must be remembered that while stimulus profiles are specific to each pa-
tient, all simulations in this paper utilise identical parameters for all patients, 
including drug clearance and distribution. Later chapters in this thesis inves-
tigate patient-specific However, the results presented are a good 
indication that the proposed system model captures the fundamental underlying 
dynamics common to most patients, and generalisable, given the use of identical 
model parameters for all 37 patients. 
6.3 Model Evaluation Summary 
The use of two independent models and the invariance hypothesis have enabled 
evaluation and identification to the limit of the data available. The invariance 
condition takes account of the fact that the P~(/PD equations model patient be-
haviour and must be independent of the stimulus and drug input. The results of 
independent optimisation-based deconvolution with a fixed stimulus, S(t), deliv-
ered very similar nurse control models and a RAND-verified average nurse model 
that is model-independent and delivers high TIB. 
Overall the results indicate that the simulations are a good representation 
of the essential fundamental dynamics captured in the recorded infusion profile, 
but that there are additional dynamics in the agitation-sedation system not cap-
tured by this initial modeL Nonetheless, the model provides a platform for the 
\J\CO\JUI.>; and analysis of control strategies and protocols that may improve patient 
agitation management. 
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Table 6.7 Evaluation metrics for the initial model 
RAND AND TIB RTD 
2 0.65 0.52 0.71 0.98 
3 0.61 0.52 0.90 0.96 
4 0.54 0.49 0.78 0.96 
5 0.55 0.42 0.71 1.00 
6 0.73 0.61 0.81 0.95 
7 0.48 0.37 0.66 0.97 
8 0.49 0.37 0.64 0.99 
9 0.52 0.41 0.64 0.98 
10 0.56 0.45 0.69 1.00 
11 0.61 0.50 0.68 0.98 
12 0.52 0.42 0.70 0.98 
13 0.51 0.42 0.66 0.95 
14 0.47 0.40 0.86 0.98 
15 0.67 0.49 0.78 0.99 
16 0.43 0.33 0.55 0.99 
17 0.50 0.43 0.59 0.99 
18 0.78 0.63 0.82 1.00 
19 0.75 0.56 0.84 0.99 
20 0.69 0.56 0.79 0.99 
21 0.52 0.39 0.57 0.98 
22 0.55 0.43 0.70 0.99 
23 0.57 0.48 0.72 1.01 
24 0.55 0.44 0.76 0.99 
25 0.50 0.38 0.56 1.00 
26 0.55 0.43 0.61 0.98 
27 0.44 0.35 0.54 0.98 
28 0.63 0.48 0.72 0.99 
29 0.38 0.32 0.68 0.94 
30 0.68 0.53 0.84 1.01 
31 0.75 0.59 0.84 0.99 
32 0.56 0.43 0.71 0.99 
33 0.72 0.56 0.80 0.99 
34 0.45 0.35 0.56 0.99 
35 0.64 0.52 0.71 0.98 
36 0.60 0.50 0.62 0.99 
37 0.61 0.55 0.81 0.98 
Max 0.78 0.65 0.94 1.01 
UQ 0.66 0.52 0.80 0.99 
Med 0.56 0.45 0.71 0.99 
LQ 0.51 0.41 0.64 0.98 
Min 0.38 0.32 0.54 0.92 
IQR 0.15 0.12 0.16 0.02 

Chapter 7 
Model Evaluation: Physiologically-based Model 
This chapter employs the physiologically-based model, without the Endogenous 
Agitation Reduction (EAR) term of Equation (3.12), for evaluation. Section 
7.1 outlines the procedure used in the simulations and presents the parameters 
used in the model. Section 7.2 presents the results of simulations using the 
physiologically-based model, and discusses their implications. 
The model used in this chapter is presented again here for clarity: 
1. Pharmacokinetics of Morphine: 
(7.2) 
(7.3) 
II. Pharmacokinetics of Midazolam: 
(7.4) 
V s dC: KS Cs KS CS e dt = - ec e + ce c (7.5) 
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III. Pharmacodynamics of Morphine and Midazolam: 
(7.6) 
where Ge , Gp and Ge are the drug concentrations (mg/L) in the central, periph-
eral and effect compartments, Ve , Vp and 11;, are the distribution volumes (L) 
of the central, peripheral and effect compartments, U is the IV infusion rate 
(mL/min), A is an agitation index, S is the stimulus invoking agitation, Kij is 
the transfer rate (L/min) from compartment i to compartment j, KCL is the 
drug clearance (L/min), KT is the effect time constant (min-I), and Ra and RS 
are the concentrations of Morphine ('0') and Midazolam ('s') in the infusion so-
lution respectively (mg/mL). Time is represented by t (min), T is the variable of 
integration, and the terms WI and W2 are the stimulus and sedative sensitivities 
respectively. Finally, EComb is the combined PD effect of the individual effect site 
drug concentrations of Morphine and Midazolam, determined using response sur-
face modelling displayed in the lower portion of Figure 3.3. Note that Equation 
(7.6) is missing the EAR term, -W3A, of Equation (3.12). 
7.1 Model Evaluation Methods 
Equations (7.1)-(7.6) are implemented in conjunction with the nurse control 
model, IIR filter for the InfuseRite device, and patient-specific stimulus profile 
detailed in Chapter 4. Each patient is simulated by solving the differential equa-
tions throughout the length of the recorded infusion, yielding drug concentration 
profiles, an agitation profile, and a simulated infusion profile for each patient. 
The simulated and recorded infusion profiles are then compared using the graph-
ical probability band and numerical metrics RTD, TIB and RAND evaluated for 
each patient, as described in Chapter 5. 
7.1.1 Patient Specific Parameters and Variability 
In this chapter, the physiologically-based model is employed and time-invariant 
parameters are used for all patients. This agitation-sedation model consists of 
several PK and PD components. The PK parameters form the basis for the drug 
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distribution and elimination half-life, while the PD parameters define the shape 
of the response surface and drug sensitivities. 
It is commonly accepted that significant inter-patient variability is observed 
in the pharmacology of sedatives the critically ill and elderly and Donner, 
1995; Young et al., 2000]. However, there is evidence that inter-patient variabil-
ity appears to be due primarily to variations in PD parameters, such as drug 
sensitivity, rather than PK parameters, such as drug clearance or volume of dis-
tribution [Oldenhof et al., 1988; Vinik et al., 1983; Albrecht et al., 1999; Rudge 
et al., 2005b]. 
Therefore, identical PK parameters representative of a typical ICU patient 
were adapted from the literature [Meineke et al., 2002; Latsch et al., 2002; Persson 
et al., 1987; Bolon et al., 2003] and applied across all patients. The general shape 
of the PD response surface in Figure 3.3 is approximated by information in the 
literature [Wagner and O'Hara, 1997; De Jonghe et al., 2003]. In particular, the 
response surface is defined to capture the synergistic sedative effects observed 
when Morphine and Midazolam are administered concomitantly [Wagner and 
O'Hara, 1997; De Jonghe et al., 2003], the mild sedative effect of Morphine alone 
[Barr and Donner, 1995; Levine, 1994]' and saturation dynamics. 
7.1.1.1 PK Parameters 
The PK parameters required for the model described by Equations (7.1)-(7.6) 
are those for Morphine: K~p, K~e' K;c, K:c, K OL ' v:.:a, y;,a, v"a; and those for 
Midazolam: K~e, K:c' Ktn, v:.:8 , 1/;,8. These parameters are selected based on an 
extensive literature search of PK parameters in both healthy and ICU patients. 
Standard PK studies typically record infusion and plasma concentration data, 
and use fitting techniques to select the PK parameters that result in the best 
fit to a proposed a PK model. Therefore, the PK parameters obtained in these 
studies are specific to the selected model, and are therefore not directly applicable 
to other model structures. However, in many cases conversion/translation of key 
parameters, such as volume of distribution, overall clearance rate, and internal 
transfer rates is possible by simple rearrangement of the model equations into 
similar forms. In many cases, this task simply requires multiplying or dividing 
by respective volumes of distribution or average weights of patients. The results 
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in this study, where necessary, have used this method to present parameters in a 
format suited to the model described by Equations (7.1)-(7.6). 
As a result of the recent increased popularity of Midazolam, the literature 
contains more PK studies for Midazolam than for Morphine. However, for both 
Morphine and Midazolam, the majority of studies focus on the PK profiles of 
healthy subjects, rather than critically ill patients. Further, many studies are 
specifically designed to study the PK profiles of patients with a particular popu-
lation, such as aged patients, or patients with critical illnesses such as ARF, or 
CRF, the latter two of which significantly impact drug clearance. 
While the internal PK transport rates are important, the primary PK pa-
rameters in the compartmental model are the total volume of distribution, VT , 
which is the sum of the volumes of the individual compartments, and the clear-
ance rate, K CL ' Some studies also report a Minimum Effective Concentration 
(MEC) or a Observed Concentration Range (OCR), which provide information 
on the observed drug concentration levels. A summary of the PK studies, and 
their published PK values is presented for Morphine and Midazolam in Tables 
7.1 and 7.2, respectively. In addition to the data presented in Table 7.1, Milne 
et aL [1996] presents a MEC range for Morphine of 0.0001-0.27mg/L. Similarly, 
Meineke et al. [2002] presents a OCR for Morphine ofO.2-DAmg/L. 
Table 7.1 General PK parameters in the literature for Morphine 
Study Population n VT KCL 
Type L L/min 
Milne et al. [1996] n/a n/a 125-238 1-2 
Bion et al. [1986] Healthy 8 1.1 
Bion et al. [1986] ARF 4 1.7 
Osborne et al. [1993] Healthy 10 232.2 1.97 
Osborne et al. [1993] RF 8 127.3 1.17 
Aitkenhead et aL [1984] Healthy 11 221.2 0.85 
Aitkenhead et al. [1984] CRF 9 169A 0.721 
Meineke et al. [2002] Neuro ICU 9 302.7 1.84 
L6tsch et al. [2002] Healthy 8 304.1 1.26 
After consideration of the values in Table 7.1, parameters V; and KCL for 
Morphine were selected to be 200L and 1.5L/min respectively. Similarly, after 
consideration of the values in Table 7.2, parameters VT and Ken for Midazolam 
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Table 7.2 General PK parameters in the literature for Midazolam 
Study Population n Vr KCL OCR 
Type L L/min mg/L 
Fragen [1997] Healthy 8 73.1 0.456 0.35-0.74 
Fragen [1997] Elderly 10 152.6 0.285 
Fragen [1997] Young 10 159.6 0.427 
Driessen et al. [1991] 6 159.0 0.132 
Driessen et al. [1991] lCU 33 106.0 0.198 
MaIacrida et aI. [1992] lCU 8 217.0 0.441 0.19-0.65 
Malacrida et al. [1992] HeaIthy 8 63.0 0.343 
Oldenhof et al. [1988] lCU 17 56~119 0.2-0.4 0.34 
Mandema et aI. [1992] Healthy 8 60 0.523 
Shafer [1998] lCU n/a 29~239 0.023-0.502 
Vinik et aL [1983] CRF 14 265.3 0.798 
Vinik et aI. [1983] Healthy 14 152.6 0.471 
Persson et al. [1987] Healthy 15 135.8 0.483 0.317~1.25 
Bolon et al. lCU 30 28.14 0.537 0.0015~1.0 
were selected to be 150L and 0.5L/min respectively. These values represent an 
average over a variety of studies, with particular emphasis on patient populations 
similar to the lCU population. 
Of the studies in Table 7.1, both Meineke et al. [2002] and Latsch et al. [2002] 
employ compartmental models for Morphine, and both present a good explana-
tion of the model, including the compartmental diagram. Latsch et al. [2002] 
develops a PK model of Morphine and M6G for healthy subjects. Their overall 
model employs a 3-compartment sub-model for the Morphine portion, and com-
pares two different sub-models for the M6G portion of the overall modeL Meineke 
et al. [2002] also presents a model of the PK of Morphine and its metabolites, but 
attempts to model the distribution of M3G and M6G in both the plasma and the 
CSF in neurological patients in an lCU. Like Latsch et aI. [2002], Meineke et aI. 
[2002] employs a 3-compartment model to represent the basic Morphine PK, and 
adds compartments to represent the PK of M3G) M6G) and the additional CSF 
concentrations for Morphine and its metabolites. While there is significant debate 
over the activity and relevance of the Morphine metabolites, the PK of Morphine 
is more established. Therefore, a 3-compartment model is selected for use in 
this thesis, and the results from Latsch et al. [2002] and Meineke et al. [2002], 
excluding the metabolite portions, are used as the basis for the selection of the 
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internal transfer rates (K~, K~~, K;e, K~c, KCL ) and individual compartmental 
volumes (Vea, v;a, v:,a), and are presented in Table 7.3. 
Table 7.3 Compartmental PK parameters in the literature for Morphine 
Parameter Unit Meincke et al. [2002] Latsch et al' [2002] 
Population Neuro ICU Healthy 
n 9 8 
Ve L 12.7 17.8 
Vp L 111.0 87.3 
Ve L 179.0 199.0 
VT L 302.7 304.1 
KCL L/min 1.84 1.26 
Kce L/min 2.09 2.27 
Kcp L/min 0.18 0.33 
Kee L/min 2.09 2.27 
Kpc L/min 0.18 0.33 
Of the studies in Table 7.2, Persson et al. [1987] and Bolon et al. [2003] employ 
compartmental models for Midazolam, and both present the relevant parameters 
clearly. Persson et al. [1987] develops a PK model Midazolam for healthy subjects, 
employing 2-compartments. Bolon et al. [2003] also presents a 2-compartment 
model of the PK of Midazolam, but uses a PK Software package to determine 
the PK parameters for patients in an ICU. Therefore, a 2-compartment model 
is selected for use in this thesis, and the results from Persson et al. [1987] and 
Bolon et aL [2003] are used as the basis for the selection of the internal transfer 
rates (K:.e, K:e1 Ken) and individual compartmental volumes (Y::s, V;n, and are 
presented in Table 
Table 7.4 Compartmental PK parameters in the literature for Midazolam 
Parameter 
Population 
n 
Vc 
Ve 
VT 
Unit 
L 
L 
L 
Bolon et al. [2003] 
lCU 
30 
28.14 
0.0 
28.14 
0.537 
0.464 
0.323 
Persson et al. [1987] 
Healthy 
15 
32.97 
102.83 
135.8 
0.483 
0.610 
1.00 
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After consideration of the published model parameter values in Tables 7.3-7.4, 
the remaining model parameter values to be employed in this model were selected. 
These remaining parameters are presented in Table 7.6 and are representative of 
a typical leU patient. Note that these PK parameter values are also applied 
across all patients. 
7.1.1.2 PD Parameters 
The general shape of the PD response surface in Figure 3.3 is approximated by 
information in the literature [Wagner and O'Hara, 1997; De Jonghe et al., 2003]. 
In particular, the response surface is defined to capture the synergistic sedative 
effects observed when Morphine and Midazolam are administered concomitantly 
[Wagner and O'Hara, 1997; De Jonghe et al., 2003], the mild sedative effect of 
Morphine alone [Barr and Donner, 1995; Levine, 1994], and saturation dynamics. 
The overall shape of the response surface is that of dual sigmoids, which are 
(individually) encountered frequently in this type of modelling. 
The PD response surface methodology presented by Minto et al. [2000], and 
employed in this research, has 18 defining' parameters, including 15 polynomial 
coefficients, (3i((}), described in Section 3.3. Furthermore, of the small number 
of PD studies in the literature, there are few, if any, reporting PD parameters 
suitable for quantitative use. The fact that inter-patient PD variability is very 
large only compounds the difficulties associated with PD parameter estimation. 
Minto et al. [2000] presented an example response surface that was defined 
by parameters obtained from fitting data from 400 subjects. However, the fitting 
procedure was completed using a comprehensive parameter estimation package, 
and the experimental conditions were strictly uniform. Unfortunately, neither the 
large data sets, nor the uniform experimental conditions are available in popula-
tions such as the critically ill, making precise fitting of the response surface to the 
empirical data difficult. Fortunately, the main purpose of the response surface 
in the agitation-sedation model is to capture the synergistic and saturation dy-
namics, which are features that pertain to the overall shape of the surface, rather 
than the particular parameters used to define it. Response surface parameter 
selection is, therefore, based upon the formation of a suitable response surface. 
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It is commonly accepted that while Morphine is primarily an analgesic, it 
is also a mild sedative [Berger and Waldhorn, 1995; Schmidt et al., 2004; Tver-
skoy et al., 1989]. Further, while there are some studies suggesting that the 
Morphine/Midazolam interaction is additive [Tverskoy et al., 1989], most agree 
that a synergistic sedative relationship exists between Morphine and Midazolam 
[Wagner and O'Hara, 1997; Barr and Donner, 1995; Fragen, 1997; Gilliland et al., 
1996J. The response surface, therefore, must capture this synergism and the mild 
sedative effect of Morphine, when used alone, in its shape. 
It is commonly accepted that the relationship between drug concentration 
and PD effect is non-linear [Minto et al., 2000; Fragen, 1997]. Further, one of 
the important aspects of the observed non-linearity is the saturation of effect 
at high concentrations. This dynamic creates the plateau in the concentration-
effect curve, as seen in the sigmoid curve originally presented in Figure 1.2. The 
response surface must also capture this important saturation dynamic. 
The parameters defining the PD response surface are manually selected to 
ensure that the surface captures each of these dynamics. In particular, the surface 
is defined such that the minimum effect is 0, the maximum effect approaches 100, 
the sedative potency of Morphine is half that of Midazolam, as an approximation 
of mild effect, and the steepness parameter, 'I/J., is in the range of example values 
presented in Minto et al. [2000]. The selected parameters are presented in Table 
7.5, and together with patient-specific selection of C50 , define the response surface 
represented in Figure 7.1 for clarity. 
Table 7.5 Parameters detlmmgthe PD response surface employed in the physiologically-based 
model 
o 
40 + 210 . 8 - 210 . 82 + 40 . 83 + 0 . 84 
1 0.1·8 + 0.1.82 + 0 . 83 + 0 . 84 
4 - 8 + 82 + 0 . 83 + 0 . (}4 
All parameters are time-invariant, and those applied across all patients are 
listed in Table 7.6. remaining PD parameters, WI and KT , are obtained using 
techniques similar to those described in Section 6.1 adapted for the physiological 
model. In particular, a KT value of 0.0015 was chosen, corresponding to a half-
life of 2.5 hours. This value is near the lower end of reported range of 2-8 
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Figure 7.1 Schematic representation of the physiologically-based model, including the com-
partmental PKs (upper portion) and the PD response surface (lower portion). 
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hours described in Section 6.1.2 because the PK model now incorporates drug 
accumulation, which it did not in the initial model selection in Section 6.1.2. 
Hence, the lower value is now a better and still conservative choice. 
Table 7.6 Constant parameter values employed in the physiologically-based model 
Parameter Value Unit 
va 
c 10 L 
va p 70 L 
va 
e 120 L 
Ken 1.5 L/min 
K~e 2.1 L/min 
K~ 0.22 L/min 
K:c 2.1 L/min 
K;c 0.22 L/min 
Ra 1 mg/mL 
VB 
C 30 L VB 
e 120 L 
KCL 0.5 L/min 
K~e 0.5 L/min 
K:c 0.7 L/min 
RS 0.5 mg/mL 
WI 0.0360 
KT 0.0046 min-I 
Kp 0.0004 mL/min 
Kd 0.4 mL 
While most parameters are both time-invariant and constant across all pa-
tients, some PD parameters in the physiological model, such as drug sensitivity, 
W2, and concentration associated with 50% effect, C50 , are time-invariant but vary 
between patients. The C50 are manually selected based on individual recorded 
infusion profiles and W2 values selected based on the principles described in Sec-
tion 6.1.3. The values of C~O) C50 and W2 used for each patient in the results in 
this chapter are presented in Table 7.7. Due to size, Table 7.7 is located at the 
end of this Chapter for clarity and ease of use. Time-varying parameters and 
their identification are discussed in Chapter 8. 
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7.2 Results and Discussion 
Figure 7.2 illustrates, for Patient 3 how the state variables for the model of 
Equations (7.1)-(7.6)(C%, C~, c;, c~, C: and A) change over time in response to 
the simulated infusion, U, and the presence of the stimulus, S. In this figure, the 
solid lines represent the model responses to the simulated infusion using the nurse 
control model and IIR filter of Chapter 4, while the lighter filled areas represent 
the actual recorded infusion profile. 
Similarities between the simulated and recorded infusion profiles are clear in 
this case. Figure 7.3 presents examples of the probability band, with the simu-
lated infusion overlaid, for three patients. In Figure 7.3 the grey area represents 
the 99% probability band, the thin line represents the recorded infusion profile, 
and the solid dark line represents the simulated infusion profile. Again, the sim-
ilarities between the recorded and simulated infusion rates are clear, and these 
figures can be directly compared to Figures 6.4-6.5 in Chapter 6 for the initial 
modeL 
The PK parameters selected in Section 7.1.1.1 determine the rates of distri-
bution between the compartments and the overall clearance, and therefore the 
compartmental concentrations. The magnitudes of the simulated drug concentra-
tions can therefore be compared to the magnitude of the MEC and OCR values 
observed in the PK studies presented in Section 7.1.1.1. Simulations for most 
patients resulted in average Morphine central compartment drug concentrations 
in the approximate range of 0.03-0.0Smg/L, which lies within the minimum ef-
fective concentration range (0.0001-0.27) presented in the Morphine review by 
Milne et aL [1996], but lower than the OCR (0.2-0.4) presented by Meineke et aL 
[2002] . 
There are some patients in the cohort with large infusion rates whose simu-
lated central compartment concentrations reached almost 0.2mg/L, nearing the 
upper end of observed concentrations in Milne et al. [1996]. One plausible 
reason that the simulated concentrations are not as high as those observed in 
Meineke et aL [2002] relates to the population of patients studied in Meineke 
et al. [2002] and the delivery method. Meineke et aL [2002] studied 9 neuro-
logical/neurosurgical ICU patients, and delivered the Morphine over a relatively 
short time intravenously. This infusion method may have resulted in initially 
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Figure 7.2 Example of modelled responses of recorded and simulated infusion profiles using 
the physiologically-based model for Patient 3. 
high concentrations, or perhaps the dose required by the neurological ICU pa-
tients may be higher than general ICU patients. In general, the concentrations 
observed in the simulations are aligned with the concentrations observed and pre-
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Figure 7.3 Examples of the probability bands with simulated infusion profile using the 
physiologically-based model for three patients (Patients 7, 18 and 22 from top to bottom). 
sented in the available literature, confirming the selection of the PK parameters 
for Morphine. 
Simulations for most patients resulted in Midazolam central compartment 
drug concentrations in the approximate range of 0.05-0. 12mgjL, which is within 
the OCR (0.00015-1.0) presented in the Midazolam study on ICU patients by 
Bolon et al. [2003]. There are some patients in the cohort with large infusion 
rates whose simulated central compartment concentrations exceeded 0.2mgjL, 
which also falls within the observed OCR of leU patients in Malacrida et al. 
[1992]. In general, the concentrations observed in the simulations are aligned 
with the concentrations observed and presented in the available literature, and in 
particular those studies on which the PK parameters were based. These results 
verify the selection of the PK parameters used for Midazolam. 
Figure 7.3 shows that the simulated infusion profile lies predominantly within 
the grey 99% probability band, and tracks the mean recorded infusion rate closely 
for these three patients. Similar graphs are observed for all 37 patients, as demon-
strated by the high median time within the band of 0.70 across all patients seen 
108 CHAPTER 7 MODEL EVALUATION: PHYSIOLOGICALLY-BASED MODEL 
in Table 7.8. Due to size, Table 7.8 is located at the end of this chapter for clarity 
and ease of use. The TIB has a median of 0.70 with a range of [0.39, 0.95], show-
ing that while for most patients the simulated infusion rate lies predominantly 
within band, there are some patients where the simulated infusion rate leaves the 
probability band for approximately 40~50% of the time. 
The RA='JD has a median of 0.57, with a range of [0.32, 0.84]. The low 
values for RAND are a combined result of the stringent criteria imposed by 
the RAND metric and the general capability of the physiologically-based model. 
Visually, the simulated infusion rate clearly captures all the overall of the 
recorded infusion rate. However, the RAND metric remains relatively low for 
many patients, highlighting the stringency of the RA='JD metric. 
Upon inspection of simulation profiles, it is clear that for most patients 
the simulated infusion rate remains within the probability band most of the time. 
However, there are periods of time for many patients where there is a distinct 
difference between the recorded and simulated infusion rates. In these specific 
regions the model does not appear to capture the observed patient dynamics. 
In some cases this result occurs when absence of stimulus and low drug con-
centrations coincide with an agitation level that is decreasing, but not close to 
zero. In such situations, agitation remains at a constant non-zero level, per Equa-
tion (7.6), even though the recorded infusion rate drops to near-zero values. For 
other patients, often those with very long stays in the ICU, the observed differ-
ence between recorded and simulated infusion rate may be due to patient-specific 
parameters varying over the duration of the recorded data, as seen in Figure 7.4. 
For example, such an effect might be due to drug storage of Morphine and Mi-
dazolam in fatty tissues being released later [Crippen, 1990; Hughes et aI., 1992; 
Arbour, 2000]. Simulations incorporating changes in these parameters over time 
are further investigated in Chapter 8. 
The RTD has a median value of 1.01 with a range of [0.87, 1.16]. This result 
indicates that, across all patients, the simulated infusion rates are very close to 
the recorded infusion rates. This median RTD value is very close to the ideal 
value of 1.0, although it is slightly higher than the median RTD from the initial 
model of 0.99. 
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Figure 7.4 Example of the apparent changes in parameters over time for the physiologically-
based model for Patient 10. 
The physiologically-based model contains the physiological drug effect sat-
uration dynamic, seen by the dual-sigmoid surface in Figure 3.3. However, at 
this stage Michaelis-Menton (MM) clearance saturation dynamics have not been 
implemented. Physiological metabolism and secretion of Morphine and Midazo-
lam is limited by renal and hepatic clearance capacity. However, the maximum 
clearance rate and plasma concentrations at which the dynamics change from 
being first-order to zero-order kinetics are not easily obtained, particularly in the 
ICU population. A lack of available parameter values therefore makes the imme-
diate implementation of MM kinetics difficult. However, the model still captures 
the fundamental agitation-sedation dynamics common to most ICU patients, and 
therefore provides a platform for the testing and analysis of control strategies and 
protocols that may improve patient agitation management. 
It should be noted that the evaluation metrics in Table 7.8 were achieved using 
only a few patient-specific PD parameters and identical PK parameters across all 
patients. This with published reports that inter-patient pharmacological 
variability is due primarily to PD differences rather than PK differences [Olden-
hof et aL, 1988; Vinik et al., 1983; Albrecht et al., 1999; Rudge et al., 2004bj. 
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The subsequent fit of the model simulations using these parameter values fur-
ther supports the model as an appropriate physiological representation of the 
agitation-sedation system. 
Although the evaluation metrics for the physiologically-based model are only 
moderately improved over the initial model results in Table 6.7, the physiologically-
based model is a more realistic representation of the physiology and is developed 
upon proven studies in the literature. In addition, it is clear from the plots of 
the simulation results that the physiologically-based model captures more of the 
fundamental dynamics most of the time, but lacks a dynamic that causes severe 
deviations from the recorded infusion rate for short, but distinct, periods of time. 
rrhis result can be seen by the fact that for many patients the simulations using 
the physiologically-based model are a distinct improvement over those using the 
initial model ( e.g. Patients 6, 17, 21, 23, 26, 36), while there are some patients 
for whom the results are worse (e.g. Patients 10, 11, 18, 22, 28, 31). The sim-
ulations for these patients show that most of the time the physiologically-based 
model performs much better, but for distinct periods of time in particular patients 
there is a particular deviation of the simulated infusion rate from the recorded 
infusion rate. This implies that while the physiologically-based model lacks some 
dynamics of the agitation-sedation system, it captures many of the important 
aspects and is a distinct improvement over the initial model. 
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Table 7.7 Patient-specific parameter values employed in the physiologically-based model 
'W2 
xl0-4 
mg/L mg/L 
1 1.45 0.015 0.015 
2 1.95 0.020 0.020 
3 4.00 0.040 0.040 
4 6.00 0.030 0.070 
5 3.00 0.020 0.050 
6 3.00 0.020 0.050 
7 1.90 0.020 0.020 
8 10.0 0.060 0.150 
9 5.00 0.050 0.050 
10 5.00 0.030 0.070 
11 8.50 0.040 0.070 
12 5.00 0.030 0.070 
13 7.50 0.050 0.080 
14 2.15 0.015 0.030 
15 7.50 0.060 0.110 
16 10.0 0.090 0.110 
17 4.50 0.040 0.050 
18 10.0 0.090 0.130 
19 20.0 0.150 0.250 
20 4.00 0.028 0.052 
21 2.00 0.030 0.015 
22 9.50 0.050 0.150 
23 4.00 0.020 0.040 
24 5.50 0.040 0.080 
25 5.50 0.060 0.055 
26 1.36 0.020 0.010 
27 8.00 0.070 0.070 
28 6.00 0.060 0.055 
29 5.25 0.022 0.080 
30 2.85 0.020 0.040 
31 10.0 0.120 0.080 
32 10.0 0.120 0.080 
33 10.0 0.130 0.070 
34 7.00 0.090 0.060 
35 3.50 0.020 0.040 
36 6.00 0.080 0.040 
37 7.00 0.030 0.080 
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Table 7.8 Evaluation metrics for the physiologically-based model 
RAND AND TIB RTD 
1 0.79 0.73 0.95 0.96 
2 0.59 0.48 0.72 1.02 
3 0.72 0.61 0.92 0.97 
4 0.58 0.52 0.79 0.97 
5 0.65 0.49 0.73 1.04 
6 0.84 0.71 0.88 1.01 
7 0.37 0.28 0.48 1.07 
8 0.55 0.41 0.65 1.01 
9 0.52 0.42 0.64 1.01 
10 0.32 0.25 0.39 1.16 
11 0.40 0.33 0.54 0.87 
12 0.66 0.53 0.83 0.96 
13 0.44 0.36 0.68 1.01 
14 0.61 0.52 0.91 1.00 
15 0.58 0.42 0.70 1.04 
16 0.48 0.37 0.67 1.02 
17 0.70 0.59 0.71 0.99 
18 0.57 0.46 0.67 1.05 
19 0.62 0.46 0.70 1.00 
20 0.66 0.54 0.83 1.03 
21 0.69 0.52 0.75 1.02 
22 0.44 0.34 0,59 1.01 
23 0.82 0.70 '0.91 0.98 
24 0.55 0.44 0.71 1.07 
25 0.56 0.43 0.71 1.03 
26 0.84 0.66 0.82 1.00 
27 0.51 0.41 0.62 1.03 
28 0.40 0.30 0.46 1.08 
29 0.46 0.39 0.75 0.91 
30 0.78 0.60 0.85 0.99 
31 0.49 0.39 0.60 1.04 
32 0.48 0.37 0.56 1.02 
33 0.34 0.26 0.44 1.07 
34 0.46 0.35 0.55 1.01 
35 0.45 0.37 0.51 0.99 
36 0.65 0.53 0.66 1.03 
37 0.57 0.52 0.82 0.99 
Max 0.84 0.73 0.95 1.16 
UQ 0.66 0.53 0.82 1.03 
Med 0.57 0.44 0.70 1.01 
LQ 0.46 0.37 0.60 0.99 
Min 0.32 0.25 0.39 0.87 
IQR 0.20 0.16 0.22 0.04 
Chapter 8 
Parameter Identification and Sensitivity 
Analysis 
The physiologically-based model employed in Chapter 7 captures many of the fun-
damental observed dynamics in the agitation-sedation system. However, there are 
some periods in some patient profiles where it is clear that this physiologically-
based model does not capture all the observed dynamics. Clinically, for con-
trol applications, these periods affect the model's ability to accurately predict 
ahead to stabilise a patient, requiring the addition of either extra dynamics or 
time-varying parameters. The importance of time-varying parameters to capture 
patient behaviour and predict ahead has been shown for similar and analogous 
glucose-insulin models [Hann et al., 2005], and has been demonstrated clinically 
in [Chase et al., 2005b]. Thus, for future clinical application, it is important 
to show that the agitation-sedation model and methods presented in this the-
sis can be readily extended to include time varying parameters whose real-time 
identification as the patient evolves will aid prediction and control. 
This chapter introduces time-varying sensitivity parameters and the EAR 
dynamic to the physiologically-based model, and presents a parameter fitting 
method enabling the estimation of the potentially time-varying and critical model 
parameters. Note that the main purpose of this analysis is to provide a general 
way of dealing with unmodelled dynamics which will become important in future 
work once further sensors for objectively measuring agitation become available. 
The integral-based parameter fitting method is adapted from Hann et al. 
[2005] for the model presented in Section 3.3. This method reduces the standard 
non-linear, recursive, least squares regression method typically employed [Carson 
and Cobelli, 2001] into a linear optimisation. This approach requires minimal 
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computation and allows significant scope to add further dynamics into the model 
to better match clinical data, due to its low computational intensity and ease of 
use. The minimal computation required in this method also makes it particularly 
suitable for clinical application. The model and fitting method are applied to the 
37 lCU patient cohort, and parameter variability and sensitivity are analysed. 
8.1 Methods 
The aim of system identification in this context is to obtain the parameter values 
that lead to the best fit of the simulated infusion rates to the recorded infusion 
rates. This parameter fitting method uses identical parameters to those previ-
ously defined in Chapter 7, with the exception of 0 50 , W2, and the introduction 
of W3. The PD parameters, such as drug sensitivity, W2, and concentration as-
sociated with 50% effect, 0 50 , are fitted and can vary widely between patients, 
whereas other PK parameters can be held constant, per the discussion in Section 
7.1.1 [Oldenhof et al., 1988; Vinik et al., 1983; Albrecht et al., 1999]. Endogenous 
Agitation Reduction (EAR) is introduced into the model, and the selection of 
the EAR sensitivity parameter, W3, is also presented. 
8.1.1 Selection of G50 
The parameter 0 50 represents the concentration at which the drug, administered 
alone, would have 50% effect. Using the PK model parameters and employing 
the recorded infusion rate as the administered drug input, Equations (3.7)-(3.11) 
yield Morphine and Midazolam effect site concentration profiles for each patient. 
These profiles can be used to estimate patient-specific 0 50 values. 
These estimated 0 50 values are based on the assumption that clinical effect 
site concentration rarely becomes completely saturated. Therefore, natural initial 
estimates for 0 50 would be either the average, or 50% of the maximum, effect site 
drug concentration from Equations (3.9) and (3.11). However, the synergistic 
nature of the effect surface means that the total combined effect of the drugs 
is higher than the simple sum of the individual drug effects, regularly causing 
saturation using these estimates. Setting 0 50 to be 80% of the max effect site 
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concentration provides an effective estimate based on the data currently available, 
c~o 0.8 X max[C~(t)openloopl (8.1) 
where C~(t)openloop represents the concentration profile resulting from the concen-
tration profiles resulting from Equations (3,7)-(3.11) and employing the recorded 
infusion rate as the administered drug input, 
8.1.2 Identifying Sedative Sensitivity, W2(t) 
An integral-based fitting method is adapted from Hann et aL [2005], and ap-
plied to the agitation-sedation model to obtain the patient-specific, time-varying, 
sedative sensitivity parameter, W2(t), and the patient-specific EAR parameter, 
W3' The aim of the method is to obtain a time-varying W2 profile and time-
invariant W3 for each patient that produces a close fit of the simulated infusion 
profile to the recorded infusion profile. 
The literature supports high inter- and intra-patient variability of PD drug 
sensitivity [Barr and Donner, 1995; Young et aL, 2000; Oldenhof et al., 1988; 
Vinik et aL, 1983; Albrecht et al., 1999], Therefore, the sedative drug sensitiv-
ity parameter W2 is allowed to vary over time and between patients. On the 
other hand, the EAR sensitivity parameter, W3, is allowed to vary only between 
patients, and not over time. This decision is based on several factors: 
• Physiologically, the production rate of endorphins, the body's natural seda-
tive, is not expected to change dramatically over time. 
• Similar endogenous terms in other similar physiological ,,~rc)Ta1rn have been 
shown to be time-invariant [Hann et aL, 2005]. 
• The fitting method employed can compensate for small, time-varying changes 
in other parameters by changes in W2 over time. 
Defining E(t) KT J; EComb(T)e-KT(t-r), and integrating both sides of Equa-
tion (3.12), the following expression holds for all time, t: 
(8.2) 
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The nurse control model defined in Section 4.2 is presented again for clarity. 
U(t) (8.3) 
Substituting Equations (3.12) and (8.2) into Equation (8.3) yields an expression 
for the bolus infusion rate U(t). 
U(t) = K p e-w3t lt wlSewsT dr K p e-w3t lt w2(r)E{r)eWST dr + KdwlS 
KdW2(t)E(t) KdWae-w3t lt 111iSeW3T dr 
+ KdWae-wst lt w2(r)E(r)eW3T dr (8.4) 
Equation (8.4) can be simplified, yielding 
U(t) (Kpe-W3t Kdwae-w3t) lt w1SeW3T dr 
(Kp e-w3t - KdWae-w3t) lt w2(r)E(r)eW3Tdr 
+ KdwlS - KdW 2(t)E(t) (8.5) 
Because the recorded infusion data is updated hourly, Equation (8.5) is only 
satisfied hourly when used to fit model parameters to recorded clinical data. In 
between points, the infusion rate remains constant creating a piecewise-
constant profile. Given recorded bolus infusion data and the goal of matching 
recorded and simulated infusion rates, the recorded bolus infusion data, Urec1 can 
be used for fitting W2(t) in Equation (8.5). To accomplish this task, a piecewise-
constant W2 (t) is defined over time intervals of 1 hour: 
n 
W2 L w2(i){ H(t - 60(i 1)) H(t 60i)} 
i=l 
H{t) = { 0 if t < 0 
1 if t > 0 
(8.6) 
(8.7) 
where H (t) is the Heaviside function, n is the number of hours of data available 
for the patient's stay, and w2(i) are constant values to be determined. Letting 
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t=60min in Equation (8.5) yields: 
Ur €c(60+) = (Kpe-60W3 KdW3e-60W3) 160 w1SeW3T dT 
_(Kpe-60W3 Kdw3e-60W3)w2(1) 160 E(T)eWaTdT 
+ Kdw1S(60-) Kdwd1)E(60-) (8.8) 
where 60- and 60+ indicate the value immediately before or after the step change 
in value, respectively. Similarly, at t=120min, Equation (8.5) yields: 
(20 (Kpe-120W3 - Kdw3e-120W3) io w1SeW3T dT 
(Kpe-12Ow3 _ KdW3e-12Ow3) [W2(1) 160 E(T)eW3T dT 
+ w2(2) 1:20 E( T)eW3T dT] + KdWlS(120-) 
Kdw2(2)E(120-) (8.9) 
Hence, the general equation for the ith hour is defined: 
[60 (Kpe-60iwa - KdW3e-60iw3) io w1SeW3T dT 
_(Kpe-60iw3 _ KdW3e-60iw3) [W2(1) 160 E(T)eW3TdT 
1~ 1~] + w2(2) E(T)eW3T dT + ... + W2(n) E( T)eW3T dT 60 60(n-l) 
+ Kdw1S(120-) - Kdw2(2)E(120-) (8.10) 
where the only unknown terms in Equation (8.10) are w2(1), w2(2), ... , w2(n) and 
W3. However, if a value for W3 is assumed, the unknown terms are reduced to 
w2(1), w2(2), ... , w2(n). Writing this equation for each hour in the patient's profile 
defines a set of n equations in n unknowns, w2(1), w2(2), ... , w2(n), which can be 
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written as a matrix system for each patient: 
x =b (8.11) 
where X is a (n x m) matrix of variable coefficients from Equation (8.10) and b 
is a (n x 1) vector of resulting constants. Equation (8.11) is readily solved, for 
a given value of W3, using any least squares solver for [w2(1),w2(2), ""w2(n)]T. 
The trapezium rule is used to numerically evaluate the integrals for the known 
recorded bolus infusion, Urec(t), and stimulus, S(t), to obtain X and b. Selecting 
an array of W3 values and solving the system of equations for each value of W3 
allows the patient-specific selection of W3, with simultaneous identification of 
W2(t). 
To reduce the effects of noise, pre- and post- three-point moving average 
smoothing steps are used in conjunction with upper and lower constraints on 
W2(t) to eliminate unrealistic high-frequency parameter changes. The constraints 
placed on W2(t) are 1e-6 < W2 < 1e-2 to prevent non-physiological small (or 
negative) and large values, respectively. 
The parameter fitting method described above is used to obtain the W2(t) 
parameter profile for the array of sedative sensitivity values W3 = [0 0.000001 
0.00001 0.0001 0.001 0.01] for each patient. The resulting W2(t) vector, and 
the associated W3 value, can then be used in a model simulation with the nurse 
control protocol and IIR filter, and the resulting simulated U(t) compared to the 
recorded infusion data to verify the identified parameters. 
To assess the sensitivity of the model to the time-varying W2(t), the fitted 
W2(t) profile is also smoothed using a 12-hour moving average. The results of the 
model are also observed when the sedative sensitivity, W2, is set equal to the mean 
value of the central 50% of the fitted W2(t) profile. In all cases, the initial portion 
of the W2(t) profile for each patient remains as per the parameter-fitting, as the 
initial phase is influenced by the zero-value initial conditions. The overall set of 
three simulations (fitted, 12-hour smoothed, and constant W2) provide insight as 
to how W2(t) actually varies with time and its impact on the model and results. 
The three levels of time-variance investigated are: 
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.. Fitted W2(t) profile 
• 12-hour smoothed W2(t) profile 
III Constant W2 profile 
8.2 Results and Discussion 
This section presents the results of the parameter fitting processes. In partic-
ular, the selected O~ij' values are presented, and the summary statistics for the 
time-varying W2(t) are presented for each patient, along with figures displaying 
examples of the resulting fitted W2(t) profiles. The results of different W3 are 
then presented. These selected parameters are then implemented in the model 
and the resulting evaluation metrics presented. Finally, the time variation of 
sedative sensitivity is investigated and the results presented. 
8.2.1 C50 Parameter Selection 
The G50 values for Morphine and Midazolam are evaluated for each patient using 
the method described in Section 8.1. The resulting selected values are presented 
in Table 8.1. Due to size, all tables in this chapter, including Table 8.1, are 
located at the end of this Chapter for clarity and ease of use. For Morphine, 
G50 has a range of [0.014, 0.143] across all patients, and a median value of 0.052 
respectively. For Midazolam, Gso has a range of [0.013, 0.132] across all patients, 
and a median value of 0.042 respectively. The large range of both Ggo and 0 50, 
along with the high IQR, indicate a high inter-patient variability. This result 
is consistent with published results [Oldenhof et al., 1988; Vinik et al., 1983; 
Albrecht et al., 1999]. 
The method described to estimate the patient-specific, time-invariant G50 
value for Morphine and Midazolam is simple and effective. Although the values 
are only an estimate, it is clear from the model formulation in Figure 3.3 that 
the system is not particularly sensitive to the G50 value. More specifically, if the 
Gso values are moderately altered, it shifts the locus of the simulation on the 
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response surface only a small amount. Note also that the fitting method used to 
fit sedative sensitivity is capable of compensating for minor discrepancies in G50 . 
Table 8.1 shows that lQR of the G50 values is large enough to indicate 
that while employing a time-invariant G50 may be satisfactory for a given patient, 
G50 is clearly not constant across all patients. If fixed values of G50 were used 
across all patients, some patients would remain high in the saturated plateau of 
the response curve of Figure 3.3, while others would be on the low portion where 
the drugs have little sedative effect, leading to poor model performance. There-
fore, while the exact patient-specific determination of G50 is not important, these 
values are clearly patient-specific. This result indicates that each lCU patient 
has a different sensitivity to the drugs. For example, a plasma concentration 
of 0.02mg/L may have a significant effect on one patient, whereas it may have 
little effect on another. This last result is regularly observed and well accepted 
in clinical practice [Albrecht et aL, 1999; Wagner and O'Hara, 1997]. 
8.2.2 Fitting Sedative Sensitivity, w2(i) 
The method for W2 (t) described in Section 8.1.2 requires the initial selection 
of a W3 value. The specific results of W3 selection are presented in Section 8.2.4. 
However, for Sections 8.2.2 and 8.2.3, the selected value of W3 = 0.0001 is used 
without explanation. Implementing W3 = 0.0001 for all patients and fitting W2(t) 
yields a time-varying sedative sensitivity profile for each patient. Examples of 
these profiles are presented in Figures 8.1-8.3, and the summary statistics of 
each patient's fitted W2(t) are presented in Table 8.2, located at the end of this 
Chapter for clarity and ease of use. 
The parameter fitting method presented to identify W2(t) is seen to 
tive, both the high numerical evaluation metrics in Table 8.3 at the end of this 
chapter, and the close proximity of the simulated infusion rate to the probabil-
ity band in the Figures 8.1-8.3. The parameter identification method employed 
is both effective at fitting the recorded data and computationally inexpensive, 
making it suited to real-time clinical applications 
Table 8.2 highlights the importance of a time-varying, patient-specific seda-
tive sensitivity. The median value across all patients of the median W2(t) has 
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Figure 8.1 Plot showing the effect of time-invariance in W2(t) using the physiologically-based 
model for Patient 5. 
a value of 4.60 x 10-4 and IQR=6.34 x 10-4 . The final column of Table 8.2 
presents the IQR of each patient's profile, and shows that the median and IQR 
are 2.96xlO-4 and 5.79x10-4 respectively. The large median ofthe IQR column 
compared to the median of the median column indicates that there are important 
variations in sedative sensitivity throughout time for most patients. However, the 
lower quartile and minimum values of the IQR in the final column suggest that 
the time-varying nature of sedative sensitivity is not necessarily important for all 
patients. 
Similarly, the large range in the first column and high IQR in the second 
column of Table 8.2 indicate that sedative sensitivity has significant inter-patient 
variability. These results with studies that have found that PD parameters 
vary significantly between patients [Oldenhof et al., 1988; Albrecht et al., 1999J. 
Therefore, identifying these changes is critical for understanding and optimising 
agitation management. 
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Figure 8.2 Plot showing the effect of time-in variance in W2(t) using the physiologically-based 
model for Patient 14. 
8.2.3 Effect of Time-Variation on Model Evaluation Met-
rics 
Tables 8.3-8.5, located at the end of this Chapter for clarity and ease of use, 
present the evaluation metrics RAND, AND, TIB and RTD for simulations with 
the fitted, smoothed and constant W2(t) for all patients with W3 0.0001, com-
paring model performance with increasing levels of time-invariant drug sensitivity. 
Results are presented for three levels of time-variance: 
!II Fitted W2(t) profile 
!II 12-hour smoothed W2(t) profile 
• Constant W2 profile 
Table 8.6 presents only the RAND for the fitted, smoothed and constant profiles 
for clear comparison, and is also located at the end of this chapter. 
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Figure 8.3 Plot showing the effect of time-invariance in W2(t) using the physiologically-based 
model for Patient 33. 
The median and IQR of the RAND values with fitted W2(t) in Table 8.3 
is 0.94 and 0.09 respectively, with range [0.65, 1.00]. The median and IQR of 
the TIB values with fitted W2(t) is 0.93 and 0.05 respectively, with range [0.87, 
0.97]. The median and IQR of the RTD values with fitted W2(t) is 0.99 and 0.02 
respectively, with range [0.93, 1.02]. 
The median and IQR of the RAND values with smoothed W2(t) in Table 8.4 
is 0.78 and 0.08 respectively, with range [0.55, 0.91]. The median and IQR of the 
TIB values with smoothed W2(t) is 0.89 and 0.06 respectively, with range [0.81, 
0.97]. The median and IQR of the RTD values with smoothed W2(t) is 0.99 and 
0.03 respectively, with range [0.93, 1.01]. 
The median and IQR of the RAND values with constant W2(t) in Table 8.5 
is 0.54 and 0.21 respectively, with range [0.18, 0.80]. The median and IQR of the 
TIB values with constant W2(t) is 0.68 and 0.25 respectively, with range [0.19, 
0.93]. The median and IQR of the RTD values with constant W2(t) is 0.95 and 
0.12 respectively, with range [0.48, 1.09]. 
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Figures 8.1-8.3 present examples of the fitted, smoothed and constant W2(t) 
profiles, and the fit to the available recorded data when these W2(t) profiles are 
implemented in the model in with W3 = 0.0001. In these figures, the upper 
plot presents the sedative sensitivity, W2(t), while the lower plot presents the 
associated simulated infusion profiles. In both the upper and lower plots, the dark 
solid line represents the fitted profile, the dashed line represents the smoothed 
profile, the dotted line represents the time-invariant profile and the shaded grey 
area indicates the 99% probability band overlaid on the thin-line recorded infusion 
profile. 
Comparing the graphical results of the probability band and the RAND val-
ues, it is clear that RAND is a very stringent measure and is very sensitive to 
minor deviations. This result is particularly obvious when Figures 8.1 and 8.2 
are compared to the numerical values of RAND in Tables 8.3-8.5 for Patients 
5 and 14. Where these figures display a slightly worse fit to the recorded data 
in the case of the smoothed and time-invariant profiles, the RAND values for 
Patient 5 decreases from 1.00 to 0.84 for the 12-hour smoothed case, and further 
to 0.63 using a constant W2(t). Therefore, as previously mentioned, RAND> 0.5 
is considered a reasonable model evaluation threshold. 
The high median RAND of 0.94 and range [0.65, 1.00], as well TIB and RTD 
values with medians of 0.93 and 0.99, indicate that the fitting method produces a 
sedative sensitivity profile, W2(t), for each patient that produces simulated results 
closely fitting the recorded data. The W2(t) profile captures physiological changes 
in sedative sensitivity, as well as any other time-varying dynamics that may be 
present, including noise. These other dynamics can include things such as model 
shortfalls, transient dynamics not captured by the model, time-varying changes 
to the state of the patient, errors/inconsistancies in any of the other parameters, 
sensor error, and/or errors/subjectivity embedded in the recorded infusion data. 
Hence, some portion of the observed variation for a given patient may be due to 
any of these issues. 
By increasing the time invariance of W2(t), the effect of many of these other 
influences is reduced. Using a 12-hour moving average filter smoothes out short-
term changes in W2(t) to represent a more physiologically-realistic sedative sen-
sitivity profile. The results can be seen graphically in Figures 8.1-8.3, and nu-
merically in Table 8.6. The dashed lines in the upper plots of Figures 8.1-8.3 
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clearly show the small time-scale changes that are removed by 12-hour smooth-
ing. As seen in the lower plots, the simulated infusion profile for the smoothed 
parameter is not drastically different from the un smoothed version. Due to the 
greater stringency of the RAND value, the decrease in fit is more obvious in this 
metric. However, with a minimum RAND across all patients of 0.55, the fit is 
still acceptable by this standard. 
For some patients, the removal of short term dynamics from the fitted W2(t) 
by smoothing has very little effect, as seen in Figures 8.1 and 8.2. For other 
patients, the variations are more important, at least for some portion of their 
stay. This impact would be more evident for those patients with noticeably 
decreased RAND. A good example of a case where there are distinct regions 
in which changes in W2(t) are important can be seen in Figure 8.3. From 0-50 
hours, W2(t) remains relatively high. From 50-100 hours W2(t) is significantly 
reduced. From 100-150 hours, W2(t) returns to a high value. Finally, from 150 
hours onward W2(t) is much lower again. In each region, the level of fluctuation 
around the smoothed line varies as well. While the exact cause for this feature is 
unknown, it may be a result of changes in the physiological status of the patient 
as their condition in the IOU evolves. 
Figures 8.1-8.3 also display the sedative sensitivity profile and resulting in-
fusion rate for time-invariant W2(t). In this case, W2(t) equals the mean of the 
central 50% of the fitted W2(t) values, as a representative value for the whole 
record. In some cases, the result has minimal effect, as seen in Table 8.6 for 
Patients 1-3 and 5, for example, and observed in Figure 8.1. For over half of 
the patients, constant sedative sensitivity still results in RAND values greater 
than 0.5. This result does not suggest that for the remaining nearly 50% of pa-
tients a time-invariant sedative sensitivity cannot result in a good fit, but rather 
that the particular sedative sensitivity value employed does not result in a good 
fit. In many of these cases, the poor fit is due to the specific selection of the 
time-invariant sedative sensitivity value. For example, in Figure 8.3 it is clear 
that a lower time-invariant sedative sensitivity value would result in a better fit, 
at least for the majority of the recorded period. Hence, experience and initial 
analysis indicate that significant improvements in fit can be made by utilising a 
very simple piecewise-constant sedative sensitivity with slow time variation. 
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Finally, it is clear that W2(t) is a patient-specific parameter relating to overall 
drug sensitivity, which is a critical parameter if sedation management is to be 
optimised for each patient. The results of smoothed and time-invariant forms of 
W2(t) indicate that the agitation-sedation system is insensitive to minor, short-
term changes in this parameter. However, in many patients long term changes 
in sedative sensitivity over time are observed and are important features. These 
results contribute important insights toward understanding the agitation-sedation 
system, and the way patient parameters change over time. 
8.2.3.1 Summary 
The parameter identification method employed is both effective at fitting the 
recorded data and computationally inexpensive, making it suited to real-time 
clinical applications. RAND is seen to be an effective, statistically rigorous, and 
stringent evaluation metric for model assessment and evaluation. The parameter 
C50 is time-invariant but shown to have a high inter-patient variability. However, 
the model is reasonably insensitive to accurate selection of C50 for a given patient 
and the subsequent W2(t) fitting method is capable of adapting accordingly. 
Acceptable RAND values for all 37 leU patients resulted from the 12-hour 
smoothed sedative sensitivity and support the model as a sound platform for 
the development and testing of advanced control protocols for semi-automated 
sedation systems. Sedative sensitivity, W2(t), is found to be both patient-specific 
and time-varying. However, while the variation between patients can be as large 
as a factor of 10, the variation in time is smaller, and varies only slowly over a 
period of days rather than hours. This last result indicates that drug sensitivity 
is not likely to be regulated by hormonal action or patient condition (as might 
be expected), and instead may be due to the physiology surrounding the blood 
brain barrier. It may also vary, over days, as patient condition evolves. 
Finally, the high evaluation metrics reported for RAND, TIB and RTD show 
that the extended agitation-sedation model explored in this chapter is capable of 
capturing the fundamental dynamics of the agitation-sedation system, particu-
larly in comparison to prior models. While there are clearly observed dynamics 
that the model does not capture, many of the dynamics common to most patients 
are incorporated in the model. Overall the model captures the fundamental dy-
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namics, both long and short term, seen in critical care patients. 
8.2.4 Selecting W3 
This section presents the results of using the parameter fitting method presented 
in Section 8.1.2 to fit W2(t) for an array of values for W3. The RAND values can 
then be used to select an optimal W3 value for each patient. Table 8.7, located at 
the end of this chapter, presents the RAND values of the simulations resulting 
from the use of the smoothed W2(t) sedative sensitivity profiles for varying values 
of W3 from Section 8.2.3. The W3 value corresponding to the best fit between 
the simulated and recorded data for all patients was w3=0.0001. The evaluation 
metrics in Table 8.7 shows high values for the model with the EAR dynamic 
(w3=0.0001) and without (W3=0). 
The RAND values for simulations without EAR have a median of 0.77 with 
IQR 0.09 and range [0.51, 0.89]. Similarly, the RAND values for simulations 
including EAR have a median of 0.78 with IQR 0.08 and range [0.55, 0.91]. 
For W3 =0.00001 (column 2) slightly lower values of the evaluation metrics are 
observed, and for W3 0.001 (column 4) even lower values are observed, when 
compared to W3 0.0001 (column 3). 
These generally high evaluation metrics correspond to very close fits of the 
simulated infusion rate to the recorded infusion rate, as shown in Figures 8.4~8,6. 
In these figures, the upper plot shows the time-varying profile of the fitted W2(t), 
while the lower plot shows the resulting fit of the simulated and recorded infusion 
rates. In each of these figures, the dark solid line shows the results without the 
inclusion of EAR, and the dark dotted line shows the results including EAR. The 
light solid line in the lower plots shows the recorded infusion rate, and its 99% 
probability band is the grey band around it. 
The best fit between the simulated and recorded data was obtained using 
w3=0.0001 for all patients, which shows the low inter-patient variability and 
sensitivity of the EAR parameter. Although in many cases (e.g. Patients 1, 
30) other values of W3 produce similar performance and patient-specific values 
of W3 may improve the fit for specific patients, an optimum value of w3=0.0001 
for all patients indicates that W3 is relatively insensitive and can be assumed 
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Figure 8.4 Plot of the effect of EAR using the physiologically-based model for Patient 2. 
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Figure 8.5 Plot of the effect of EAR using the physiologically-based model for Patient 36. 
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Figure 8.6 Plot of the effect of EAR using the physiologically-based model for Patient 37. 
constant across all patients. The sensitivity of the model to the value of W3 is 
reduced further by the fitting process for w~(t), which can compensate for slightly 
incorrect selection of W3 [Hann et al., 2005]. 
This result indicates that while other PD parameters, such as G50 , are patient-
specific and exhibit a high inter-patient variability, W3 remains constant across 
all patients. This result is in contrast to most PD studies that support high 
inter-patient variability in PD dynamic parameters. One reason why the same 
value is optimal for all patients may be the fact that the resolution of the array 
of W3 was too coarse. If an array W3 = [0 0.0001 0.0002 0.0004 0.0006 0.0008] 
was used, more patient-specific W3 values may result. 
However, Table 8.7 shows that even with a selection of W3 differing by orders 
of magnitude, the performance summary statistics are not drastically altered. 
Whether W3 is patient-specific, time-varying, or non-existent, has only a mild 
effect on the resulting evaluation metrics across all the patients. These results 
show the insensitivity of the model to the W3 parameter, a..s experienced in other 
similar physiological systems [Hann et al., 2005]. However, while the effect of the 
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EAR term is minimal across all patients, the dynamic is particularly important 
for some patients and/or clinical scenarios in particular. 
The impact of EAR can be seen by comparing columns 1 and 3 in Table 8.7. 
The median and upper and lower quartiles of the RAND and TIB for the model 
including EAR are all higher than those without EAR, and the IQR of these 
metrics is reduced for the model including EAR. These results indicate that the 
addition of the EAR dynamic improves the ability of the model to capture the 
observed dynamics of the agitation-sedation system. 
The upper plots in Figures 8.4-8.6 show that while the difference is small, 
the inclusion of EAR results in a slight decrease in W2(t) throughout the entire 
profile, especially where infusion rates in the lower plot are very low. Note that 
when infusion rates are very low the primary means of agitation reduction would 
be due to EAR. Hence, the EAR dynamic has the greatest effect during periods 
of low sedation infusion where there is less exogenous agitation reduction from 
sedative agents. Such periods would most notably include sedative weaning prior 
to extubation. 
Visually, the lower plots on Figures 8.4-8.6 show that both models produce 
infusion profiles closely approximating the recorded infusion profiles. The fact 
that the solid and dotted dark lines on the bottom plot in these figures are 
difficult to distinguish indicates that the simulated infusion rates are very similar 
whether EAR is included or not. High median RAND values for both models 
of 0.77 (without EAR) and 0.78 (with EAR), support this visual finding with a 
statistically-based objective measure. Minimum RAND values of 0.51 and 0.55 for 
the two respective models reinforce this result. These results support both models 
as appropriate representations of the fundamental agitation-sedation dynamics 
present in a broad spectrum of ICU patients. 
While the addition of the EAR dynamic increases the ability of the model to 
capture the observed dynamics of the agitation-sedation system, the improvement 
is relatively small. Further, the sensitivity of the model to the W3 parameter is low. 
This feature is also found in non-drug mediated endogenous removal mechanisms 
in similar dynamic systems such as the glucose-insulin system [Hann et al., 2005; 
Chase et al., 2005b]. 
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This last result offers the question of whether the EAR dynamic should be 
included at all. It may be possible that the errors and assumptions in the devel-
opment of the model and the evaluation metrics are larger than the difference in 
performance between the model with and without EAR. Although this issue may 
represent a limitation of the model, it is important to note that the inclusion of 
EAR is important for accurately capturing periods of low, or no, sedative infusion 
that occur clinically, such as weaning. 
The evaluation metrics summarised in Table 8.7 are achieved using very few 
patient-specific PD parameters and identical PK parameters across all patients. 
This result further supports the finding that inter-patient pharmacological vari-
ability is due primarily to PD differences rather than PK differences, as reported 
in the literature [Vinik et al., 1983; Albrecht et al., 1999]. However, the insensi-
tivity of the W3 parameter and its smaller impact on results indicate that EAR is 
not a significant PD parameter in this case. However, EAR becomes important 
when simulating low infusion rates, such as during weaning. Therefore, although 
EAR is not always a significant dynamic, it is important during specific clinical 
periods. Because it has no negative impact during other periods and introduces 
no additional parameter identification burden, it should be retained in the modeL 
some patients high W2 values are <?bserved immediately after periods of 
relatively constant W2, as seen in Figure 8.4-8.6. Although this feature is some-
times located centrally in recorded data, in many cases this feature is observed at 
the end of recorded data and may correspond to sedative weaning. More specif-
ically these observations may be the result of an actual physiological change in 
sedative sensitivity as the patient's health improves prior to leaving the lCU. 
However, the magnitudes of the changes are in some cases quite large, which 
indicates that the change in observed sedative sensitivity may also be the result 
of an entirely separate dynamic. 
One such dynamic could be the delayed release of drugs stored in fatty tissue 
[Hughes et aL, 1992]. Although the peripheral compartment includes the fatty 
tissues into which these drugs and/or metabolites can be deposited, this dynamic 
may be considerably more prominent than currently modelled, requiring an addi-
tional separate storage compartment. Because benzodiazepines are lipid soluble, 
long-term infusions can lead to depositions of large amounts of the administered 
drug in fatty tissues [Arbour, 2000; Hughes et al., 1992; Kress et al., 2002]. When 
132 CHAPTER 8 PARAMETER IDENTIFICATION AND SENSITIVITY ANALYSIS 
the sedative administration stops, the stored drug is released back into circula-
tion as concentrations fall [Kress et al., 2000; Barr and Donner, 1995; Arbour, 
2000; Hughes et al., 1992]. If this dynamic was present during the clinical data 
recordings, the effect would be an inflated observed sedative sensitivity, W2, at 
the end of the record due to "extra" drug availability in the system. It would also 
have the effect of lowering W2(t) through the middle of the record where there 
was actually less drug available due to this storage for later release. Further 
investigation is required to determine the effects of this storage dynamic. 
Finally, the model incorporates physiological drug effect saturation dynam-
ics, seen in the dual-sigmoid surface in Figure 3.3. Physiological metabolism 
and excretion of Morphine and Midazolam is limited by renal and hepatic clear-
ance capacity. However, the maximum clearance rate and plasma concentrations 
at which the dynamics change from first-order to saturated zero-order kinetics 
are not easily obtained, particularly in the lCU population. A lack of avail-
able parameter values therefore makes the immediate implementation of more 
representative Michaelis-Menton saturation dynamics difficult, particularly with 
regard to drug clearance. Clinical trials with quantified agitation sensors [Chase 
et al., 2004c,b] and measured plasma drug concentrations could provide the data 
to improve these model parameters and add any necessary additional dynamics. 
8.2.4.1 Summary 
The physiologically-based model captures the essential dynamics of the agitation-
sedation system, both with and without the EAR dynamic. High median RAND 
values of 0.77 (without EAR) and 0.78 (with EAR) and minimum RAND values 
of 0.51 and 0.55 for the two respective models show that both models are appro-
priate representations of the fundamental agitation-sedation dynamics present in 
a broad spectrum of lCU patients. While the addition of the EAR dynamic in-
creases the ability of the model to capture the observed dynamics of the agitation-
sedation system, the improvement is relatively small and the sensitivity of the 
model to the W3 parameter is low. Although this may represent a limitation of 
the model, the inclusion of EAR is important for accurately capturing periods of 
low, or no, sedative infusion, such as weaning. 
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Table 8.1 Selected patient-specific Gso values employed in the physiologically-based model 
oa 50 Oso 
1 0.025 0.018 
2 0.018 0.014 
3 0.030 0.022 
4 0.065 0.050 
5 0.019 0.016 
6 0.073 0.061 
7 0.018 0.016 
8 0.107 0.091 
9 0.045 0.042 
10 0.041 0.035 
11 0.122 0.096 
12 0.041 0.034 
13 0.086 0.066 
0.017 0.016 
15 0.055 0.049 
16 0.085 0.078 
17 0.050 0.035 
18 0.085 0.074 
19 0.116 0.111 
20 0.041 0.036 
21 0.021 0.017 
22 0.063 0.060 
23 0.040' 0.029 
24 0.052 0.038 
25 0.052 0.049 
26 0.014 0.013 
27 0.091 0.082 
28 0.030 0.028 
29 0.053 0.041 
30 0.025 0.020 
31 0.104 0.094 
32 0.143 0.132 
33 0.113 0.111 
34 0.063 0.053 
35 0.045 0.039 
36 0.071 0.057 
37 0.070 0.054 
Max 0.143 0.132 
UQ 0.085 0.066 
Med 0.052 0.042 
LQ 0.030 0.028 
Min 0.014 0.013 
IQR 0.055 0.038 
134 CHAPTER 8 PARAMETER IDENTIFICATION AND SENSITIVITY ANALYSIS 
Table 8.2 Summary of the fitted patient-specific W2(t) values employed in the physiologically-
based model 
1 
2 1.37 
3 2.16 
4 5.86 6.20 
5 1.55 1.08 
6 12.2 8.07 
7 1.79 2.96 
8 9.13 4.55 
9 3.88 1.75 
10 4.60 7.18 
11 15.5 47.0 
12 3.17 1.39 
13 10.4 14.6 
14 1.38 1.11 
15 4.53 2.53 
16 7.17 3.09 
17 3.47 1.31 
18 8.53 18.2 
19 10.4 3.67 
20 4.13 2.12 
21 1.69 .1.24 
22 5.68 2.66 
23 3.88 3.96 
24 3.74 1.48 
25 4.50 2.06 
26 1.20 0.57 
27 10.4 11.8 
28 2.79 1.11 
29 4.79 3.55 
30 1.88 1.11 
31 10.4 6.74 
32 13.2 7.52 
33 11.5 15.3 
34 5.04 2.28 
35 5.02 3.33 
36 6.74 22.4 
37 13.3 16.2 
Max 15.5 47.0 
UQ 9.13 7.18 
Med 4.60 2.96 
LQ 2.79 1.39 
Min 1.20 0.57 
IQR 6.34 5.79 
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Table 8.3 Evaluation metrics for the physiologically-based model employing the fitted W2(t) 
RAND AND TIB RTD 
2 0.94 0.75 0.94 0.98 
3 0.87 0.73 0.96 1.00 
4 0.72 0.65 0.88 0.94 
5 1.00 0.76 0.92 0.98 
6 0.89 0.75 0.94 0.99 
7 0.96 0.74 0.91 0.95 
8 1.00 0.76 0.92 0.99 
9 0.94 0.75 0.91 1.00 
10 0.99 0.80 0.95 0.99 
11 0.87 0.71 0.92 1.02 
12 0.89 0.71 0.95 0.98 
13 0.90 0.74 0.91 0.97 
14 0.65 0.56 0.94 0.96 
15 0.97 0.71 0.95 1.00 
16 0.99 0.76 0.94 0.99 
17 0.96 0.81 0.94 0.97 
18 0.93 0.75 0.90 0.99 
19 1.00 0.77 0.96 1.00 
20 1.00 0.82 0.96 0.99 
21 0.94 0.70 0.90 0.98 
22 0.89 0.69 0.88 0.99 
23 0.79 0.67 0.89 0.93 
24 0.95 0.76 0.94 0.99 
25 0.82 0.62 0.88 1.00 
26 1.00 0.79 0.96 0.99 
27 0.96 0.76 0.91 0.99 
28 0.94 0.72 0.93 1.00 
29 0.66 0.56 0.93 0.94 
30 0.96 0.74 0.94 0.99 
31 1.00 0.80 0.95 1.00 
32 1.00 0.77 0.93 0.99 
33 0.98 0.76 0.95 1.00 
34 0.94 0.72 0.90 0.99 
35 0.89 0.73 0.87 1.01 
36 0.89 0.72 0.87 0.99 
37 0.84 0.75 0.90 0.96 
Max 1.00 0.82 0.97 1.02 
UQ 0.98 0.76 0.95 1.00 
Med 0.94 0.75 0.93 0.99 
LQ 0.89 0.71 0.90 0.98 
Min 0.65 0.56 0.87 0.93 
IQR 0.09 0.05 0.05 0.02 
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Table 8.4 Evaluation metrics for the physiologically-based model employing the 12-hour 
smoothed W2 (t) 
RAND AND TIB RTD 
1 0.79 0.73 0.97 1.00 
2 0.84 0.67 0.92 0.98 
3 0.74 0.63 0.95 1.00 
4 0.69 0.62 0.89 0.96 
5 0.84 0.64 0.86 0.97 
6 0.83 0.70 0.92 0.99 
7 0.79 0.61 0.86 0.93 
8 0.77 0.58 0.85 0.99 
9 0.75 0.60 0.82 1.01 
10 0.82 0.66 0.89 0.98 
11 0.75 0.62 0.89 1.01 
12 0.76 0.61 0.91 0.98 
13 0.82 0.68 0.88 0.97 
14 0.55 0.47 0.90 0.97 
15 0.77 0.56 0.88 1.01 
16 0.73 0.56 0.84 1.00 
17 0.86 0.73 0.89 0.98 
18 0.84 0.68 0.84 0.98 
19 0.89 0.66 0.94 1.00 
20 0.91 0.74 0.94 0.99 
21 0.81 0.60 0.85 0.96 
22 0.72 0.57 -0.83 0.98 
23 0.76 0.65 0.89 0.93 
24 0.78 0.62 0.91 0.99 
25 0.69 0.53 0.81 1.01 
26 0.88 0.68 0.92 0.99 
27 0.77 0.61 0.83 0.97 
28 0.82 0.62 0.88 1.00 
29 0.70 0.59 0.94 0.93 
30 0.87 0.68 0.90 0.99 
31 0.86 0.68 0.93 1.00 
32 0.79 0.61 0.87 0.99 
33 0.81 0.63 0.89 0.99 
34 0.77 0.59 0.84 1.00 
35 0.78 0.64 0.84 1.00 
36 0.74 0.60 0.84 0.97 
37 0.76 0.68 0.89 0.96 
Max 0.91 0.74 0.97 1.01 
UQ 0.83 0.68 0.91 1.00 
Med 0.78 0.62 0.89 0.99 
LQ 0.75 0.60 0.85 0.97 
Min 0.55 0.47 0.81 0.93 
IQR 0.08 0.08 0.06 0.03 
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Table 8.5 Evaluation metrics for the physiologically-based model employing the constant W2 
RAND AND TIB RTD 
1 0.66 0.61 0.86 0.86 
2 0.64 0.52 0.75 1.01 
3 0.75 0.63 0.93 0.94 
4 0.54 0.48 0.75 1.02 
5 0.63 0.48 0.71 1.02 
6 0.63 0.53 0.72 0.86 
7 0.28 0.22 0.32 0.90 
8 0.33 0.25 0.46 0.87 
9 0.56 0.45 0.66 1.02 
10 0.27 0.22 0.36 0.48 
11 0.18 0.15 0.19 0.80 
12 0.71 0.57 0.89 0.97 
13 0.37 0.30 0.57 0.96 
14 0.51 0.43 0.89 1.00 
15 0.71 0.52 0.83 1.00 
16 0.55 0.42 0.71 0.97 
17 0.70 0.59 0.75 0.96 
18 0.47 0.38 0.50 0.82 
19 0.58 0.43 0.62 1.08 
20 0.65 0.53 0.74 0.92 
21 0.59 0.44 0.67 0.94 
22 0.43 0.34 0.51 0.90 
23 0.65 0.56 0.80 0.91 
24 0.58 0.47 0.76 0.98 
25 0.53 0.40 0.55 1.09 
26 0.80 0.62 0.83 0.99 
27 0.29 0.23 0.36 0.87 
28 0.62 0.47 0.75 0.97 
29 0.43 0.36 0.76 0.91 
30 0.60 0.46 0.71 1.07 
31 0.32 0.25 0.36 0.86 
32 0.42 0.32 0.50 0.97 
33 0.19 0.15 0.24 0.74 
34 0.53 0.41 0.64 0.95 
35 0.45 0.37 0.55 0.99 
36 0.35 0.28 0.38 0.94 
37 0.45 0.41 0.68 0.78 
Max 0.80 0.63 0.93 1.09 
UQ 0.63 0.52 0.75 0.99 
Med 0.54 0.43 0.68 0.95 
LQ 0.42 0.32 0.50 0.87 
Min 0.18 0.15 0.19 0.48 
rQR 0.21 0.20 0.25 0.12 
138 CHAPTER 8 PARAMETER IDEKTIFICATION AKD SENSITIVITY ANALYSIS 
Table 8.6 Comparison of RAND for the physiologically-based model employing the fitted, 
12-hour smoothed, and constant wz(t) 
1 
2 0,94 0,84 
3 0,87 0,74 0.75 
4 0.72 0.69 0,54 
5 1.00 0.84 0.63 
6 0,89 0.83 0.63 
7 0.96 0.79 0.28 
8 1.00 0.77 0.33 
9 0.94 0.75 0.56 
10 0.99 0.82 0.27 
11 0.87 0.75 0.18 
12 0.89 0.76 0.71 
13 0.90 0.82 0.37 
14 0.65 0.55 0.51 
15 0.97 0.77 0.71 
16 0.99 0.73 0.55 
17 0.96 0.86 0.70 
18 0.93 0.84 0.47 
19 1.00 0.89 0.58 
20 1.00 0.91 0.65 
21 0.94 0.81 0.59 
22 0.89 0.72· 0.43 
23 0.79 0.76 0.65 
24 0.95 0.78 0.58 
25 0.82 0.69 0:'53 
26 1.00 0,88 0.80 
27 0.96 0.77 0.29 
28 0.94 0.82 0.62 
29 0.66 0,70 0.43 
30 0.96 0.87 0.60 
31 1.01 0.86 0,32 
32 1.00 0.79 0.42 
33 0.98 0.81 0.19 
34 0.94 0,77 0.53 
35 0,89 0,78 0.45 
36 0.89 0.74 0.35 
37 0.84 0.76 0.45 
Max 1.00 0.91 0.80 
UQ 0.98 0.83 0.63 
Med 0,94 0.78 0.54 
LQ 0.89 0.75 0.42 
Min 0,65 0.55 0,18 
IQR 0.09 0.08 0.21 
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Table 8.7 Comparison of RAND for physiologically-based model employing the 12-hour 
smoothed W2(t) and varying W3 
W3 0 1 X 10 1) 1 X 10-4 1 X 10 :3 Max 
1 0.79 0.79 0.79 0.55 0.79 
2 0.80 0.81 0.84 0.35 0.84 
3 0.69 0.69 0.74 0.23 0.74 
4 0.69 0.69 0.69 0.47 0.69 
5 0.83 0.83 0.84 0.21 0.84 
6 0.82 0.82 0.83 0.40 0.83 
7 0.77 0.78 0.79 0.44 0.79 
8 0.74 0.75 0.77 0.18 0.77 
9 0.73 0.73 0.75 0.22 0.75 
10 0.78 0.78 0.82 0.41 0.82 
11 0.71 0.71 0.75 0.49 0.75 
12 0.73 0.74 0.76 0.21 0.76 
13 0.79 0.79 0.82 0.41 0.82 
14 0.51 0.51 0.55 0.28 0.55 
15 0.76 0.76 0.77 0.18 0.77 
16 0.71 0.71 0.73 0.15 0.73 
17 0.86 0.86 0.86 0.25 0.86 
18 0.80 0.80 0.84 0.42 0.84 
19 0.88 0.88 0.89 0.15 0.89 
20 0.89 0.89 0.91 0.39 0.91 
21 0.79 0.79 0.81 0.31 0.81 
22 0.69 0.69 0,72 0.28 0.72 
23 0.75 0.75 0.76 0.51 0.76 
24 0.77 0.77 0.78 0.24 0.78 
25 0.67 0.67 0.69 0.14 0.69 
26 0.86 0.86 0.88 0.33 0.88 
27 0.70 0.71 0.77 0.45 0.77 
28 0.79 0.80 0.82 0.25 0.82 
29 0.60 0.62 0.70 0.24 0.70 
30 0.87 0.87 0.87 0.30 0.87 
31 0.83 0.84 0.86 0.34 0.86 
32 0.77 0.77 0.79 0.17 0.79 
33 0.78 0.79 0.81 0.30 0.81 
34 0.73 0.74 0.77 0.18 0.77 
35 0.75 0.75 0.78 0.39 0.78 
36 0.64 0.65 0.74 0.59 0.74 
37 0.73 0.74 0.76 0.48 0.76 
UQ 0.80 0.80 0.83 0.41 0.83 
Med 0.77 0.77 0.78 0.30 0.78 
LQ 0.71 0.71 0.75 0.22 0.75 
Min 0.51 0.51 0.55 0.14 0.55 
IQR 0.09 0.09 0.08 0.19 0.08 
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Part III 
Control 

Chapter 9 
Control Specifications 
Parts I-II of this thesis presented and evaluated the developed models of agitation-
sedation dynamics. Each of these models are used in turn as a platform for the 
development and evaluation of sedative infusion protocols to minimise agitation 
and total dose. Simple derivative-focused control approaches are explored and op-
timal and non-linear control strategies that offer additional potential and insight 
are also investigated. Rather than analysing the impact of various controllers 
on the physiological model only, controllers are evaluated on each of the mod-
els consecutively. This approach allows assessment of the impact of the various 
dynamics captured by each of the models on control, and helps to identify the 
clinically important aspects of each modeL Contrasting and comparing the im-
pact of various controllers on each of the models enables analysis of: 
• The impact of various control approaches on the initial model, thereby 
understanding the capabilities of controllers in the absence of saturation 
limits. 
• The impact of various control approaches on the physiological model, thereby 
understanding the ability of controllers to manage agitation in a non-linear 
model with physiological factors, such as saturation, limit the effectiveness 
of control. 
.. The performance of the same control approach across different models, 
hence identifying dynamics of the agitation-sedation system that have im-
portant consequences for controller development, such as saturation. 
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Therefore, each of the models presented in Parts I-II of this thesis are analysed 
with various control approaches, allowing contrasts and comparisons between 
control protocols and across models. 
9.1 Goals of Sedation 
The goal of sedation in the ICU is to reduce anxiety, control agitation, and 
produce a patient who is calm, cooperative, and preferable able to communicate 
[Fragen, 1997]. Therefore, the ideal sedative infusion protocol administers the 
optimal dose of drug at the optimal time to effectively control agitation and create 
a comfortable patient, while at the same time ensuring that the patient is able 
to communicate and co-operate by preventing over-sedation. Therefore, there is 
a trade-off between minimising agitation and minimising drug dose. Either goal 
alone is relatively simple to achieve - minimal agitation achieved via excessive 
drug dose or minimal drug dose at the cost of patient anxiety and agitation. 
In many control applications, actuation is bi-directional, such as the ability 
to push or pull a cart, or increase or decrease an input force. However, in the 
case of the agitation-sedation system, drugs may be administered to the patient, 
but are not readily removed or reversed. An alternative to drug removal is the 
use of antagonists such as the Midazolam antagonist, Flumazenil [Young and 
Prielipp, 2001], and Morphine antagonist, Naloxone [Bridges and Grimm, 1982]. 
Although drugs may hold significant potential for agitation management 
and the prevention of over-sedation in the future [Young and Prielipp, 2001; Ritz 
et al., 1990; Geller et al., 1988], they are not commonly used in the ICU and are 
not considered this thesis. More directly, these effects, while broad, would not 
likely offer the measure of control required. Finally, this problem is generic 
to almost all physiological drug infusion management control problems. 
The saturation dynamic in the physiologically-based model also restricts the 
capacity of the controller to reduce instantaneous agitation when drug levels are 
moderate to high. Even employing an approach which simply delivers additional 
drug in response to agitation, the efficacy of the drug in the body is limited by the 
upper plateau on the saturation curve. Therefore, if the instantaneous stimulus 
invoking agitation outweighs the maximum achievable cumulative PD effect of 
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the drugs, the control capacity is removed and patient agitation will 
This characteristic of the agitation-sedation system has important implications 
for agitation management and controller design. More specifically, it means that 
a desired target agitation level is not always necessarily achievable. a 
more appropriate objective of the ideal controller might be to minimise overall 
agitation, rather than achieve a pre-set level at any moment in time. 
9.2 Controller Specifications 
An infusion protocol for use in a semi-automated sedative administration con-
troller should meet the following minimax cost-benefit criteria: 
• Minimise patient agitation (benefit) 
• Minimise over-sedation (cost) 
Safety is also a critical factor, so the protocol should also maintain infu-
sion rates within clinically specified safety limits to minimise cardiopulmonary 
depression and other critical side-effects. Hence, this cost/benefit trade-ff is con-
strained by safety limits. This definition is logical and has been described as "the 
quandary that faces clinicians daily" [Kress et al., 2002]. The important concept, 
therefore, is to employ an optimal drug delivery strategy. The goal of an optimal 
sedation control protocol is therefore to use the same drugs and similar dose, but 
deliver the drug in a way that improves outcome. 
9.3 Performance Metrics 
Objective performance metrics are necessary to evaluate the performance of any 
proposed sedative infusion protocoL Clearly, if an infusion protocol does not 
provide advantages over the current practice, then its implementation offers little 
outcome benefit for significant added complexity. Therefore, the simulations 
using the nurse control protocol, presented in Sections 6.2, 7.2, and Chapter 
8.2.4 are used as the benchmark for comparison. The nurse control protocol 
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is a representation of current clinical practice that is both easily repeated and 
previously verified. The control protocol specifications in Section 9.2 form the 
backbone of the sedative protocol performance metrics. Four performance metrics 
are proposed: 
RTD Relative Total Dose is defined as the total simulated dose of the proposed 
control protocol, relative to the total recorded dose. RTD is an important 
global performance because it is a general indication of drug usage, 
which has both financial and healthcare implications. In general, the use 
of excessive drugs to increased costs, and is an indication of over-
sedation, especially compared to clinical practice. Therefore, from both a 
healthcare and financial perspective, a low RTD is desirable. 
RPIR Relative Peak Infusion Rate is defined as the maximum infusion rate of 
a proposed control protocol, relative to the maximum recorded infusion 
rate. RPIR is a particularly important parameter in leU sedation, as high 
infusion rates can be damaging to patient health and are associated with 
cardiopulmonary depression, among other side-effects [Barr and Donner, 
1995]. this reason, maximum recorded infusion rates exist, and a low 
RPIR is desirable. 
RMA Relative Mean Agitation is defined as the mean simulated agitation em-
ploying the proposed control protocol, relative to the mean simulated- ag-
itation employing the nurse control protocol. RMA is one of the most 
important global performance metrics for both the patient and the medi-
cal staff. High average agitation levels can hinder recovery process by 
preventing rest and healing. Periods of inflated average agitation levels are 
uncomfortable and dangerous for patients, and difficult and time-consuming 
for bedside medical staff. Therefore, for both patients and medical staff, a 
low RMA is desirable. 
RPA Relative Peak Agitation is defined as the maximum modelled agitation 
employing the proposed control protocol, relative to the maximum modelled 
agitation employing the nurse control protocol. RPA is a local metric that 
represents the point in time at which the patient is most likely to attempt to 
remove their life-support systems (such as removing the ET tube), or resist 
staff. These actions are both damaging to patient health and a concern for 
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staff safety. Therefore, for both patients and medical staff, a low RPA is 
desirable. 
These metrics represent both local and global measures of the inputs and 
outputs of agitation management. RTD is a global measure of the sedative drug 
input while RPIR represents a local measure of the sedative drug input. These 
measures of input represent the control effort required, and hence represent the 
cost of agitation management. 
In contrast, RMA and RPA are measures of output. In particular, RMA 
represents a global performance measure, and RPA represents a local performance 
measure. These output measures represent the result of the control protocol 
employed, and hence the obtained. In this application, lower output 
metrics are desirable. 
Therefore, a combination of each of these metrics provides an indication of 
the relative cost-benefit ratio of a particular control protocol. The output metrics 
provide an indication of the benefit obtained through a particular protocol, and 
the input metrics provide and indication of the cost of those benefits. In this 
case, RTD and RMA represent the global cost-benefit trade-off, and RPIR and 
RPA represent the local const-benefit trad~-off. 

Chapter 10 
Control of the Initial Model 
Having established the initial model as a platform for developing control proto-
cols, the results of the simulated nurse control protocol in Section 6.2 can be used 
as a benchmark for assessing the effects of different infusion control protocols. In 
particular, the effect of removing the IIR filter and increasing the derivative-
focused control gains is investigated. Model parameters identical to those used 
in Section 6.2 are used for all patients. Performance metrics from Section 9.3 
indicate the improvement in agitation management achieved through direct feed-
back control of agitation. Without the filter, this approach tests the impact of 
a quantified agitation measurement system and simple control protocols. Elimi-
nating the filter also removes an artificial, 'forced decay rate of drug dose that is 
only optimal if agitation-sedation requirements decay at the same rate. 
10.1 Methods 
This chapter investigates the impact of removing the IIR filter of Section 4.2 and 
replacing the nurse control protocol with an alternative sedative infusion protocol. 
In particular, the impact of a constant infusion rate throughout the entire profile 
is investigated, as well as the impact of increased control gains. Finally, the 
impact of placing upper and lower limits on the infusion rate is investigated. 
The impact of a constant continuous sedative infusion protocol on patient 
agitation is assessed through the simulated delivery of a constant infusion at a 
rate equivalent to the average recorded infusion rate. By definition, this case 
ensures that the total recorded dose and total simulated dose are equal, resulting 
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in RTD=l.O for all patients. This protocol therefore delivers a patient-specific, 
constant infusion rate throughout the entire recorded profile. The impact of this 
protocol on patient agitation has important clinical applications, as some tra-
ditional sedation administration protocols employ similar continuous infusions 
[Kress et aL, 2000; Barr and Donner, 1995; Fragen, 1997; Kress et al., 2002]. 
In clinical practice the protocol is easily implemented using electronic infusion 
pumps, and is hassle-free for bedside medical because minimal effort is re-
quired. However, there are obvious disadvantages with such a protocol, in par-
ticular the risk of over-sedation, or insufficient sedation [Fragen, 1997; Barr and 
Donner, 1995; Arbour, 2000J. In particular, if a rate is kept constant such that 
most or all agitation is eliminated it will also likely be too high for a large majority 
of the patient's stay. 
Several biological control systems employ simple forms of feedback control 
[Carson and Cobelli, 2001]. Studies have shown that artificial controllers in first 
order systems similar to the agitation-sedation system models defined Chapter 
3 have benefited from derivative-focused control [Lam et al., 2002; Doran et aL, 
2004; Rudge et al., 2004a, 2005a]. Hence, an infusion rate, U, in the form of 
a proportional-derivative control protocol using agitation, A, a.c; the feedback 
quantity can be readily defined: 
(10.1) 
where Kp and Kd are the proportional and derivative gains respectively. Choos-
control gains such that Kd » Kp implements a derivative-focused agitation 
feedback control protocol that focuses on controlling the shape of the agitation 
response rather than the specific magnitude. Note that methods to objectively 
measure agitation are emerging [Chase et al., 2004c,a; Lam et al., 2003; Starfinger 
et al., 2003; Agogu6, 2005; Lam, 2003; Starfinger, 2003J. The sedative infusion 
rate is updated hourly, matching the nurse control protocol in Section 4.2. Be-
cause of the stimulus generation procedure, there are no dynamics faster than 
approximately one hour in the stimulus profile, representing a limitation of the 
model evaluation method. However, the same fundamental trends resulting from 
the use of these control protocols should be expected for smaller time-scales. 
Substitution of Equation (10.1) into Equation (3.1) creates a feedback loop 
and is used to investigate the benefits of direct derivative-focused control on agi-
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tation management. Using this derivative-focused approach, sedative agents are 
typically not administered while agitation is falling to avoid over-sedation. The 
control gains employed by the nurse control protocol, and obtained in chapter 6 
are Kp=0.0004 and Kd=0.4. In this chapter, these control gains are multiplied 
by a Gain Factor (GF) to equally increase both the proportional and deriva-
tive gain, maintaining a ratio of 1:1000 between them. The gain factor acts as 
a magnification factor to compensate for the increased mean infusion removed 
with the removal of the IIR filter. The impact of increasing the control gains is 
investigated using four control protocols with increasing gain factor: 
GF3 This protocol employs proportional and derivative control gains multiplied 
by a factor of three. It has similar performance metrics to that of the nurse 
control protocol, and therefore represents a good comparison between direct 
controllers and the filtered nurse control protocol. 
GF4 This protocol employs proportional and derivative control gains multiplied 
by a factor of four. It shows the impact of increased control gains on infusion 
profiles and agitation levels. 
GF5 This protocol employs proportional and derivative control gains multiplied 
by a factor of five. 
GF6 This protocol employs proportional and derivative control gains multiplied 
by a factor of six. It explores any advantage of a very strong reaction to 
rising and/or falling agitation response. 
In all sedative control protocols the IIR filter of Section 4.1 is removed, creating 
four direct derivative-focused control protocols. In all cases, the only restriction 
placed on the controlled infusion rate is that negative infusion rates are not 
allowed. These protocols investigate the impact of increasing the control gains, 
without any other limitations. 
Finally, in an attempt to capitalise on the benefits of the GF6 protocol, but 
eliminate the negative consequences of excessively high infusion rates, several 
variations on the GF6 protocol are analysed. The impact of imposing upper and 
lower limits on the controlled infusion rate is investigated by comparing the GF6 
protocol with protocols employing exactly the same gain factor, but with infusion 
limits. In particular, two protocols are investigated: 
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CappedGF6 This approach employs the GF6 protocol and places an upper limit 
on the infusion rate, capping it to the maximum recorded infusion rate for 
any given patient. This approach represents an example of a protocol that 
inherently protects against excessively high infusion rates. The maximum 
infusion rate is set to the maximum of the recorded infusion rate because 
it represents a conservative indication of clinical practice. 
BoundGF6 This approach employs the GF6 protocol and places upper and 
lower limits on the infusion rate. The maximum infusion rate is set to the 
maximum recorded infusion rate and the minimum infusion rate is set to 
50% of the average recorded infusion rate for any given patient. This pro-
tocol attempts to combine the advantages of the bolus-oriented derivative-
focused approach to sedation, and a constant continuous infusion. It also 
inherently protects against excessively high infusion rates. The minimum 
infusion rate was selected somewhat arbitrarily, but provides an indication 
of the impact of such a protocol. This protocol has important clinical im-
plications because many clinical sedation administration protocols employ 
a combination of boluses and continuous infusion [Kress et al., 2002]. 
Finally, note that imposing the maximum infusion rate limit results in a maximum 
possible RPIR=l.O by definition. These protocols are designed to investigate the. 
impact of increasing gain factor combined with infusion limits on agitation man-
agement. Hence they focus more on the outcome benefits of improved agitation 
performance metrics rather than the input, dose-related, performance metrics. 
10.2 Results and Discussion 
10.2.1 Constant Infusion Protocol 
Figure 10.1 presents the results of the constant continuous infusion protocol for 
a typical patient using the initial model. The upper plot shows the infusion 
rates, and the lower plot shows the resulting agitation profile. In these plots, 
the lighter solid line represents the constant infusion protocol, and the darker 
solid line represents the nurse control protocol as a benchmark for comparison. 
Figure 10.1 shows that the constant infusion protocol initially struggles to reduce 
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agitation levels, but eventually overcomes agitation and delivers excessive drug 
when the agitation levels are low. This result is a common feature throughout 
many patients. For portions of the profile the constant infusion protocol provides 
adequate sedation, but for a majority of the profile the infusion rate is either 
too small or too great, which may indicate insufficient sedation or over-sedation, 
respectively. In particular, this protocol typically results in excessive variations 
in agitation throughout the profile. 
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Figure 10.1 Example of the simulated results employing the constant infusion protocol in 
the initial model. 
The implementation of the constant continuous infusion protocol results in a 
RTD=1.0 by definition, and RPIR is no longer relevant. Table 10.1, located at 
the end of this chapter for clarity and ease of use, presents the summary statis-
tics of the performance metrics across all 37 patients for the 7 control protocols 
analysed in this chapter. The constant infusion protocol results in median values 
of RMA=1.02 and RPA=0.98, as seen in Table 10.1. Although these values rep-
resent patient agitation similar to that achieved by the nurse control protocol, 
the constant protocol is ineffective for many patients, as seen by the large vari-
ance of RMA and RPA between patients, indicated by the high IQR in the first 
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portion of Table 10.1. Specifically, the IQRs for the constant infusion protocol 
are considerably higher than that of any other protocol, reflecting the extreme 
variability of performance across a wide range of 
Note also the negative value for the minimum RMA, indicating that for at 
least one patient, the protocol delivered drug when it was unnecessary resulting 
in 'negative agitation levels'. This feature over-uses drugs, and may indicate over-
sedation. Note that this drawback typically occurs in protocols that administer 
a component of the infusion rate independent of patient agitation levels, such as 
the constant infusion protocoL The direct derivative-focused protocols, by their 
defined agitation feedback response, rarely result in negative agitation values. 
More importantly, if agitation falls below zero, a derivative-focused control pro-
tocol typically cuts the infusion rate, quickly returning agitation above zero and 
reducing drug consumption and preventing over-sedation 
The result of the constant infusion protocol is a wide of metrics across 
patients, with overall poor performance. Although some particular patients bene-
fit dramatically from the protocol, most do not. The main the protocol 
is its inability to tailor sedative infusion rates to current patient agitation. The 
result is large variability in agitation management between patients and, over 
time, for any given patient. In particular, its tendency to deliver too much drug 
when unnecessary makes it undesirable. 
However, these results do shed some light on the success in the U.S. of sedative 
interruption protocols [Kress et aL, 2000]. In the U.S. constant infusions are often 
used. Thus, daily interruption would ease total dose to manageable levels and 
produce at least some of the reduced over-sedation and LOS observed. 
All of these results are only relevant for a constant infusion rate equal to 
the mean recorded infusion. If a different constant infusion rate were selected, it 
may be more effective. In this research, previously recorded infusion data pro-
vides a simple method of approximating this constant rate. However) prospective 
determination in clinical practice is considerably more difficult, as inter-patient 
variability and time-varying parameters make the selection of this ideal rate ex-
tremely difficult. More importantly, the consequences of incorrect selection of the 
infusion rate are either extreme over-sedation or elevated levels of agitation, both 
of which are damaging to patient health. This makes the clinical application 
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of constant continuous infusion protocols difficult, although adaptive titration 
methods or boluses may be more effective [Chase et al., 2005b]. 
If sedative drugs are administered when agitation is near, or at, zero, the 
drugs administered will likely contribute to extended length of stay and over-
sedation. Feedback control protocols employing direct or capped proportional-
derivative controllers prevent this scenario by definition. However, a direct con-
sequence of any infusion protocol that determines the infusion rate independent 
of patient agitation is the risk of insufficient sedation and/or excessive delivery 
of unnecessary drug. Both of these outcomes are damaging to patient health and 
contribute to rising healthcare costs, and represents a significant disadvantage of 
the constant infusion approach in general. 
10.2.2 GF3-GF6 Protocols 
Table 10.1, located at the end of this chapter for clarity and ease of use, presents 
the performance metrics of the direct derivative-focused control protocols, GF3-
GF6. For the GF3 protocol, the median performance metrics are RTD=0.97, 
RPIR=0.96, RMA=0.97 and RPA=0.96. These metries show that the GF3 pro-
tocol represents a direct derivative-focused control protocol with similar drug dose 
characteristics to the nurse control protocol of Section 4.2. More specifically, the 
three-fold increase in gains is seen to compensate for the removal of the IIR filter, 
delivering a similar total dose, and resulting in overall similar performance met-
rics. This result is largely due to a gain greater than 1.0 in the IIR filter design 
at lower frequencies. 
However, while the GF3 protocol delivers similar total dose, the timing of 
the drug delivery is distinctly different to that delivered by the nurse control 
protocol, as seen in Figure 10.2. This figure presents the results of the direct 
derivative-focused control protocols, GF3--GF6, for a typical patient using the 
initial model. The upper plot shows the infusion rates, and the lower plot shows 
the resulting agitation profile. In these plots, the lighter solid line represents the 
GF3 infusion protocol, the dashed line represents the GF4 infusion protocol, the 
dash-dotted line represents the GF5 infusion protocol, the dotted line represents 
the GF6 infusion protocol, and the darker solid line represents the nurse control 
protocol as a benchmark for comparison. 
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Figure 10.2' Example of the simulated results employing the GF3-GF6 infusion protocols in 
the initial model. 
The direct derivative-focused control protocols result in bolus-oriented infu-
sion profiles with gradually increasing peaks and reducing troughs with increasing 
gain factor. Similarly, the agitation profiles gradually reduce with increasing gain 
factor. Although the agitation profiles resulting from increasing gain factor fol-
Iowa clear downward trend, the agitation profile from the nurse control protocol 
does not always follow the trend. This feature is seen in many patients and is 
a result of the presence of the IIR filter employed by the nurse control protocol, 
and its absence in the direct control protocols. Where the nurse control protocol 
(incorporating the IIR filter) produces a more consistent delivery profile, the GF3 
protocol produces a more bolus-oriented approach, as seen in Figure 10.2. This 
approach is seen to employ higher infusion rates when agitation is either high or 
increasing, and lower infusion rates when agitation is low or decreasing. 
The GF4 protocol represents an increase in sensitivity to agitation levels, 
and to the rate of change of agitation, compared to GF3. As a consequence of 
the increase in gains, the infusion profile becomes even more bolus-oriented, with 
higher peaks and lower troughs, as observed in Figure 10.2. Increasing the gain 
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factor to GF=4 has minimal effect on the median RTD, but increases the RPIR 
to 1.25, as seen in Table 10.1. Although this increase is potentially less desirable, 
the advantage of this protocol is its ability to further lower the median RMA 
from 0.97 for GF3 to 0.75 for GF4, and the median RPA from 0.96 to 0.81. 
Therefore, with similar overall drug dose, the GF4 protocol is capable of 
reducing mean agitation 25% and peak agitation 19% compared to the nurse 
control protocol. In some cases, the mean and peak agitation levels are reduced 
by as much as 33% and 28% respectively. However, these benefits come at the 
cost of an increased peak infusion rate of 25% across all patients, and in some 
instances as much as a 69% increase. Although this protocol is not necessarily 
an ideal sedation protocol, it indicates that very simple controllers can provide 
significant benefits to agitation management. 
Further increasing the gains of the direct derivative-focused control protocol 
yields control protocols GF5 and GF6. Table 10.1 shows that increasing the 
gains increases the median RTD slightly to 1.04 and 1.06 respectively, while 
the median RPIR increases to 1.50 and 1.75. However, in some cases the peak 
infusion rates are much higher with a maximum RPIR of 2.54 for GF6. These 
excessive infusion rates may be unacceptably high for clinical implementation. 
However, the benefit of such protocols is tl~e large reduction in agitation metrics 
and reduced total dose. The median RMA for GF5 and GF6 is only 0.60 and 
0.47, respectively, and the median RPA is 0.71 and 0.64. These reductions in 
both mean and peak agitation have desirable implications for both patients and 
medical staff. For example, some patients experienced a reduction in mean and 
peak agitation of up to 80% and 50%, respectively, under the GF6 protocol. Even 
the patients who benefited least from this protocol had mean and peak agitation 
levels reduced to 58% and 95% of those under the nurse control protocol. 
The agitation profiles for GF5 and GF6 are seen in Figure 10.2 to drop be-
low zero for a short period. This occasionally occurs in some patients for whom 
agitation is kept low by the GF5 and GF6 infusion protocols. These instances 
represent very low levels of agitation, and hence periods where no further seda-
tive drug is required for managing agitation. As previously mentioned, a control 
protocol that delivers drug during these periods risks over-sedation and unnec-
essary use of drugs. However, the inherent design of derivative-weighted control 
protocols, such as the GF5 and GF6 protocols, typically prevent such action. 
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Therefore, although patient agitation occasionally drops below zero under these 
protocols, it remains near zero and quickly returns to positive values. Hence, in 
model terms it should be interpreted as effectively zero agitation. 
Increasing the control factor yields a bolus-oriented approach to seda-
tion management which is particularly sensitive to both absolute agitation and 
changes in agitation. bolus-oriented approach responds to increasing agita-
tion with short, sharp boluses in an attempt to douse agitation before it increases. 
This approach results in periods of very high infusion rates during periods of ag-
itation, and periods during which there is no infusion at alL However, it is noted 
that during the periods of zero infusion, the concentration in compartment 2 is 
usually non-zero. 
PD effect, and is a 
non-zero concentration means that there is still a small 
the transport delay of the drug between the first and 
second compartment, and the elimination rate of the drug. More importantly, 
this approach means that drug is not administered when it is unnecessary. There-
fore, although the RTD is similar, the drugs are delivered at completely different 
times, and results in clearly improved performance metrics. 
Whereas Target Controlled Infusion (TCI) systems deliver drugs to maintain 
constant drug concentrations, the protocols described in Section 10.1 deliver drugs 
to maintain low agitation. This distinction iE) important, as one of the primary 
objectives of ICU sedation is to appropriately manage agitation. Therefore, it 
is important that the feedback quantity for a control protocol is the intended 
quantity being regulated. In this application, because the stimulus between 
patients and with time, a constant concentration of drugs will not necessarily 
provide suitable sedation to keep agitation low. The infusion rates therefore 
respond to patient agitation, leading to drug concentrations, and hence PD effect, 
that vary in response to patient requirements. 
The relationship between concentration and PD effect is assumed to be linear 
in the initial model. This assumption creates a linear relationship between drug 
concentration and its PD effect on agitation, and means that it is theoretically 
possible to reduce agitation to any desired level, with the appropriate drug deliv-
ery profile. However, as observed in this chapter, the drug dose and/or infusion 
rates required to achieve those goals may be unrealistically high, or in the case 
of very high gains, the system may become unstable, or respond in ways not 
captured by the modeL 
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As the gains are increased, the agitation performance metrics are all reduced, 
whereas the RPIR increases and RTD remains almost unchanged. The RPIR 
increases as a direct consequence of the increased gains causing sharper responses 
to changes in agitation, and hence the higher infusion rates. The RTD remains 
almost unchanged because although increased drug is delivered in the high peaks 
of bolus delivery, less drug is used in the trough immediately following. This 
result is potentially desirable, as the drug is delivered only during periods when 
it is really necessary, and not at all when it is unnecessary. As the effect of the 
drug is directly proportional to the concentration, it appears to be more effective 
to use short-term large doses of drug in direct response to agitation, rather than 
long-term lower doses. 
The results in Table 10.1 clearly show that all patients experience lower levels 
of agitation throughout their stay under these direct derivative-focused protocols, 
compared with the nurse control protocol. More importantly, these improvements 
in agitation metrics are achieved using similar doses. The primary drawback of 
these protocols is the resulting high infusion rates. However, a fundamental 
outcome of these results is that simply through changing the timing of drug 
delivery, it is possible to dramatically influence the agitation profile. Although 
these protocols are not ideal, they indicate that very simple control protocols may 
provide significant benefits to agitation management in comparison to current 
clinical practice. .' 
10.2.3 CappedGF6 and BoundGF6 Protocols 
Applying an upper limit of the maximum recorded infusion rate to the simulated 
infusion rate results in a maximum RPIR=1.0 by definition. Table 10.1, located at 
the end of this chapter, shows the performance metrics for the GF6, CappedGF6, 
and BoundGF6 protocols. The median RTD remained almost unchanged at 1.0S 
for the CappedGF6 protocol. The median RMA increased slightly from 0.47 for 
GF6 to 0.S2 for CappedGF6, and similarly the median RPA increased from 0.64 
to 0.66. Hence, little is lost in agitation management for a major reduction in 
peak infusion rate and similar total dose. 
Imposing a maximum limit to the infusion rate of the GF6 protocol ensures 
that the infusion rate for each patient does not exceed the maximum recorded 
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infusion rate. This approach is conservative, as safe peak infusion rates may 
be higher. However, this protocol shows the effect of this limit on the benefits 
otherwise achieved. Therefore, the bolus-oriented approach of the GF6 protocol 
is maintained, but potentially undesirable large infusion rates are prevented. 
Figure 10.3 presents the results of the derivative-focused control protocols 
with infusion limits for a typical patient using the initial model. The upper plot 
shows the infusion rates, and the lower plot shows the resulting agitation profile. 
In these plots, the lighter solid line represents GF6, the dashed line represents 
CappedGF6, the dotted line represents BoundGF6, and the darker solid line 
represents the nurse control protocol, as a benchmark for comparison. 
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Figure 10.3 Example of the simulated results employing the CappedGF6 and BoundGF6 
infusion protocols in the initial model. 
The CappedGF6 protocol results in an infusion profile very similar to the GF6 
protocol. However, where the infusion rate would have exceeded the maximum 
limit, the infusion rate remains at the maximum level for a little longer before 
dropping below the maximum level. Because the rapid response of the control 
protocol to increases in agitation is limited by the capped infusion rate, its ability 
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to reduce the mean agitation and peak agitation levels is restricted, and leads to 
the small increases reported for RMA and RPA. 
However, a median reduction of 48% and 34% in mean and peak agitation 
levels, respectively, represents a significant improvement for both patients and 
medical staff. Although mean and peak agitation is only reduced by 30% and 
2% in some patients, the protocol represents an improvement for all patients, 
in some cases reducing mean and peak agitation by 63% and 47%, respectively. 
More importantly, benefits are achieved with a total dose approximately 
equal to that of the recorded dose, and without exceeding the infusion rate limits. 
This control protocol therefore represents a significant improvement in agitation 
management. It also clearly shows the impact of drug dose timing on agitation, 
as the total doses are essentially the same, but the resulting agitation is much 
different. 
Imposing minimum and maximum limits on the infusion rate of the GF6 
protocol represents a bolus-oriented approach combined with a low constant con-
tinuous infusion, as seen in Figure 10.3. The advantage of this protocol is its 
ability to reduce average agitation through consistently higher concentrations 
than the CappedGF6 protocol. Table 10.1 shows that the BoundGF6 protocol 
results in an increase in median RTD from l.05 for GF6 to l.14 for BoundGF6. 
By definition, RPIR cannot exceed l.0 for either CappedGF6 or BoundGF6. The 
median RMA is reduced from 0.52 for CappedGF6 to 0.39 for BoundGF6, and 
similarly median RPA is reduced from 0.66 to 0.6l. 
Initially, these performance metrics appear very desirable. In particular, the 
performance metrics show that across all patients, a 61% reduction of mean 
agitation and 39% reduction in peak agitation is possible. Additionally, these 
benefits are achieved at the expense of only 14% more drug and without exceed-
maximum infusion rates. However, the very low value for the minimum RMA 
indicates that for at least one patient, the protocol delivered drug when it was 
unnecessary, likely due to the constant infusion portion of the protocol. This 
feature over-uses drugs, and the results indicate that some over-sedation occurs. 
Note that this drawback primarily occurs in protocols that administer a compo-
nent of the infusion rate independent of the patient state, such as the constant 
infusion protocol or the BoundGF6 protocoL derivative-focused protocols, 
by definition, rarely let agitation fall below zero, and more importantly prevent 
162 CHAPTER 10 CONTROL OF THE INITIAL MODEL 
over-sedation by delivering minimal drug in these instances. 
10.2.4 Summary 
Constant infusion protocols are shown to provide poor agitation management as 
a result of failing to tailor drug delivery to patient requirements. This blanket 
approach to sedation can be seen in the constant and BoundGF6 protocols, and 
often results in excessive drug delivery and over-sedation, or inadequate drug 
delivery and insufficient sedation. In contrast, this analysis of the various control 
protocols using the initial model has shown that very simple control protocols can 
provide effective agitation management. More importantly, these simple control 
protocols offer considerable improvements over current clinical practice. 
In particular, direct derivative-focused feedback control of agitation is shown 
to produce a bolus-oriented approach to sedation that tailors sedative delivery 
rates to patient agitation, resulting in improved agitation management. This 
approach is seen in the control protocols GF3-GF6, in which median reductions 
of up to 53% and 36% are achieved for mean and peak agitation respectively. 
Importantly, these reductions in agitation are achieved without only a minimal 
increase in total drug dose. Finally, capping tlie maximum allowable infusion rate 
not only eliminates the higher infusion rates produced by the GF3-GF6 protocols 
but has minimal effect on the considerable improvements on these protocols. 
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Table 10.1 Agitation performance metrics for all sedative infusion protocols the initial 
model. 
Constant 
Max 1.00 0.41 2.54 2.24 
UQ 1.00 0.30 1.34 1.21 
Med 1.00 0.24 1.02 0.98 
LQ 1.00 0.20 0.74 0.81 
Min 1.00 0.12 -0.50 0.51 
rQR 0.00 0.10 0.60 0.40 
GF3 
Max 1.07 1.33 1.00 1.01 
UQ 0.98 1.11 0.98 0.98 
Med 0.97 0.96 0.97 0.96 
LQ 0.95 0.84 0.95 0.93 
Min 0.90 0.65 0.92 0.88 
0.03 0.26 0.04 0.05 
GF4 
Max 1.23 1.69 0.80 0.97 
UQ 1.03 1.40 0.76 0.84 
Med 1.00 1.25 0.75 0.81 
LQ 0.99 1.09 0.74 0.79 
Min 0.97 0.79 0.67 0.72 
0.04 0.31 0.02 0.05 
GF5 
Max 1.37 2.12 0.68 0.96 
UQ 1.08 1.68 0.62 0.75 
Moo 1.04 1.50 0.60 0.71 
LQ 1.01 1.28 0.56 0.67 
Min 1.00 0.94 0.40 0.57 
rQR 0.07 0.39 0.06 0.08 
GF6 
Max 1.49 2.54 0.58 0.95 
UQ 1.12 1.96 0.52 0.70 
Med 1.06 1.75 0.47 0.64 
LQ 1.03 1.53 0.42 0.57 
Min 1.00 1.09 0.20 0.50 
rQR 0.09 0.43 0.10 0.13 
UQ 1.10 1.00 0.58 0.76 
Med 1.05 1.00 0.52 0.66 
LQ 1.03 1.00 0.49 0.60 
Min 1.00 1.00 0.37 0.53 
rQR 0.08 0.00 0.09 0.16 
BoundGF6 
Max 1.43 1.00 0.66 0.98 
UQ 1.24 1.00 0.48 0.72 
Med 1.14 1.00 0.39 0.61 
LQ 1.08 1.00 0.32 0.56 
Min 1.03 1.00 0.03 0,48 
rQR 0.16 0.00 0.16 0.16 

Ch_apter 11 
Control of the Physiologically-based Model 
11.1 Methods 
The methods described in Section 10.1 are used in this chapter, but with the 
physiologically-based model of Chapter 7. In particular, the model employed 
in this chapter includes the PD response surface, but does not incorporate the 
EAR dynamic. The same sedative infusion protocols (Constant, GF3, GF4, GF5, 
GF6, CappedGF6, BoundGF6) are used. The use of the physiologically-based, 
more non-linear, model to determine whether the saturation and synergy 
dynamics limit the benefits observed in the previous chapter. 
11.2 Results and Discussion 
11.2.1 Constant Protocol 
Figure 11.1 presents the results of the constant continuous infusion protocol for 
a typical patient using the physiologically-based model. The upper plot shows 
the infusion rates, and the lower plot shows the resulting agitation profile. In 
these plots, the lighter solid line represents the constant infusion protocol, and 
the darker solid line represents the nurse control protocol as a benchmark for 
comparison. Figure 11.1 shows that the constant infusion initially struggles to 
reduce agitation levels, but eventually overcomes agitation, and delivers excessive 
drug delivery when the agitation levels are low. 
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Again, this is a common feature throughout many patients. For part of the 
profile the constant infusion provides adequate sedation, but for most of the 
profile the infusion rate is either too small or too great, which may indicate 
insufficient or over-sedation, respectively. In particular, the protocol typically 
results in excessive variations in agitation levels throughout the profile, in many 
cases becoming very high or very low and over-using drug. 
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Figure 11.1 Example of the simulated results employing the constant infusion protocol in 
the physiologically-based modeL 
The implementation of the constant continuous infusion protocol results in a 
RTD=1.0 by definition, and RPIR is no longer important. Table 11.1, located at 
the end of this chapter for clarity and ease of use, presents the summary statis-
tics of the performance across all 37 patients for the 7 control protocols 
analysed in this chapter. The constant infusion protocol results in median val-
ues of RMA=O.84 and RPA=O.96, as seen in Table 11.1. Although these values 
represent an improvement over the nurse control protocol, the constant protocol 
is once again ineffective for many patients, as seen by the large variance between 
patients in RMA and RPA in the first portion of Table 11.1. Specifically, the IQR 
for the constant infusion protocol are considerably higher than that of any other 
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protocol, reflecting the extreme variability of performance across a wide range of 
patients. 
Note that the negative value for the minimum RMA indicates that for at 
least one patient this protocol delivered drug when it was unnecessary, resulting 
in 'negative agitation levels'. control protocol is therefore associated with 
all the risks of insufficient sedation and potential over-sedation discussed in Sec-
tions 10.2.1 and 10.2.3. These risks have important clinical implications and are 
significant considerations for clinical sedative infusion protocols. 
11.2.2 GF3-GF6 Protocols 
As seen from results using the initial model, the GF3 control protocol represents a 
direct derivative-focused control protocol with similar performance metrics to the 
nurse control protocol. Again, the additional drug delivered via the IIR filter in 
the nurse control protocol is compensated for by the increase in gains. However, 
while the GF3 protocol delivers similar total dose, the timing of the drug delivery 
is distinctly different to that delivered by the nurse control protocol, as seen 
in Figure 11.2. This figure presents the results of the direct derivative-focused 
control protocols, GF3-GF6, for a typical patient using the physiologically-based 
model. The upper plot shows the infusion rates, and the lower plot shows the 
resulting agitation profile. In these plots, the lighter solid line represents the 
GF3 infusion protocol, the dashed line represents the GF4 infusion protocol, the 
dash-dotted line represents the GF5 infusion protocol, the dotted line represents 
the GF6 infusion protocol, and the darker solid line represents the nurse control 
protocol, as a benchmark for comparison. 
Like the infusion profiles resulting from using the initial model, the infusion 
profiles in the physiologically-based model display increased peaks and reduced 
troughs with increasing gain factor. In addition, the agitation profiles reduce with 
increasing the gain factor. Further, to a greater extent than seen in the initial 
model, clear differences exist in agitation profiles between the GF protocols and 
the nurse control protocol. In particular) the agitation profile resulting from the 
nurse control protocol differs from the trend between the direct derivative-focused 
protocols. This result is due, as in the initial model, to the presence of the IIR 
filter in the nurse control protocol, and its absence from the direct derivative-
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Figure 11.2 Example of the simulated results employing the GF3-GF6 infusion protocols in 
the physiologically-based model. 
focused protocols. A likely reason for the enhanced difference observed in the 
physiologically-based model is the effect of the non-linear PD response surface. 
Figure 11.2 shows that the GF3 protocol produces a bolus-oriented approach 
to sedation administration by delivering short, sharp timely boluses of sedative 
agents in response to rising agitation. Table 11.1, located at the end of the 
chapter, shows that the median RTD and RPIR across all patients for the GF3 
protocol is 1.05 and 1.11, respectively. This result shows that although the GF3 
protocol delivers a similar total dose of drug, the timing of the delivery is dis-
tinctly different. In particular, where the nurse control protocol has a more sig-
nificant continuous component, the GF3 protocol has more peaks and troughs. 
The GF4 protocol produces an even more bolus-oriented infusion profile than 
the GF3 protocol, with higher peaks and lower troughs, as seen in Figure 11.2. 
The agitation profile is lower than that of the GF3 protocol, and peaks are re-
duced. The GF4 protocol reduces the mean and peak agitation levels for all 
patients, but at the expense of increases in both dose and peak infusion rate. 
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The median RTD increases from 1.05 for GF3 to 1.14 for GF4, and the median 
RPIR increases from 1.11 to 1.35. increases are accompanied by reductions 
in the agitation performance metrics. The median RMA is reduced from 1.02 for 
GF3 to 0.82 for GF4, and the median RPA is reduced from 0.99 for GF3 to 0.87 
for GF4. Overall, while some patients' agitation levels are reduced without an 
increase in drug dose and peak rate, most patients experience lowered agitation 
levels at the expense of increased dose and/or peak infusion rates. 
This result is in contrast to the results of the initial model, where the GF4 
protocol achieved improvements in the agitation performance metrics with almost 
no change in RTD. This difference between the two models is probably due to the 
saturation dynamic incorporated in the response surface of the physiologically-
based model. This dynamic restricts the maximum agitation-reducing effect of 
the drugs at high concentrations. This effect corresponds to rendering the peak 
effect concentrations produced by the GF4 protocol less effective. In some cases, 
this reduction means that additional drug is delivered beyond saturation point, 
which essentially contributes to excessive drug use, but does not reduce agitation. 
For similar reasons, the RPIR is higher in the physiologically-based model than 
for the initial model. 
Increasing the control gains further to GF=5 and accentuates the 
trends observed in the GF3 and GF4 protocols. Like results from the initial 
model, the physiologically-based model results in improved agitation metrics with 
increasing gain factor. However, unlike the results from the initial model, these 
benefits are achieved at the expense of increased RTD and RPIR, as seen in Table 
11.1. This feature is attributed primarily to the saturation dynamic in the PD 
response surface. It may also be due, in part, to the somewhat arbitrary selection 
of Gso - The manual selection of Gso values may result in concentrations in the sat-
urated plateau region of the response surface, reducing the enhanced effectiveness 
of additional drug, and thereby increasing the demand for additional drug ad-
ministration. Alternatively, the selected Gso values may result in concentrations 
in the lower plateau region of the response surface, yielding only minimal effect 
and thereby demanding additional drug. In either case, the manual selection of 
Gso also contributes to this increase in RTD and RPIR. 
The GF5 and GF6 protocols in the physiologically-based model result in a 
distinct bolus-oriented approach to sedation, similar to that seen in the initial 
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model. However, the profiles observed using the physiologically-based model 
are even more bolus-oriented with higher peaks and lower troughs, as seen by 
the higher RPIR values in Table 11.1 and displayed in Figure 11.2. The me-
dian RPIR for the GF6 protocol using the physiologically-based model is 1.89, 
compared to 1. 75 for the initial model. Similar statistics are observed for the 
GF3-GF5 protocols. The sharper responses in the physiologically-based model 
are a likely result of the non-linear relationship between concentration and PD 
effect, or perhaps the slight delay between drug administration and effect. More 
specifically, the bolus peaks grow as saturation dynamics blunt the response of 
the entire bolus. This effect occurs because agitation is not reduced as much in 
the physiologically-based model as with the initial model that does not include 
effect saturation. Therefore, the limiting effect of saturation outweighs the en-
hanced effects of synergistic interaction. In both cases, the instantaneous PD 
effect is reduced, leading to an increase in agitation, and therefore leading to 
higher peak infusion rates. 
As seen in the initial model, the direct derivative-focused control protocols 
result in a bolus-oriented approach to sedation. This feature can be seen in 
Figure 11.2, where the infusion rate is high during periods of high agitation and 
rapid increases of agitation, but low, or zero, during periods of relative calm 
or decline in agitation. This approach has the benefit of delivering substantial . 
drug when needed, and preserving drug when it is unnecessary, avoiding over-
sedation and minimising drug consumption. However, it should be noted that 
even though the infusion may stop for short periods, the effect concentration does 
not usually drop to zero. Because of the transport and storage of drug from the 
other compartments, the effect site concentration is not typically not zero even 
if there is no drug delivery at that time. Hence, a small PD effect remains even 
during periods of zero infusion. 
The fundamental outcome of these results is that the saturation dynamic in 
the physiologically-based model restricts the control protocol's ability to reduce 
agitation when the effect concentrations are in, or near, the saturated plateau of 
the response surface. Therefore, if a strong stimulus invoking agitation occurs at 
the same time as saturated effect concentrations, the mechanism through which 
any control protocol can reduce agitation is disabled. In clinical practice, where 
it is assumed that everything has been done to remove and alleviate all known 
sources of stimulus, this result has important implications. Fundamentally, these 
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results imply that for any given patient, it is not always possible to achieve a 
given target level of agitation. At the point of saturation, additional delivery of 
drug simply results in unused drug and creates potential for over-sedation and 
prolonged effect through drug storage and accumulation. Hence, other alterna-
tives should be considered if this condition is detected, or estimated from the 
modeL 
This outcome represents an important consideration for clinical agitation 
management. Rather than attempting to reduce agitation to a target value, 
which is not always possible due to saturation, the goal of good agitation man-
agement should be to minimise agitation in the face of unknown stimulus, and 
simultaneously minimise unnecessary over-use of sedative drugs. This approach 
to agitation management aims to minimise agitation through timely delivery of 
sedative drugs, but recognises saturation and minimises drug delivery by ceasing 
drug administration during periods of saturation. Unfortunately, clinical imple-
mentation of this approach is not easy. There is currently, unfortunately, no 
simple method of knowing when saturation has been reached, except via model 
estimation. Although the careful medical staff can notice a lack of additional 
effect to additional drug, the saturation point is still not easily observed. 
11.2.3 CappedGF6 and BoundGF6 Protocols 
Imposing a maximum limit on the infusion rate of the GF6 protocol ensures that 
the infusion rate for each patient does not exceed the maximum recorded infusion 
rate. Therefore, the bolus-oriented approach of the GF6 protocol is maintained, 
but the undesirable large infusion rates are prevented. Figure .3 presents the 
results of the derivative-focused control protocols with infusion limits for a typical 
patient using the physiologically-based modeL The upper plot shows the infusion 
rates, and the lower plot shows the resulting agitation profile. In these plots, the 
solid line represents GF6, the dashed line represents CappedGF6, the dotted 
line represents BoundGF6, and the darker solid line represents the nurse control 
protocol as a benchmark for comparison. Imposing this upper limit to the infusion 
rate results in a maximum RPIR=1.0 by definition. Table located at the 
end of this chapter for clarity and ease of use, shows the performance metrics for 
the GF6, CappedGF6, and BoundGF6 protocols. 
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Figure 11.3 Example of the simulated results employing the CappedGF6 and BoundGF6 
infusion protocols in the physiologically-based modeL 
As can be seen in Table 11.1, the RTD decreased from 1.34 for the GF6 pro-
tocol to 1.24 for the capped GF6 protocoL This reduction of RTD is probably the 
result of the elimination of the high peaks observed in the GF6 protocol, which 
results in less drug use. In contrast to the initial model where this reduction in 
dose is compensated by an increased duration of maximum infusion, the infu-
sion rate in the physiologically-based model decreases. The infusion profile for 
CappedGF6 in Figure 11.3 is therefore more similar to that of the GF6 protocol, 
with the exception of a limit on the upper infusion rate. 
Further, the RMA only increases from 0.62 to 0.64 by the implementation of 
the capped rate, and the RPA is not affected at all. These differences are probably 
due to the non-linear PD response surface employed by the physiologically-based 
model, and the selection of G50 . Although the dose that was delivered in the 
high peaks of the GF6 protocol is eliminated, its effect appears to be negligible. 
This result may be due to the fact that drug delivered in the high peaks of 
the GF6 protocol almost no effect because the concentrations were in the 
saturated zone. Therefore, when they are eliminated in the CappedGF6 protocol, 
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the difference in PD effect is minimal, resulting is reduced RTD, no change in 
RPA and minimal change in RMA. Importantly, the reduction of RTD is a more 
significant gain than the negative impact of a slightly lower agitation reduction. 
Imposing maximum and minimum limits on the infusion rate of the GF6 pro-
tocol has a similar effect in the physiologically-based model to that of the initial 
model. Because of increased effect site concentrations resulting from the contin-
uous infusion, the PD effect reducing agitation is increased, thereby reducing the 
median RMA from 0.62 for CappedGF6 to 0.45 for BoundGF6 and the median 
RPA from 0.74 to 0.68. These reductions represent a decrease of 27.4% and 8% 
in RMA and RPA respectively. However, in contrast to the initial model, the me-
dian RTD did not increase. Rather, the RTD decreased slightly from 1.24 in the 
CappedGF6 protocol to 1.23 for the BoundGF6 protocol. This result is probably 
due to the fact that the constant infusion maintains the effect site concentrations 
in the central portion of the PD response surface so the increased drug doses 
are more effectively utilised, reducing the demand for drug, and hence reducing 
RTD. 
11. 2.4 Summary 
Constant infusion protocols are shown, once again, to provide poor agitation 
management, often resulting in excessive drug delivery and over-sedation, or 
adequate drug delivery and insufficient sedation. This analysis of the various 
control protocols using the physiologically-based model has again shown that 
very simple control protocols can provide considerably improved agitation man-
agement over current clinical practice. However, this chapter has highlighted the 
limiting effect of the saturation curve on the ability of control protocols to reduce 
agitation. 
In particular, the presence of the saturation dynamic in the response curve 
incorporated in the physiologically-based model restricts the capacity of control 
protocols to reduce agitation. This limitation represents an important consid-
eration for clinical agitation management. suggests that instead of reducing 
agitation to a target value, which is not always possible due to saturation, the 
aim of good clinical agitation management should be to minimise agitation, and 
simultaneously minimise over-sedation. This approach to agitation management 
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minimises agitation using timely bolus delivery of sedative drugs, but recognises 
saturation limits and minimises drug delivery by ceasing drug administration 
during these periods of saturation. Unfortunately, no simple method of know-
ing when saturation has been reached, making clinical implementation difficult. 
However, a potential solution could be to estimate saturation limits using PKPD 
models, and limit doses accordingly [Chase et al., 2005bj. 
The limit of the saturation dynamic means that improved benefits (reduced 
agitation) come only at the expense of increased costs (drug dose). However, in 
spite of this trade-off, considerable improvements over current clinical practice 
are achieved through the use of direct derivative-focused feedback control pro-
tocols GF3-GF6. In particular, median reductions of up to 40% and 36% are 
achieved for mean and peak agitation respectively. However, these benefits were 
achieved at the cost of a 34% increase in median total drug dose and 89% increase 
in peak infusion rate. Capping the infusion rate results in the CappedGF6 pro-
tocol achieving median reductions of up to 40% and 36% are achieved for mean 
and peak agitation respectively, at the expense of 24% more drug. These re-
ductions represent considerable benefit to critically ill patients and medical staff, 
for relatively small cost. However, these costs and benefits must be weighed ap-
propriately to determine the advantages of such a protocol to clinical agitation 
management. 
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Table 11.1 Agitation performance metrics for all sedative infusion protocols using the 
physiologically-based modeL 
RTD RPIR RMA RPA 
Constant 
Max 1.00 0.41 3.38 2.53 
UQ 1.00 0.30 1.13 1.12 
Med 1.00 0.24 0.84 0.96 
LQ 1.00 0.20 0.44 0.65 
Min 1.00 0.12 -2.82 0.10 
0.00 0.10 0.69 0.47 
GF3 
Max 1.22 1.56 1.10 1.07 
UQ 1.08 1.34 1.04 1.01 
Med 1.05 1.11 1.02 0.99 
LQ 1.01 0.92 0.98 0.96 
Min 0.91 0.73 0.93 0.87 
rQR 0.07 0.42 0.06 0.05 
GF4 
Max 1.46 2.03 0.95 1.00 
UQ 1.19 1.76 0.85 0.89 
Med 1.14 1.35 0.82 0.87 
LQ 1.10 1.20 0.80 0.82 
Min 1.04 0.89 0.74 0.77 
rQR 0.09 0.56 0.05 0.07 
GF5 
Max 1.69 2.54 0.88 0.98 
UQ 1.30 2.16 0.73 0.84 
Med 1.23 1.63 0.69 0.78 
LQ 1.19 1.44 0.66 0.73 
Min 1.07 1.07 0.58 0.63 
0.11 0.72 0.07 0.11 
GF6 
Max 1.91 3.04 0.83 0.98 
UQ 1.41 2.55 0.64 0.80 
Med 1.34 1.89 0.60 0.74 
LQ 1.28 1.65 0.56 0.67 
Min 1.10 1.24 0.46 0.54 
IQR 0.13 0.90 0.08 0.13 
CappOOGF6 
Max 1.50 1.00 0.88 0.99 
UQ 1.27 1.00 0.72 0.80 
Moo 1.24 1.00 0.62 0.74 
LQ 1.20 1.00 0.57 0.68 
Min 1.09 1.00 0.50 0.57 
lQR 0.07 0.00 0.15 0.12 
BoundGF6 
Max 1.58 1.00 0.76 0.99 
UQ 1.30 1.00 0.56 0.75 
Med 1.23 1.00 0.45 0.68 
LQ 1.17 1.00 0.41 0.60 
Min 1.10 1.00 0.28 0.49 
rQR 0.13 0.00 0.15 0.15 

Chapter 12 
Control of the Extended Physiological Model 
12.1 Methods 
The methods described in Section 10.1 are used in this chapter, but with the 
extended physiologically-ba.sed model of Section 8.2.4. In particular, the model 
employed in this chapter includes the PD response surface and the EAR dynamic, 
as well as the parameter identification techniques presented in Chapter 8. The 
same sedative infusion protocols (Constant, GF3, GF4, GF5, GF6 CappedGF6, 
BoundGF6) are used. The use of the extended physiologically-based model seeks 
to determine the effects parameter identification techniques employed and the 
EAR dynamic. 
The differences between the physiologically-based model of Chapter 7 and 
the extended physiologically-based model include: 
1. The inclusion of the EAR dynamic, -wsA, from Section 8.2.4. 
2. The time-varying, fitted W2(t), from Section 8.1.2. 
3. The consistent selection of C50 , as seen in Section 8.1.1. 
The EAR dynamic is likely to reduce the amount of drug required to achieve 
a particular agitation level, or for a given agitation level reduce the drug re-
quirements, as a result of the combined endogenous and exogenous agitation 
reduction. The time-varying fitted w2(l) is expected to affect the capacity of 
the control protocol to reduce agitation by the time-varying nature of the seda-
tive sensitivity. Because W2(t) is fitted using the procedure in Section 8.1.2, the 
time-varying W2(t) is likely to reduce agitation levels through increased sedative 
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sensitivity where required. The consistent selection of C50 creates more con-
sistent PD response surface between patients, and reduces over-saturation and 
under-utilisation due to any associated model error. This, in turn, alters the PD 
response surface and saturation dynamic to be more patient-specific. 
12.2 Results and Discussion 
12.2.1 Constant Protocol 
Figure 12.1 presents the results of the constant continuous infusion protocol for a 
typical patient using the extended physiologically-based modeL upper plot 
shows the infusion rates, and the lower plot shows the resulting agitation profile. 
In these plots, the lighter solid line represents the constant infusion protocol, 
and the darker solid line represents the nurse control protocol as a benchmark 
for comparison. As with the initial model and the physiologically-based model, 
Figure 12.1 shows that while the constant infusion initially struggles to reduce 
agitation levels, it eventually overcomes agitation, and delivers excessive drug 
delivery when the agitation levels are low. Again, this is a common feature 
throughout many patients. For part of the profile the constant infusion provides 
adequate sedation, but for most of the profile the infusion rate is either too great 
or too small, which may indicate insufficient or over-sedation. In particular, the 
protocol typically results in excessive variations in agitation levels throughout 
the profile, in many cases becoming very high or very low and over-using drug. 
The implementation of the constant continuous infusion protocol results in a 
relative total dose of 1.0 by definition, and RPIR is no longer relevant. Table 12.1, 
located at the end of this chapter, presents the summary statistics of the perfor-
mance metrics across all 37 patients for the 7 control protocols analysed in this 
chapter. The constant infusion protocol results in median values of RMA=0.45 
and RPA=0.91, as seen in Table 12.1. Although these values represent a signifi-
cant improvement over the nurse control protocol and appear to produce desirable 
results, the constant protocol is once again ineffective for many patients resulting 
in severe over-use of sedative drugs. This feature is seen by the large variance 
between patients in the IQR of RMA and RPA in the first portion of Table 12.1. 
Specifically, the IQR for the constant infusion protocol is considerably higher 
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Figure 12.1 Example of the simulated results employing the constant infusion protocol in 
the extended physiologically-based model. 
than that of any other protocol, reflecting the extreme variability of performance 
across a wide range of patients. Specifically, agitation values regularly fall below 
zero, and the protocol the continues to deliver unnecessary drugs. 
Note that the multiple negative values for the RMA column of Table 12.1 
indicate that for many patients this protocol delivered drug when it was unnec-
essary resulting in 'negative agitation levels'. This control protocol is therefore 
associated with all the risks of insufficient sedation and potential over-sedation 
discussed in Section 10.2.1 and 10.2.3. These risks have important clinical impli-
cations and are significant considerations for clinical sedative infusion protocols. 
It is interesting to note that this protocol results in an exceptionally high 
number of patients with 'negative agitation levels' for this modeL This result is 
probably primarily due to the PD response surface and the selection method for 
G50 . During the constant infusion the effect site concentrations will remain at a 
constant elevated level. Because of the G50 selection criteria, the constant effect 
site concentration will correspond to a relatively high PD effect, accentuated by 
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the synergistic nature of Morphine and Midazolam. Further to this effect, the 
EAR dynamic may also contribute to the increased reductions in agitation and 
thus the increased negative agitation results. 
12.2.2 GF3-GF6 Protocols 
As seen from results using the initial and physiologically-based models in Chap-
ters 10 and 11, the GF3 control protocol represents a direct derivative-focused 
control protocol with similar performance metrics to the nurse control protocol, 
but with a distinctly bolus-oriented approach. Figure 12.2 presents the results 
of the direct derivative-focused control protocols, GF3~GF6, for a typical pa-
tient using the physiologically-based model. The upper plot shows the infusion 
rates, and the lower plot shows the resulting agitation profile. In these plots, the 
lighter solid line represents the GF3 infusion. protocol, the dashed line represents 
the GF4 infusion protocol, the dash-dotted line represents the GF5 infusion pro-
tocol, the dotted line represents the GF6 infusion protocol, and the darker solid 
line represents the nurse control protocol as a benchmark for comparison. 
Table 12.1, located at the end of the chapter, shows that the median RTD and 
RPIR across all patients for the GF3 protocol is 0.97 and 1.03, respectively. This 
result shows that although the GF3 protocol delivers a very similar total dose 
of drug, the timing of the delivery is distinctly different. In particular, whereas 
the nurse control protocol has a more significant continuous component, the GF3 
protocol has more peaks and troughs. This dose is also lower than in Chapter 
11, likely due to the EAR dynamic. 
Like in the initial and physiologically-based models, the GF4 protocol in the 
extended physiologically-based model produces a more bolus-oriented approach 
to sedation administration. The median RTD increased from 0.97 for GF3 to 1.05 
for GF4. This increase of RTD is also seen in the physiologically-based model, 
but in this extended model the change is not a'l large. Similarly, the median 
RPIR increased from 1.03 for the GF3 protocol to 1.30 for the GF4 protocol, 
which is also observed in the physiologically-based model. The median RMA 
dropped from 0.96 for GF3 to 0.78 for GF4, and the median RPA dropped from 
0.95 to 0.84. 
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Figure 12.2 Example of the simulated results employing the GF3-GF6 infusion protocols in 
the extended physiologically-based modeL 
These performance metrics show that while the extended physiologically-
based model exhibits the same trends as the physiologically-based model of Chap-
ter 11, some of the changes are not as severe, and the trends tend to lie between 
those of the initial model and physiologically-based modeL This result is a direct 
consequence of the combination of the EAR dynamic, the time-varying W2(t) 
and the C50 selection. This more patient-specific model with added agitation 
reduction dynamics better suits the feedback control approach and its ability to 
customise sedation to agitation response. 
Similar trends in the extended physiologically-based model for performance 
metrics are observed when the gain factor is increased to 5 and 6, as those in 
the physiologically-based model. The median RTD increases to 1.08 and 1.10 for 
GF5 and GF6 protocols, and the RPIR increases to 1.57 and 1.83, respectively. 
Like the results from both the initial and physiologically-based model, the median 
RMA is reduced to 0.64 and 0.55 for GF5 and GF6 respectively, and the median 
RPA is reduced to 0.77 and 0.72. Like the physiologically-based model, the 
RTD and RPIR increase with increasing gain factor because the saturation curve 
182 CHAPTER 12 CONTROL OF THE EXTENDED PHYSIOLOGICAL MODEL 
limits the effectiveness of the additional drug. However, the time-varying W2(t) 
and EAR dynamic in the extended model mediate the effect of the saturation 
dynamic. Therefore, although the RTD with increasing gains, as in the 
physiologically-based model, the increase is not as dramatic, while the agitation 
management improvements are retained. 
These reductions in mean and peak agitation levels using the GF5 and GF6 
protocols are significant. The median reduction in mean agitation is 45%, with 
some patients experiencing a reduction of up to 90%. Similarly, peak agitation 
levels are dramatically reduced, with the median reduction of 28%, and maxi-
mum reduction of 67%. Although these improvements are clinically desirable, 
these benefits are achieved at the expense of an increase total dose and peak 
infusion rate. However, the increase in total dose is relatively small, and not 
as important as the increase in peak infusion rate. The GF6 protocol, although 
showing significant agitation reduction, results in a median in peak in-
fusion rates of 83%, and in some cases up to 203%. These high infusion rates are 
likely to be unacceptable for clinical practice, and are also likely to be minimally 
effective due to saturation. 
As previously discussed in Chapter 11, the saturation dynamic the ex-
tended physiologically-based model is a major factor limiting the performance of 
any sedative infusion protocol. This feature is highlighted by the fact that the 
initial model, which does not incorporate the saturation dynamic, is capable of 
significantly improved reductions in both mean and peak agitation for any given 
control protocol. However, in spite of this issue, the GF6 protocol shows potential 
for improved agitation management if the high infusion rates are reduced. 
12.2.3 CappedGF6 and BoundGF6 Protocols 
Imposing a maximum limit on the infusion rate of the GF6 protocol ensures 
that the infusion rate for each patient does not exceed the maximum recorded 
infusion rate. Therefore, the bolus-oriented approach of the GF6 protocol is 
maintained, but the undesirable large infusion rates are prevented. Figure 12.3 
presents the of the derivative-focused control protocols with infusion limits 
for a typical patient using the extended physiologically-based model. The upper 
plot shows the infusion rates, and the lower plot shows the resulting agitation 
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profile. In these plots, the lighter solid line represents GF6, the dashed line 
represents CappedGF6, the dotted line represents BoundGF6, and the darker 
solid line represents the nurse control protocol as a benchmark for comparison. 
Imposing this upper limit on the infusion rate results in a maximum RPIR=1.0 
by definition. 
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Figure 12.3 Example of the simulated results employing the CappedGF6 and BoundGF6 
infusion protocols in the extended physiologically-based model. 
Table 12.1 shows the performance metrics for the GF6, CappedGF6, and 
BoundGF6 protocols. Like the physiologically-based model, the median RMA 
increases slightly from 0.55 to 0.57, and RPA increases slightly from 0.72 to 0.74, 
as seen in Table 12.1. However, in contrast to the physiologically-based model, 
and more like the initial model, the extended model shows an increase in RTD 
from 1.10 to 1.21. This is most likely due to the increased time that the infusion 
rate is at peak value, and may differ from the physiologically-based model because 
of the different C50 selection and values. 
However, for approximately 20% more drug dose and no increase in peak 
infusion rates, the CappedGF6 protocol results in a median reduction of mean 
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agitation of 43%. Further, some patients experience a mean agitation reduction 
of up to 90%. Similarly, the median reduction in peak agitation is 26%, and in 
some cases a reduction of up to 66% is observed. These results show that the 
Capped GF6 protocol is an effective protocol all round, and emphasises again 
how a simple control protocol can be extremely effective. 
Applying maximum and minimum limits to the infusion rate of the GF6 
protocol has a similar effect in the extended model to that of the initial and 
physiologically-based models. Because of increased effect site concentrations 
resulting from the continuous infusion, the PD effect reducing agitation is in-
creased, thereby reducing the median RMA from 0.57 for CappedGF6 to 0.38 for 
BoundGF6 and the median RPA from 0.74 to 0.67. Unlike the physiologically-
based model, the RTD increased slightly from 1.21 in the CappedGF6 protocol 
to 1.23 for the BoundGF6 protocol. However, the dominating feature of the re-
sults of the BoundGF6 in the extended model is the fact that, once again, the 
continuous infusion causes some patients to experience 'negative agitation levels'. 
This once again highlights the point that protocols that deliver a component of 
the infusion rate independent of patient agitation run the 
insufficient sedation. 
12.2.4 Summary 
of over-sedation or 
This analysis of the various control protocols using the extended physiologically-
based model has reiterated the results of the previous chapter. In particular, the 
results indicate that constant infusion protocols provide poor agitation manage-
ment, while very simple control protocols can provide improved agitation man-
agement over current clinical practice. Further, this chapter has once em-
phasised the limiting effect of the saturation dynamic on the capacity of any given 
control protocol to reduce agitation. 
Although the patient-specific identification of PD parameters and the effect 
of the EAR dynamic are shown to mediate the effect of the saturation dynamic, 
the saturation curve still represents the dominant feature restricting the capacity 
of control protocols to reduce agitation. However, in spite of this restriction, 
considerable improvements over current clinical practice are achieved. In partic-
ular the CappedGF6 protocol achieved median reductions of up to 63% and 28% 
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for mean and peak agitation, respectively. More importantly these benefits are 
achieved without exceeding conservative safety infusion limits, and at the expense 
of only 21% more total drug dose. The important feature of this bolus-oriented 
approach to agitation management is the use of timely boluses of sedatives in re-
sponse to patient agitation, rather than a continuous infusion rate. The result of 
this bolus-oriented approach is a reduction in the unnecessary over-use of drugs, 
and reductions in both mean and peak agitation. 
These reductions represent considerable benefit to critically ill patients and 
medical staff. However, the presence of the saturation dynamic means that these 
benefits (reduced agitation) come only at the expense of increased costs (drug 
dose). This trade-off between benefits and costs makes agitation management 
a complex issue involving the value of reduced agitation levels and improved 
healthcare, compared to the cost of increased drug dose. 
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Table 12.1 Agitation performance metrics for all sedative infusion protocols using the ex-
tended physiologically-based model. 
RTD RPIR RMA RPA 
Constant 
Max 1.00 0,41 1.31 1.64 
UQ 1.00 0.30 0.93 1.14 
Med 1.00 0.24 0.45 0.91 
LQ 1.00 0.20 -0.30 0.52 
Min 1.00 0.12 -7.85 0.05 
0.00 0.10 1.23 0.62 
GF3 
Max 1.09 1.53 1.01 1.05 
UQ 0.99 1.29 0.98 0.99 
Med 0.97 1.03 0.96 0.95 
LQ 0.94 0.94 0.90 0.92 
Min 0.80 0.71 0.75 0.81 
IQR 0.05 0.35 0.08 0,07 
GF4 
Max 1.20 2.02 0.85 0.93 
UQ 1.08 1.63 0.80 0.88 
Med 1.05 1.30 0.78 0.84 
LQ 0.98 1.21 0.71 0.82 
Min 0.80 0.90 0.47 0.61 
0.10 0.42 0.09 0.06 
GF5 
Max 1.29 2.52 0.78 0.85 
UQ 1.16 1.99 0.69 0.80 
Med 1.08 1.57 0.64 0.77 
LQ 0.97 1.46 0.55 0.74 
Min 0.63 1.07 0.25 0.44 
IQR 0.19 0.53 0.14 0.06 
GF6 
Max 1.39 3.03 0.73 0.81 
UQ 1.22 2.39 0.62 0.74 
Med 1.10 1.83 0.55 0.72 
LQ 0.93 1.73 0.44 0.69 
Min 0,41 1.22 0.10 0.33 
IQR 0.29 0.66 0.18 0.05 
CappedGF6 
Max 1.42 1.00 0.84 0.88 
UQ 1.26 1.00 0.67 0.76 
Med 1.21 1.00 0.57 0.74 
LQ 1.12 1.00 0.52 0.70 
Min 0.96 1.00 0.10 0.34 
IQR 0.14 0.00 0.15 0.06 
BoundGF6 
Max 1.54 1.00 0.67 0.88 
UQ 1.30 1.00 0.50 0.71 
Med 1.23 1.00 0.38 0.67 
LQ 1.15 1.00 0.15 0.60 
Min 1.04 1.00 -0.11 0.24 
IQR 0.15 0.00 0.35 0.11 
Chapter 13 
HOC! Control of the Physiologically-based Model 
H eo control is selected over other approaches for formal control systems analysis 
based on its ability to minimise the transfer function between an unknown stim-
ulus and the resulting patient agitation. H= applications are more common in 
the pharmacokinetically similar glucose-insulin system, where it has been used in 
simulations studies to regulate blood glucose in diabetes [Kienitz and Yoneyama, 
1993; Ruiz-Velazquez et al., 2004]. In agitation management, the primary advan-
tage of Heo methods is that the input disturbance need not be explicitly known to 
control steady state response, offering a significant advantage in this case. This 
chapter develops an Heo methodology USiilg the physiologically-based model of 
Chapter 7. 
13.1 Linearity Assumptions 
Using the physiologically-based agitation-sedation model of Chapter 7, a linear 
matrix inequality (LMI) Heo static output feedback control design methodology is 
developed. By optimally reducing the maximum magnitude of the transfer func-
tion between the unknown stimulus input, S, and the measured patient agitation 
output, A, Heo control doesn't require the stimulus, S, to be known. 
First, a linear version of the agitation-sedation system presented in Equations 
(7.1)-(7.6) is required. The non-linear Equation (7.6) can be expanded into two 
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separate difi'erential equations. Equation (7.6) can be re-written: 
E - KT lt 
KTe- KTi lt ECombeKTT dT 
f(t)g(t) (13.1) 
Difi'erentiating Equation 13.1 using the product rule and the fundamental 
theorem of calculus yields: 
dE 
dt f'(t)g(t) + f(t)g'(t) 
- K~e-KTt. [I t ECombeKTT dT] + KTe-KTt . [ECombeKrt] 
- K T · [KTe-KTt lt ECombeKTT dT] + KT . EComb 
-KTE+ KTEcomb (13.2) 
Note that this form of the PD efi'ect equation indicates that the pharmacologically 
active drug is transported to the effect site via a diffusion process, in this case 
presumed to be the diffusion across the blood brain barrier into the brain and 
central nervous system. Substituting Equation (13.1) into Equation (7.6) yields 
a linear form of Equation (7.6) in terms of E. 
(13.3) 
Next, the non-linear effect response surface in Figure 3.3 is replaced by the 
linear surface shown in Figure 13.1. The dark fiat surface represents the linear 
response surface, and the line-mesh white curved surface represents the non-linear 
surface for comparison. This linear surface is defined: 
(13.4) 
where ""a and ""s are chosen to ensure the centre of the non-linear and linear 
surfaces coincide. Hence, Figure 13.1 is a linear approximation of the net slope 
of the sigmoid in Figure 3.3, rather than its middle slope, capturing an average 
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type of response. 
Figure 13.1 Schematic of the linearised PD response surface. 
13.2 Hoo Control Methodology 
Equations (7.1)-(7.5) and (13.2)-(13.3), incorporating the linear response surface 
in Equation (13.4), forms a simplified linear state-space model of the agitation-
sedation system. 
oa 
c an a12 al3 a a a a ea c Ra a 
oa 
p a21 a22 a a a a a ea p a a 
oa 
e a31 a a33 a a a a ea e a a 
Os 
c a a a a44 a45 a a es c + RS u+ a s 
Os 
e a a a a54 a55 a a es e a a 
€ a a a63 a a65 a66 a E a a 
A a a a a a a76 a A a Wl 
x=Ax+B1U+B2 S (13.5) 
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where 
-Kh -K:;e-K:;p ~ 0 0 0 0 va va 
c c 
K~ 0 0 0 0 0 Vpa 
K6e 0 K~c 0 0 0 0 Vea - Vea 
A= 0 0 0 -Ktn,-Kg. 0 0 
v s c 
0 0 0 0 0 
0 0 ",aKT 0 ",SKT 0 
0 0 0 0 0 -W2 0 
The measured output, y, is defined a.s a 2-signal vector of the patient 
tation, A, and its rate of change, Ii, both of which are becoming available from 
newly developed agitation sensing methods [Chase et al., 2004c,a; Lam et al., 
2003; Starfinger et al., 2003; Agogue, 2005; Lam, 2003; Starfinger, 2003; Chase 
et al., 2004b]: 
y [ 1] 
[ "7 ] 
W2X6 +w1S 
Xl 
X2 
[ ~ 0 0 0 0 0 ~ ] X3 + [ ~1 ] S 0 0 0 0 X4 -W2 
Xs 
X6 
X7 
C1x+D1S (13.6) 
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A static output feedback controller for determining the sedation input to this 
system is therefore a proportional-derivative controller. 
u -
(13.7) 
The derivative-focused proportional-derivative control protocol employing K 
[-0.0004 0.4] x 3 in Section 11.2.2 provides an essentially bolus-driven man-
agement approach, which is shown in Chapter 11 to be effective in managing 
patient agitation given a consistent agitation measurement. Adopting the simple 
approach of increasing the original control gains by a factor of six (GF6 protocol) 
reduced mean patient agitation by 40% across all patients, and by as much as 
54% for some patients, in comparison to the infusion methods currently employed. 
These ideas are further investigated and validated using H = control methods as 
a formal means of control systems analysis. 
The closed-loop system state space equations are defined: 
(13.8) 
where Ad and Bcl represent the closed-loop plant and external disturbance map-
ping matrices, respectively. 
To derive Hoo optimality conditions, a quadratic Lyapunov function can also 
be defined [Vidyasagar, 1993] : 
(13.9) 
where P = pT is assumed. Differentiating Equation (13.9) and substituting 
Equation (13.8) yields: 
(13.10) 
If P = pT > 0 can be found such that v < 0, vx =I 0 then stability is eIlsured 
via standard Lyapunov stability theory. This stability criterion can be augmented 
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to include an HCXJ bound criteria [Boyd and Ghaoui, 1993]: 
(13.11) 
,where the regulated output, z, is defined as patient agitation for this case: 
Z = A = [0 0 0 0 0 0 l]x = C1x (13.12) 
Note that this metric will be reduced in an l2 or rms sense, similar to the average 
agitation metrics of Chapters 10-12. 
Substituting Equations (13.10) and (13.12) into Equation (13.11) and simpli-
fying yields: 
However, Equation (13.13) is not easily simplified, but is clearly valid [Chase 
and Smith, 1996; Chase et al., 2005a] if: 
xT[A~P + PAc! + CiC1]x + wTB~Px + xTpBc!W - 'lwTw+rTr :s; 0 
(13.14) 
where a careful selection of r yields: 
1 
r = -(B~Px -')'w) 
')' 
(13.15) 
Substituting Equation (13.15) into Equation (13.14) and simplifying yields a more 
readily solved matrix condition to find a matrix P = p T > 0 that also satisfies 
Equation (13.11): 
(13.16) 
Equation (13.16) is satisfied when the matrix is negative definite, or negative 
semi-definite: 
(13.17) 
Finally, using Schur complements, Equation (13.17) can be expressed as a Linear 
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Matrix Inequality (LMI): 
(13.18) 
If a positive definite symmetric matrix P can be found to satisfy Equation 
(13.18) for a given value of I> 0, then the system Hoo norm is bound by 
I [Chase and Smith, 1996]. Note that Ael and Bel both contain the gain matrix 
K, making this LMI non-convex in the variables P, K and I' It is therefore not 
possible to directly use semi-definite programming tools to simultaneously find 
the gain matrix K, the minimum I, and P. 
However, for a given gain matrix K, semi-definite programming can be used 
to find P and minimise I' Repeating this process over a grid of gains Kp and 
Kd yields a I-surface. SDPSOL, a LMI matrix optimisation software package 
was used for this process [Wu and Boyd, 2000]. In this section, these values are 
termed linear Hoo bounds, Ilinear. 
Clinical Hoo norms, Idin, can also be calculated for each patient from the non-
linear simulation data generated using the agitation-sedation model of Chapter 
7 and nurse control protocol. 
Ie/in = 
II A 112 
II S 112 (13.19) 
These Ie/in values represent the best available assessment of current clinical 
practice. Non-linear simulations implementing the derivative-focused GF3 and 
GF6 control protocols enable the calculation of the Hoo norms, IGF3 and IGF6, 
for comparison with the clinical Ie/in values and the linear bounds. These Hoo 
norms represent the non-linear equivalent of the linear Hoo bounds, Ilinear. 
The non-linear norms, IGF6, can then be compared to the linear val-
ues Ilinea.., obtained using the linear system to determine the impact of non-
linearities. In addition, Idin can then be compared to non-linear results obtained 
using the Hoo optimal control gains to determine whether these optimal control 
gains provide enhanced performance. Finally, the overall grid search of control 
gains enables the analysis of which gain balance (derivative-focused or propor-
194 CHAPTER 13 Hoo CONTROL OF THE PHYSIOLOGICALLY-BASED MODEL 
tional focused) is optimal. 
This last point is clinically relevant because derivative-focused methods lead 
to bolus-based delivery and proportional-focused methods lead to more continu-
ous infusion oriented delivery. Hence, this analysis compares and contrasts these 
two approaches formally. It also provides a measure of analytical proof, given 
the optimal Hex; approach chosen for this analytical In summary, five 
different Hex; norms are calculated: 
Clinical: {din Based upon simulated results generated in Chapter 7. 
GF3: {GF3 Based upon simulated results generated using the direct derivative-
focused GF3 control protocol representing the direct derivative-focused pro-
tocol with total dose similar to the nurse control protocol. 
GF6: {GF6 Based upon simulated results generated using the direct derivative-
focused GF6 control protocol, representing an improved control protocol. 
Linear: {linear Based upon Hex; analysis using linear system. 
Optimal: {H
oo 
Based upon simulated results generated using the Hex; optimal 
control gains. 
13.3 Results and Discussion 
Lyapunov stability analyses show that the linear open-loop system is borderline-
stable, and the closed-loop system is asymptotically stable for all values of the 
patient-specific parameters. These results are confirmed by checking the 
values of the plant matrix A. The stability characteristics of the open and 
closed-loop systems are not unexpected. Inspection of the system described by 
Equations (7.1)-(7.5) and (13.2)-(13.3) reveals that the open-loop system is 
herently borderline stable. Similarly, inspection of the closed-loop system matrix, 
Acb reveals an inherently stable, or at least full rank, plant matrix. Note that 
the inclusion of the -W3A EAR dynamic would make the open loop matrix, A, 
stable, as might be expected. 
The of changing the control gains on the Hex; norm is displayed in Table 
13.1, where the normalised H~ bounds are presented in a grid of control gains Kp 
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and K d . Note that the values are normalised to the average linear system { from 
all patients using the gain values K [0.0004 0.4], shown by the normalised { 
value of unity. No value indicates instability in the linear model for at least 1 of 
the 37 patients. The thin lines in the diagram represent the boundary between 
regions of improved and degraded average HiXJ norm relative to the gain values 
K = [0.0004 OAl of the system. Areas with values less than 1.0 are 
gains that might provide improved performance. Finally, note that proportional-
weighted (Kp » K d ) or equal-weighted (Kp ~ K d ) gain combinations are in the 
unstable gain region. This last result might be expected given the results from 
Chapters 10-12 for constant infusions. 
As the magnitude of control gains increases, the linear system becomes 
increasingly less stable, where stability is defined as a bound output in response 
to a bound input. Table 13.1 shows the regions of instability by regions with no 
values, which clearly represent unsuitable choices for the control gains. This rapid 
progression toward instability is probably a result of the linear simplification, as 
previous simulations have shown that some of these regions remain stable in the 
non-linear model. If saturation dynamics are included, the agitation abating 
effect of the drugs at high concentrations is significantly reduced, lessening the 
tendency for instability, but still resulting in a higher { value. 
The development of the H iXJ design LMI in this paper is based upon the linear 
approximation the non-linear system presented in Equations (7.1)-(7.6). To 
obtain a linear system, the non-linear response surface presented in Figure 3.3 
is replaced by a linear response surface, defined in Equation (13A), and shown 
in Figure 13.1. This linear approximation removes the saturation dynamics at 
higher doses. lower results using the linear model, {linear, compared to results 
from the non-linear analysis, are therefore a result of these non-linear saturation 
dynamics. 
The consequence of removing the effect saturation dynamic from the drug 
response surface is that the drugs become more effective at higher effect site con-
centrations, much like the initial results in Chapter 10. Therefore, by Equation 
(7.6), for a stimulus profile, the agitation levels will be more greatly reduced 
in the linear model, resulting in lower HiXJ bounds. To compensate, the gains are 
increased by a factor of 3, yielding the GF3 protocol which is shown to provide 
similar agitation management to the nurse control protocol in Chapters 10-12. 
196 CHAPTER 13 Hoo CONTROL OF THE PHYSIOLOGICALLY-BASED MODEL 
Table 13.1 can be used to find an improved set of control gains over the GF6 
protocol, shown to provide enhanced agitation management in Chapters 10-12. 
Using the information gained from the based grid-search, an improved con-
trol gain matrix, K = [0.0005 0.5], is obtained. These control gains in the linear 
model correspond to what is termed the GF7.5 protocol for the non-linear model. 
The non-linear clinical Hcc norms, Ie/in, non-linear Hcc norms using the GF3 
control protocol of Section 10.1, IGF3, non-linear Hcc norms using the GF6 con-
trol protocol, IGF6, linear Hoo bounds, Ilinear, and non-linear Hoo norms using 
the optimal Hoo control gain protocol GF7.5, determined via grid search, are 
presented for all 37 patients in Table 13.2. The Iclin values have a mean value 
of 28.13, and the IGF3 values have a mean value of 28.16. The Ilinear values 
have a mean value of 10.20, whereas the IGF6 values have a mean value of 17.79, 
where the difference between IGF6 and Ilinear is due to the impact of drug effect 
saturation limiting the effect of the drugs infused in the non-linear case, and the 
increase in gains. The result of implementing the optimal control protocol, 
GF7.5, produced Hoo values with a mean value of 15.34. Finally, these improve-
ments are achieved at the expense of increased median drug dose of 34% and 
47% for the G F6 gains and optimal H 00 control gains respectively. These higher 
doses would lead to RTD values closer to 1.0 if the inputs were capped to avoid 
excessive saturation at the high end where the controller demands input. 
Table 13.2 shows that the derivative-focused GF3 control protocol an 
IGF3 across all patients of 28.26, compared to an average of 28.13 for the 
nurse control protocoL This result highlights the similar agitation management 
provided by the nurse control protocol and the GF3 protocoL In contrast, the 
mean IGF6 across all patients is 17.79, showing that the simple derivative-focused 
GF6 control protocol is capable of reducing the transfer of stimulus to patient ag-
itation. Implementing the optimal control protocol, GF7.5, resulted in a reduced 
average Hoo of 15.34 using non-linear simulations, compared to 17.79 using the 
previous control gains. Hence, Hoo analysis and control design yielded over 14% 
improvement over prior manual control design, and an over 45% improvement 
versus current clinical practice. Equally importantly, these results show that 
while specific differences between results from the linear and non-linear systems 
exist, general trends in the linear system are reflected in the non-linear system 
and provide useful information for gain selection. 
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The clinical Hoo norms, Idin, are an indication of the non-linear transfer from 
stimulus to modelled agitation obtained clinically. The range of Idin from 15.54-
38.16 is a direct result of the selected Wl value used in the model. In both the 
linear and non-linear cases, the stimulus profiles used in these simulations range in 
magnitude from approximately 1-10 units, whereas the agitation levels typically 
range from 10-100 units. The benefit of Iclin is that it provides a benchmark 
against which non-linear simulations of improved controllers may be evaluated. 
The wide range may also be indicative of the wide range of clinical practice and 
effectiveness using a coarse subjective agitation assessment scale, as well. 
The region in Table 13.1 with values less than 1.0 indicates control gains 
that reduce the transfer from stimulus to patient agitation below that of the 
control gains developed by trial and error in Section 10.1. However, reducing 
patient agitation is not the sole aim of automated sedative infusion systems, as 
reduced levels of agitation may be simply achieved through the administration of 
excessive drug dose. The aim of an effective automated sedative infusion system 
is to minimise patient agitation using minimal drug dose. Therefore, control gain 
selection must be based not only on the direct impact on patient agitation, but 
also on the resulting control effort, or total dose, required to achieve reduced 
agitation levels. 
Simple techniques, such as placing upper limits on the commanded infusion 
rate, were shown to reduce agitation levels in Section 11.2.2. However, if the 
methodology presented here were enhanced to minimise control effort, as well 
as patient agitation, then further insight into Hoo control gain selection may be 
obtained. This goal can be achieved by changing the regulated output, z, to 
include effect concentrations C~·8, which reflect control effort, by redefining 
the matrix C1 in Equation (13.6). 
13.3.1 Summary 
This formal analysis approach using optimal control theory confirms the results 
of Chapters 10-12. In particular, this Hoo analysis has provided optimal control 
gains corresponding to the lowest magnitude of transfer function from any 
given stimulus to patient agitation. Although the linear assumptions of the anal-
ysis lead to discrepancies between the simulated non-linear results and the linear 
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theoretical results, the trends observed hold. 
Importantly, the results of the H 00 analysis show that the optimal control 
gains represent a derivative-focused agitation feedback controller and agree with 
the results of Chapters 10-12. A derivative-focused control protocol produces 
sedative infusion profiles with high infusion rates during increasing agitation, and 
low infusion rates during periods of low agitation. More importantly, this bolus-
oriented approach to sedation is shown in Chapters 10-12 to provide considerable 
improvements in agitation management over current clinical methods. 
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0.000004 92.36 
0.00004 92.36 
0.0004 92.36 
0.004 92.36 
0.04 92.36 
0.1 92.36 
0.2 92.36 
0.3 92.36 
92.36 
0.6 92.36 
0.7 92.36 
0.8 92.36 
0.9 92.36 
1 92.36 
1.2 92.36 
1.6 92.36 
2 
0.00004 0.0001 0.0002 
9.24 4. 3.85 
9.24 4.15 3.85 
9.24 4.13 3.82 
9.24 4.03 3.62 
9.24 3.70 2.39 
9.24 3.70 1.85 
9.24 3.70 1.84 
3.70 1.84 
3.70 1.84 
9.24 3.70 
9.24 3.70 1.84 
9.24 3.70 1.84 
3.70 1.85 
9.24 3.70 1.86 
9.24 3.70 1.87 
9.24 3.70 1.94 
9.53 4.38 151.11 
Table 13.1 Normalised Hoc bounds 
0.0003 0.0004 0.0005 0.0006 0.0007 0.0008 0.0009 0.001 0.002 0.004 
5.04 
5.04 
4.99 
4.56 88.03 
2.61 3.16 4.24 143.66 
1.58 1.75 2.02 6.41 
1.25 1.11 1.21 1.90 2.21 
1.25 1.01 0.98 1.32 1.45 
1.25 1.00 0.96 1.13 1.21 130.63 
1.25 1.00 0.92 1.07 1.11 65.44 
1.25 1.02 0.93 1.03 1.07 1.95 
1.26 1.03 0.95 0.94 1.03 1.07 1.78 
1.28 1.06 0.98 0.97 1.06 1.10 1.75 
1.30 1.10 1.03 1.01 1.04 1.11 1.14 1.77 
1.34 1.15 1.10 1.07 1.10 1.17 1.21 1.87 
1.44 1.28 1.24 73. 1.36 1.41 2.75 
73.70 85.66 
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1 
2 26.40 27,26 8,75 16,63 14.43 
3 27.25 27.85 8.76 16.24 13.54 
4 23.11 23.13 9.64 15.81 14.06 
5 26.49 25.59 13.75 15.13 12.51 
6 22.82 23.12 13.75 17.52 16.25 
7 22.82 23.94 8.78 17.59 16.46 
8 29.75 30.47 12.38 19.01 16.30 
9 32.97 32.96 8.76 19.13 15.86 
10 34.41 35.21 11.56 20.01 16.45 
11 25.09 26.31 8.83 20.20 18.80 
12 27.45 28.44 11.56 18.05 15.70 
13 22.41 23.74 8.86 16.64 14.74 
14 24.20 22.73 11.55 15.37 13.26 
15 31.43 30.95 12.16 18.38 14.88 
16 31.95 33.25 9.16 18.19 14.53 
17 25.11 26.11 9.25 18.11 16.18 
18 32.06 31.12 10.29 17.49 13.90 
19 35.30 34.84 10.37 18.41 14.31 
20 28.38 29.74 10.78 18.18 15.47 
21 26.36 24.98 9.29 14.97 12.90 
22 28.24 28.97 12.98 18.22 15.35 
23 19.26 18.61 8.59 11.94 10.37 
24 30.60 31.26 12.04 18.03 14.84 
25 31.17 29.12 8.78 19.63 17.45 
26 29.86 28.02 9.32 21.98 21.03 
27 27.31 29.19 8.90 18.45 15.73 
28 36.25 35.79 8.86 16.88 12.51 
29 18.45 19.02 12.47 16.12 15.60 
30 28.31 27.47 11.62 16.42 13.82 
31 35.32 35.78 9.12 21.48 18.40 
32 35.19 36.07 9.12 23.42 20.54 
33 38.16 38.77 9.45 23.14 19.85 
31.41 31.23 9.00 16.78 13.70 
35 31.93 32.63 9.46 20.73 17.88 
36 24.66 23.82 9.60 20.64 20.20 
37 23.57 23.47 9.42 13.85 11.55 
Mean 28.13 28.26 10.20 17.79 15.34 
Chapter 14 
Robustness Analysis 
The intra- and inter-patient parameter variations observed in Section 8.2 have 
important implications for patients, medical staff, systems modelling, and control 
design. Parameter variability may be a marker of clinical outcome or of therapy, 
and knowledge of parameter variations over time and between patients can be 
used to improve patient care. From a modelling and control systems perspective, 
changes in parameters are an important consideration. If parameter changes 
between patients or over time are unaccounted for, the usefulness of the model 
is limited. More importantly, the clinical effectiveness of a given control protocol 
depends on its ability to manage agitation in the face of changing parameters. 
The sedative infusion control protocols in Section 10.1 represent protocols 
that, upon clinical implementation in conjunction with quantitative agitation 
sensors [Lam et al., 2003; Lam, 2003; Starfinger et al., 2003; Starfinger, 2003; 
Shaw et al., 2003b; Chase et al., 2004aj, could result in improved clinical agi-
tation management. However, clinical implementation of such control protocols 
introduces many additional complicating factors that were not accounted for in 
the previous simulations. Two examples include noise in the feedback signal, and 
unpredictable, immeasurable changes in patient parameters over time. While 
many of these factors cannot be properly analysed in simulations and require 
clinical trials, some simple aspects of them may be analysed through simulations 
before clinical trials begin. 
In particular, the robustness of a control protocol against the time-varying 
nature of patient parameters is of clinical importance. Specifically, prior to clin-
ical implementation of a control protocol, the protocol's response to stocha.'3tic, 
immeasurable changes in patient parameters must be analysed. Control proto-
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cols that become unstable or produce undesirable outcomes a."l a result of such 
variation in patient parameters may put patients and/or medical staff at risk 
Preferably, control protocols should be robust against such changes in param-
eters, either continuing to function effectively, or at least remaining safe and 
stable. 
This chapter employs statistical ARMA models to capture the parameter 
changes in fitted sedative sensitivity profiles, W2(t), from Chapter 8 and uses 
these models to generate virtual sedative sensitivity profiles, W2(t). These virtual 
profiles are then used to evaluate the CappedGF6 protocol for robustness and 
sensitivity to realistic parameter variations in the extended physiologically-based 
model evaluated Chapter 8. In particular, the robustness of the CappedGF6 
control protocol against the stochastic, immeasurable time-variation of sedative 
sensitivity, W2(t) , is compared to the robustness of current clinical practice, the 
nurse control protocol of Section 4.2. 
14.1 Methods 
14.1.1 Modelling Parameter Tr~nds 
The generation of virtual sedative sensitivity profiles, W2, for each patient, re-
quires a method of modelling the trends and patterns in the patient's fitted 
sedative sensitivity profile, W2(t). Since the values of W2(t) do not change inde-
pendently from one time step to the next, W2(t) is a correlated time series, and 
an Auto Regressive Moving Average (ARMA) model is used. 
An ARMA(p,q) model, in general, has the form: 
x(k) alx(k 1) + a2x(k - 2) + ... + apx(k p) + 
+z(k) + b1z(k - 1) + b2z(k - 2) + ... bqz(k q) (14.1) 
where x(l), x(2), ... is time series being modelled, z(l), z(2), ... are random 
terms, aI, a2, ... , ap are the coefficients of the AR component of the model, bl , b2, ... , bq 
are the coefficients of the MA component of the model, and p and q are the AR 
and MA model orders, respectively. 
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For agitation-sedation models of the sedative sensitivity, 11!2(t), as an ARMA 
process, Equation (14.1) is written: 
al11!2(k - 1) + o,211!2(k - 2) + ... + o,p11!2(k p) + 
+z(k) + b1z(k 1) + b2z(k - 2) + ... + bqz(k - q) (14.2) 
Equation (14.2) assumes that the random terms, z, take the form of a normally 
distributed, independent random variable with zero mean. For a complete de-
scription of the ARMA model representing the 11!2(t) profile for any given pa-
tient, the orders p and q must be selected and the coefficients aI, 0,2, ... , ap and 
b1 , b2 , ... , bq that best represent the stochastic time 11!2 (1) , 11!2 (2), ... , 11!2 (n) 
from Chapter 8 determined. 
MATLAB's System Identification Toolbox is designed for building accurate, 
simplified models of complex systems from noisy time-series data. It provides 
general tools for creating mathematical models of dynamic systems based on 
observed input/output data. The identification techniques provided with this 
toolbox are useful for applications ranging from control system design and sig-
nal processing to time-series analysis and vibration analysis. However, there are 
some tools required for the complete identification of ARMA models that are lack-
ing from the standard System Identificati~n Toolbox. The MATLAB ARMASel 
toolbox is specifically designed for ARMA analysis, and contains some tools for 
ARMA models not available in the standard MATLAB system identification tool-
box. It is a program capable of generating a time-series model from a stationary 
stochastic signal with unknown characteristics [Broersen, 2002]. It is written by 
P. Broersen [2002]' and is available on MATLAB Central in MATLAB's open file 
exchange platform [Mathworks, 2005]. Thus, the MATLAB system identification 
toolbox, and associated ARMASel toolbox, are used to find the ARMA model 
parameters which most closely model the observed sedative sensitivity profiles 
obtained via the fitting process developed in Chapter 8. 
More specifically, the MATLAB toolbox is found to have excellent tools for 
creating ARMA models, but lacks a tool for the selection of the order to the AR 
and MA polynomials. ARMASel has useful tools for selecting the model orders, 
but its model estimation methods are not as robust as those found MATLAB. 
The ARMASel toolbox is therefore used for order selection, and the System Iden-
tification Toolbox used to create the ARM A model by determining the coefficients 
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aI, a2, .'" ap and bl , b2, "., bq • The model is then checked by evaluating the auto-
correlation of the residuals for various lags using the RESID command found in 
the System Identification Toolbox. 
The automatic selection of AR and MA orders is based on statistical crite-
ria, designed to select the order with the smallest expectation of the prediction 
error. The AR order, p, is selected using the Combined Information Criteria 
(CIC), which combines the asymptotic balance between under- and over-fit and 
the finite sample resistance against the selection of model orders that are too 
high [Broersen, 2000, 2002]. The MA order is selected using the generalised in-
formation criteria (GIC), obtaining a compromise between over-fit and under-fit 
[Broersen, 2000, 2002]. 
ARMASel selects model orders, p and q, given a stochastic input time series 
and an order difference, d = p - q. Therefore, to select the best combination 
of coefficient orders, an array of order differences d = 1,2, "., l is tested and 
the orders resulting in models with minimum residual are selected. The MAT-
LAB command ARMAX creates an ARMA model from an input data set and 
model orders p and q. ARMAX creates a full ARMA model including the coef-
ficients aI, a2, "., ap and bl , b2, "., bq , as well as the variance and noise structure. 
MATLAB's ARMAX function minimises a robustifiedquadratic prediction error 
criterion using an iterative search algorithm. A stability test of the predictor 
is performed to ensure that only models corresponding to stable predictors are 
tested [Ljung, 1999]. The System Identification toolbox also provides the model 
evaluation tool RESID, which can be used to check fit by testing whether the 
residuals are uncorrelated. However, this test provides necessary but not suf-
ficient evidence for an appropriate model. Models failing the residual test are 
therefore rejected, while models passing the residual test are kept for further 
analysis. 
The numerical output of RESID also provides a useful method for selecting a 
model from various models that have all passed the residual test. When deciding 
between two models that have passed the residual test, the model with lowest 
sum of absolute residuals is selected. Although this selection method does not 
necessarily guarantee the ideal model, it eliminates failed models and provides an 
objective selection criterion. All models are manually checked after this selection 
process, and their resulting outputs evaluated against the original input data set. 
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Therefore, the ARMA model creation process for each patient includes: 
1. The patient's W2 profile is passed to ARMASel to select the best orders p 
and q from an array of order differences d = [0,1,2, ... ,10]. 
2. The selected combinations of p and q for each order difference are used to 
create an ARMA model using ARMAX. 
3. Each p/q combination model is tested using RESID. 
4. Models that fail the residual test are rejected, while models that pass are 
kept. 
5. The sum of absolute values of the residuals is evaluated for each p/q com-
bination model. 
6. The p/ q combination resulting in the lowest sum of absolute residual terms 
is selected. 
7. The selected p and q orders are used with the ARMAX command to create 
the ARMA model. 
This process is used to create an ARMA model for each patient in MATLAB. The 
resulting model structure contains the coefficients all a2, ... , ap and bI , b2, ... ) bq ) as 
well as the variance and noise structure. The process is based on the hourly fitted 
W2(t) profile described in Chapter 8. For all patients the 12 hours and the 
final 12 hours of the fitted W2 profile is not used in the model estimation step due 
to the impact of boundary conditions on ARMA model estimation. In addition, 
some small portions of the W2(t) profiles of some patients are manually excluded 
to obtain an ARMA model that passes the residual test. The structure can then 
be used to generate a time-series based on this model for each patient. 
14.1.2 Generating Virtual Patient Parameter Profiles 
The ARMA model structures created using the process defined in Section 14.1.1 
enable the generation of 'virtual' sedative sensitivity profiles, W2(t), for each 
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patient. The process simply employs the equation defining the ARMA process: 
w2(k) = alw2(k - 1) + a2w2(k - 2) + ... + apw2(k - p) + 
+z(k) + b1z(k - 1) + b2z(k - 2) + ... + bqz(k - q) (14.3) 
where w2(1), w2(2), ... is the generated stochastic time-series, z(l), z(2), ... are 
the random terms, aI, a2, ... , ap are the AR coefficients, b1 , b2, ... , bq are the MA 
coefficients, and p and q are the AR and MA model orders, respectively. The 
model coefficients are contained in the model structure generated using ARMAX, 
along with information about the nature of the random terms, z(l), z(2), ... , in 
particular, their standard deviation, (J. 
The initial values of the series, w2(1),w2(2), ... ,W2(P), are set to the aver-
age value of the fitted W2 (12), W2 (13), ... , W36(P) series which ensures that the W2 
profile is initialised, and enables the generation of a complete W2(t). Reflective 
boundaries are applied to the virtual parameter generator, set at the upper and 
lower limits of the fitted W2 profile. These boundaries cause a reflection of the 
generated W2 term if it approaches one of the limits, thereby ensuring that the 
virtual profiles generated remain in similar range to that of the fitted W2' 
14.1.3 Control Protocol Robustness Analysis 
Section 14.1.2 outlines a procedure for generating patient-specific virtual sedative 
sensitivity profiles, W2(t), based on ARMA models developed from the fitted 
W2(t) profiles from Section 8.2.2. Therefore, while the changes observed in the 
patient-specific virtual sedative sensitivity profiles are physiologically realistic 
and characteristic of the original fitted W2 (t) profiles, they are clearly stochastic 
and uncorrelated to the patient-specific recorded time-series data. Therefore, the 
stochastic changes in the virtual sedative sensitivity profiles represent potential 
changes in a patient's sedative sensitivity that may be observed clinically, but are 
immeasurable to a real-time controller. 
These virtual profiles are therefore employed to assess the response of a con-
trol protocol to these unpredictable changes in W2(t) that are anticipated in clin-
ical implementation. More specifically, no controller can accurately and consis-
tently predict what change this parameter might take in the forthcoming time 
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frame. Hence, its ability to control agitation is reduced by this stochastic vari-
ation, which can also impact robustness. A similar problem arises with insulin 
control of glucose and insulin sensitivity [Chase et al., 2005bJ. 
This chapter employs the virtual profiles in the physiologically-based agitation-
sedation model described in Section 3.3. All parameters used in this chapter are 
identical to those employed in the evaluation of the physiologically-based model 
in Section 8.2, except that the fitted sedative sensitivity profiles, W2(t), are re-
placed by the virtual sedative sensitivity profiles, W2(t). Note that the virtual 
profiles are generated from the fitted W2(t) profiles, and are therefore smoothed 
using the 12-hour smoothing filter to create physiologically-realistic changes, as 
in Section 8.2.3. In addition, the initial 12 hours of the virtual profiles, W2(t), are 
replaced by the initial 12 hours of the fitted sedative sensitivity profile, W2(t), for 
the same initialisation reasons mentioned in Section 8.2.3. 
Ten patients are randomly selected from the 37 patients in the study cohort. 
For each of these ten patients, 50 virtual W2(t) profiles are generated using the 
procedure in Section 14.1.2. A virtual trial is simulated using each of the 50 
corresponding virtual sedative sensitivity profiles, yielding 50 simulation results 
per patient. Performance metrics, representing the effectiveness of the control 
protocol, are evaluated for each virtual trial and summary statistics of the per-
formance metrics are then calculated for each patient. The performance metrics 
are defined: 
TD Total Dose is defined as the total simulated dose of the proposed control pro-
tocoL TD is an important global performance metric because it is a 
indication of drug usage, which has both financial and healthcare implica-
tions. In general, the use of excessive drugs leads to increased costs, and 
may be an indication of over-sedation. Therefore, from both a healthcare 
and financial perspective, a low TD is desirable. 
PIR Peak Infusion Rate is defined as the maximum infusion rate of a proposed 
control protocol. PIR is a particularly important parameter in ICU se-
dation, as high infusion rates can be damaging to patient health and are 
associated with cardiopulmonary depression and other side-effects [Barr and 
Donner, 1995J. For this reason, a low PIR is desirable. 
MA Mean Agitation is defined as the mean simulated agitation employing the 
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proposed control protocol. MA is one of the most important global perfor-
mance metrics for both the patient and the medical staff. High average agi-
tation levels can hinder the recovery process by preventing rest and healing. 
Periods of inflated average agitation levels are uncomfortable and danger-
ous for patients, and difficult and time-consuming for bedside medical staff. 
Therefore, for both patients and medical staff, a low MA is desirable. 
PA Peak Agitation is defined as the maximum simulated agitation employing 
the proposed control protocol. PAis a local metric that represents the 
point in time at which the patient is most likely to attempt to remove 
their life-support systems (such as removing the ET tube), or resist staff. 
These actions are damaging to patient health and a concern for staff safety. 
Therefore, for both patients and medical staff, a low PA is desirable. 
STDA Standard Deviation of Agitation is defined as the standard deviation of 
the agitation profile resulting from employing the proposed control protocol. 
This global metric is a general measure of the size of the oscillations in 
the resulting agitation profile. It is limited because it fails to recognise 
the agitation profile as a correlated time-series, and instead treats it as 
selection of independent values. However, STDA is an important metric, 
as large oscillations between sedation and agitation may be dangerous to 
patients' health. 
The simulation process described above is followed for both the nurse control 
protocol incorporating the IIR filter, described in Section 4.2, and the CappedGF6 
protocol described in Section 10.1. For both of these control protocols the same 
ten patients with the same 50 virtual profiles are used. This process yields sum-
mary performance metrics across the 50 virtual trials for each of the ten patients 
for both control protocols. Comparing the summary performance metrics result-
ing from use of the CappedGF6 protocol to those resulting from the nurse control 
protocol provides an indication of the performance ability of the CappedGF6 pro-
tocol. 
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14.2 Results and Discussion 
The ten randomly selected patients used in this chapter are patients 1, 3, 8, 16, 
19, 20, 21, 26, 30, 32. The results of three of the fifty virtual trial simulations, 
including the virtual W2(t) profiles, for Patient 3 are presented in Figures 14.1-
14.3. upper plot of these figures presents the sedative sensitivity profile, the 
middle plot presents the infusion rate, and the lower plot presents the agitation 
profile. In the upper plot, the lighter solid line represents the virtual sedative sen-
sitivity profile, W2(t), and the darker solid line represents the smoothed sedative 
sensitivity profile identified in Section 8.2.3. In the middle and lower plots, the 
dashed lines represent the modelled responses of the CappedGF6 protocol in the 
virtual trial, the dotted lines represent the modelled responses of the nurse con-
trol protocol in the virtual trial, and the dark solid line represents the modelled 
responses of the nurse control protocol using the smoothed W2(t) profile from the 
model evaluation procedure in Section 8.2.3. 
Note that the virtual sedative sensitivity profiles, W2(t), in the upper plots 
of Figures 14.1-14.3 have similar characteristics to the corresponding original 
smoothed sedative sensitivity, W2(t), from Section 8.2.3, yet are distinctly differ-
ent. This difference results from the fact that ARMA models used to generate 
the virtual profiles are based on these original profiles, but are generated using 
a stochastic process. Note alsQ in these figures that the initial 12 hours of both 
the smoothed and virtual profiles are identical. 
In the middle plots of Figures 14.1-14.3 the difference between the bolus-
oriented approach of the CappedGF6 protocol and the approach of the nurse 
control protocol should be noted. The CappedGF6 protocol employs a bolus-
oriented approach, whereas the nurse control protocol delivers drug in a more 
uniform approach. This feature is also seen in the earlier results of Section 12.2.3. 
Finally, note in the lower plots of Figures 1-14.3 the effect of the W2(t) 
on modelled agitation. Figure 14.2 highlights the result of a decrease in W2(t), 
and Figure 14.3 highlights the result of an increase in W2(t). A decrease in W2(t) 
corresponds to an unpredictable decrease in a patient's sedative sensitivity, which 
leads to decreased effect of the sedative drug. Decreased effect leads to increasing 
patient agitation, as seen in the lower plot of Figure 14.2. Conversely, an increase 
in W2(t) corresponds to an unpredictable increase in a patient's sedative sensitiv-
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ity, which leads to lower patient agitation, as seen in Figure 14.3. The important 
aspect in these results is the way that the sedative infusion protocols deal with 
these changes in parameters, and hence agitation- i.e. controller robustness. 
A summary of the performance metrics across all 50 virtual trials is shown 
in crable 14.1 for each of the ten patients. These values are the summary perfor-
mance metrics of the CappedGF6 protocol relative to the summary performance 
metrics of the nurse control protocol. The values in Table 14.1 therefore provide a 
comparative indication of the performance of the CappedGF6 protocol compared 
to the nurse control protocol, under the same virtual conditions. A value greater 
than 1.00 indicates a higher value for the CappedGF6 control protocol than for 
the nurse control protocol, whereas a value less than 1.00 indicates a lower value 
for the CappedGF6 control protocol than for the nurse control protocol. 
For example, the median value of TD=1.20 for Patient 1 indicates that the 
median total dose across all 50 virtual trials for the CappedGF6 protocol is 20% 
higher than the median total dose across all 50 virtual triaJs for the nurse control 
protocol. Similarly, the IQR of TD=0.89 for Patient 1 indicates that the inter-
quartile range of total dose across all 50 virtual trials for the CappedG F6 protocol 
is 11% lower than the inter-quartile range of total dose across all 50 virtual trials 
for the nurse control protocol. Because the. values in this table are those of 
the CappedGF6 protocol relative to the nurse control protocol, some apparently 
confusing numbers result. In particular, the fact that the maximum TD for 
Patient 1 is smaller than the minimum TD seems odd. However, this result can 
be understood by simply recognising that the values in Table 14.1 are relative. 
Thus, the maximum value of TD=1.20 for Patient 1 shows that maximum TD 
of the fifty virtual simulations for Patient one using the CappedGF6 protocol is 
20% higher than the maximum TD of the fifty virtual simulations for Patient 1 
using the nurse control protocoL Similarly, the minimum value of for 
Patient 1 shows that minimum TD of the fifty virtual simulations for Patient 1 
using the CappedGF6 protocol is 28% higher than the minimum TD of the fifty 
virtual simulations for Patient one using the nurse control protocol. 
Table 14.1 shows that the performance of the CappedGF6 protocol, relative 
to the nurse control protocol, varies between patients. For example, for Patient 
1, the median TD=1.20, whereas for Patient 3, the median TD=1.49 
to the nurse control protocol. This result shows that the median performance of 
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the CappedGF6 protocol differs between patients. However, the overall summary 
statistics in Table 14.1 provide an indication of how much the median TD varies 
between patients. The median TD of the virtual trials has a median of 1.21 with 
an inter-quartile range of 0.09 across all ten patients. The median value of 1.21 
indicates that, in response to stochastic time-variance in patient sedative sensi-
tivity, the CappedGF6 protocol delivers a total dose 21% higher than the nurse 
control protocol, across all patients. The inter-quartile range of 0.09 indicates 
that this increased dose varies a small amount between patients. 
Because a higher total dose is less desirable, this result implies that the 
CappedGF6 protocol performs worse than the nurse control protocol in regard 
to total dose, under the stochastic time-variance of sedative sensitivity. However, 
the results in Table 12.1 of Section 12.2.3 indicate that even under well-defined 
conditions, the Capped GF6 protocol delivers a total dose 21% higher than the 
nurse control protocol. Therefore, based on these results, the total increase in 
dose delivered by the CappedGF6 control protocol over the nurse control protocol 
is unaffected by the volatile, time-varying changes in sedative sensitivity that may 
encountered be in clinical applications. 
Table 14.1 shows that the median PIR of the virtual trials has a median 
of 1.66 with an inter-quartile range of 0.49 across all ten patients. The median 
value of 1.66 indicates that, in response to stochastic changes over time in patient 
sedative sensitivity, the CappedGF6 protocol delivers peak infusion rates 66% 
higher than the nurse control protocol across all patients. However, the high IQR 
of 0.49 suggests that this comparative value varies considerably between patients. 
The high PIR indicates that the CappedGF6 protocol results in significantly 
higher peak infusion rates than the nurse control protocol under the time-varying 
conditions seen in clinical practice. Further, in contrast to the total dose, this 
value is also considerably higher than RPIR=1.0, obtained under well-defined 
conditions and presented in Table 12.1. 
However, it must be remembered that the definition of the CappedGF6 pro-
tocols includes a maximum limit on the infusion rate equal to the maximum 
recorded dose. This leads to the RPIR in Table 12.1 of 1.0, and means that al-
though the peak infusion rate for the CappedGF6 protocol is considerably higher 
than that of the nurse control protocol, the rates are still within conservative 
clinical safety limits. Therefore, although the PIR in Table 14.1 indicates that 
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the peak infusion rates of the CappedGF6 protocol are higher than the nurse 
control protocol, they are still within the conservative clinical safety limits, and 
are therefore acceptable. 
The median MA of the virtual trials has a median of 0.54 with an inter-
quartile range of 0.20 across all ten patients, as seen in Table 14.1. The median 
value of 0.54 indicates that, in response to stochastic changes in patient sedative 
sensitivity over time, the CappedGF6 protocol results in mean agitation levels 
46% lower than the nurse control protocol across all patients. The inter-quartile 
range of 0.20 suggests that this comparative value varies between patients. Fur-
ther, this value is similar to the mean agitation value of RMA=0.57 in Table 12.1, 
which is the result of simulations under well-defined conditions. Therefore, based 
on these results, the reduction in mean agitation achieved by the CappedGF6 
control protocol over the nurse control protocol is only mildly affected by the 
stochastic time-variance in sedative sensitivity that may be encountered in clini-
cal applications. 
Note the negative minimum value that appears in the mean agitation column 
of the summary results for Patients 1 and 21 in Table negative values 
indicate that the CappedGF6 protocol, for at least one of the virtual sedative 
sensitivity profiles, reduced agitation below zero fora significant proportion of 
the total profile. This result has not yet been observed in simulations for a 
derivative-focused control protocol, even the CappedGF6 protocol, and is a direct 
result of the combination of a particular virtual sedative sensitivity profile, W2(t), 
and the CappedGF6 protocol. Figure 14.4 shows an example of one such profile 
for Patient In this figure, the upper plot presents the sedative sensitivity 
profile, the middle plot presents the infusion rate, and the lower plot nr,'<:!"'nt,, 
the agitation profile. In the upper plot, the lighter solid line represents the 
virtual sedative sensitivity profile, W2(t), and the darker solid line represents 
the smoothed sedative sensitivity profile from Section 8.2.3. In the middle and 
lower plots, the dashed lines represent the modelled responses of the CappedGF6 
protocol in the virtual trial, the dotted lines represent the modelled responses of 
the nurse control protocol in the virtual trial, and the dark solid line represents 
the modelled responses of the nurse control protocol using the smoothed W2(t) 
profile from the evaluation procedure in Section 8.2.3. 
Figure 14.4 shows that the small negative mean agitation value typically 
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results from two features: 
1. A large initial bolus resulting in initially low agitation, that continues for 
a considerable proportion of profile. This dynamic may also be accom-
panied by an initially high sedative sensitivity. 
2. Continuously high W2 values 
The first feature, a large initial bolus accompanied by a high sedative sensitivity, 
is seen in the first portion of the upper plot of Figure 14.4. These features 
sometimes result in agitation levels below zero for a period at the beginning of 
a profile. For profiles with relatively short total time, this dynamic can have a 
significant impact on the mean agitation, and result in a negative mean agitation 
value. This feature, primarily due to initialisation, is not expected to present a 
problem in clinical implementation of the control protocol. 
The second feature, continuously high W2 values, can be seen for hours 15-34 
in the upper plot of Figure 14.4. High W2 corresponds to a high patient sensitivity 
to sedatives, and results in low patient agitation, as seen for hours 25-40 in the 
lower plot of Figure 14.4. Although the modelled agitation is below zero during 
hours 25-40, there are some points within this period where the CappedGF6 
delivers drug. This drug delivery occurs because although the agitation level 
may be below zero, the rate of change may in fact be positive. If this positive 
rate of change of agitation, combined with the control gains employed, is N'r"''''''-'''' 
than the negative component contributed by the absolute agitation level, then 
a positive infusion rate results, as per Equation (10.1). The delivery of sedative 
drugs during periods of negative agitation is an undesirable feature not only in 
the CappedGF6 protocol, but all the derivative-focused control protocols. A 
simple, yet effective, method of preventing this is to apply an additional rule 
to CappedGF6 requiring zero infusion when A :s: O. This additional condition 
requires further investigation, and is briefly investigated in Chapter 15. 
Peak agitation observed in the virtual trials, as seen in Table 14.1, has a 
median value of 0.73 with an inter-quartile range of 0.09 across all ten patients. 
This result shows that, in response to stochastic changes in sedative sensitivity, 
peak agitation is reduced using the CappedGF6 protocol compared to the nurse 
control protocol. In particular, the peak agitation resulting from the CappedGF6 
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protocol is reduced by a median value of 27% across all ten patients compared 
to the nurse control protocol. The inter-quartile range of 0.09 suggests that this 
reduction varies between patients. Again, this median value is similar to the peak 
infusion rate of 0.74, resulting from simulations under well-defined conditions 
presented in Table 12.1 Therefore, with regard to the peak infusion rate, the 
CappedGF6 control protocol is almost unaffected by the time-varying nature of 
sedative sensitivity encountered in clinical application. 
The standard deviation of agitation is a limited measure of the size of the 
oscillations in the agitation profile. However, it does correlate with observed 
oscillations and fluctuations in the agitation profiles and is therefore an approx-
imate measure of the cyclic nature of agitation-sedation dynamics. As seen in 
Table 14.1, the median STDA of the virtual trials has a value of 0.93 with an 
inter-quartile range of 0.12 across all ten patients. The median value of 0.93 indi-
cates that the oscillations and fluctuations resulting from use of the CappedGF6 
protocol are less than those resulting from use of the nurse control protocol in cir-
cumstances of stochastically varying sedative sensitivity. However, the relatively 
high IQR reduces the strength of this argument. Nonetheless, an important out-
come of this result is that, based on these results, the CappedGF6 protocol does 
not induce increased oscillations or fluctuations in the agitation profile. This 
result has important clinical implications, as larger oscillations in agitation can 
be dangerous to patients' health. 
14.3 Summary 
The fundamental outcome of these virtual trial results points to the robustness 
of the CappedGF6 protocol, and its ability to provide tight control of agitation 
in spite of the unpredictable, immeasurable time-variation of sedative sensitiv-
ity encountered in clinical practice. The fact that the CappedGF6 protocol is 
still capable of improved reductions in mean and peak agitation over the nurse 
control protocol, in spite of the stochastic changes in sedative sensitivity, shows 
that the CappedGF6 protocol is robust to these changes. results of this 
chapter show that in spite of the clinical time-variance of the sedative sensitivity, 
the CappedGF6 protocol achieves median reductions of 46% and 27% in mean 
and peak agitation, respectively. Further, these improvements in agitation per-
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formance metrics are achieved without exceeding maximum infusion rate safety 
requirements, and at the relatively small cost of approximately 20% more total 
drug dose. These results highlight the robustness of the CappedGF6 to unpre-
dictable changes in the sedative sensitivity parameter. 
In addition to its robustness, the CappedGF6 protocol is shown to provide ef-
fective agitation management through a bolus-oriented approach. This approach 
employs short, sharp timely boluses during periods of agitation and reduces over-
use of drugs through minimal delivery during periods of low agitation. This pro-
tocol therefore offers significant advantages for clinical agitation management) 
and has the potential to improve healthcare for critically ill patients. 
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Table 14.1 Virtual trial summary statistics of the CappedGF6 control protocol, relative to 
the summary statistics of the nurse control protocol. 
Patient 1 Patient 20 
Max 1.20 1.50 0.16 0.74 1.09 1.45 1.61 0.73 0.84 0.95 
UQ 1.18 1.63 0.10 0.73 1.16 1.36 1.73 0.65 0.77 0.95 
Med 1.20 1.71 0.05 0.73 1.17 1.35 1.99 0.61 0.75 0.95 
LQ 1.23 1.92 0.00 0.73 1.20 1.30 2.17 0.52 0.70 0.82 
Min 1.28 2.28 -0.12 0.60 1.24 1.27 2.28 0.40 0.68 0.70 
IQR 0.89 0.00 1.01 0.78 0.95 1.55 0.00 1.08 1.00 1.15 
Patient 3 Patient 21 
Max 1.66 2.52 0.83 0.89 1.01 1.13 1.68 0.37 0.57 0.94 
UQ 1.52 2.64 0.77 0.83 0.99 1.07 1.82 0.29 0.43 0.86 
Med 1.49 2.64 0.76 0.82 0.96 1.05 1.86 0.25 0.39 0.86 
LQ 1.45 2.64 0.73 0.80 0.93 1.08 1.99 0.15 0.36 0.81 
Min 1.41 2.64 0.69 0.76 0.92 1.06 2.14 -0.03 0.28 0.72 
IQR 1.92 0.00 0.97 0.97 1.12 1.01 0.00 1.05 1.51 1.13 
Patient 8 Patient 26 
Max 1.22 0.97 0.62 0.81 0.93 1.26 1.40 0.68 0.75 0.82 
UQ 1.19 1.07 0.57 0.78 0.94 1.22 1.45 0.62 0.68 0.80 
Med 1.18 1.17 0.53 0.77 0.92 1.22 1.48 0.59 0.66 0.80 
LQ 1.17 1.24 0.50 0.75 0.89 1.20 1.49 0.55 0.66 0.76 
Min 1.16 1.50 0.38 0.65 0.72 1.17 1.49 0.51 0.63 0.69 
IQR 1.37 0.00 1.28 0.90 1.10 1.29 0.00 0.95 0.93 1.12 
Patient 16 Patient 30 
Max 1.31 1.06 0.70 0.85 1.01 1.27 1.57 0.48 0.72 1.02 
UQ 1.27 1.29 0.64 0.78 0.98 1.19 1.84 0.42 0.68 1.05 
Med 1.24 1.42 0.57 0.74 0.93 1.19 2.02 0.38 0.65 1.04 
LQ 1.21 1.58 0.51 0.70 0.88 1.20 2.23 0.31· 0.59 1.02 
Min 1.19 1.68 0.43 0.67 0.81 1.18 2.91 0.23 0.56 1.07 
IQR 1.60 0.00 1.40 1.14 1.44 1.15 0.00 0.88 1.08 1.14 
Patient 19 Patient 32 
Max 1.33 1.25 0.70 0.81 0.90 1.16 1.06 0.59 0.80 0.90 
UQ 1.31 1.44 0.66 0.77 0.86 1.12 1.26 0.52 0.70 0.83 
Med 1.29 1.60 0.64 0.73 0.82 1.11 1.39 0.48 0.66 0.79 
LQ 1.27 1.67 0.63 0.70 0.80 1.10 1.53 0.43 0.61 0.79 
Min 1.22 1.80 0.57 0.68 0.73 1.07 2.13 0.30 0.47 0.69 
IQR 1.68 0.00 1.02 1.14 1.13 1.36 0.00 1.22 1.16 1.01 
Summary Statistics 
Med IQR Med IQR Med IQR Med IQR Med IQR 
Max 1.26 0.12 1.45 0.49 0.65 0.19 0.80 0.09 0.94 0.10 
UQ 1.20 0.12 1.54 0.47 0.60 0.20 0.75 0.09 0.94 0.13 
Med 1.21 0.09 1.66 0.49 0.54 0.20 0.73 0.09 0.93 0.12 
LQ 1.20 0.08 1.80 0.59 0.50 0.20 0.70 0.10 0.85 0.12 
Min 1.18 0.09 2.13 0.57 0.39 0.24 0.64 0.10 0.73 0.19 
IQR 1.37 0.41 0.00 0.00 1.03 0.20 1.04 0.20 1.13 0.04 
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Figure 14.4 Results of one virtual trial for Patient 21 showing the features contributing to 
negative mean agitation values. 
Chapter 15 
Non-linear Control Protocols 
Chapters 9~13 assessed the performance of several derivative-focused and con-
stant infusion-based agitation feedback control and sedation management pro-
tocols. In particular, Chapters 9~ 12 assessed the performance of these direct 
controllers through simulations, and Chapter 13 employed a more formal theo-
retical analysis, confirming the results of the earlier chapters. All of these control 
protocols are linear, in which the feedback quantities, agitation and its deriva-
tive, appear linearly in the agitation feedback law of Equation 10.1, or not at all 
for a constant infusion protocol. This chapter goes a step further to analyse the 
impact of non-linear control protocols on agitation-sedation management using 
the extended physiologically-based model employed in Chapters 8 and 12. 
15.1 Methods 
This chapter employs an identical method to that of Section 12.1 to analyse five 
non-linear control protocols. The extended physiologically-based model is used, 
incorporating the EAR dynamic, smoothed time-varying sedative sensitivity pro-
file, W2(t), and patient-specific C50 selection. The performance metrics of Section 
9.3 are once again used as a measure of the ability of the non-linear control 
protocols to meet the goals outlined in Sections 9.1~9.2. 
The non-linear feedback control laws investigated are all of the form: 
(15.1) 
where Kp and Kd are the proportional and derivative gains respectively, 7r and 
222 CHAPTER 15 NON~LINEAR CONTROL PROTOCOLS 
o are the powers of agitation and rate of change of agitation terms, respectively, 
and Kd are gains of the non-linear terms, and absC) indicates the absolute 
value. The gain values, Kp and Kdl employed in this chapter are those of the GF6 
protocol in Chapters 9-12. The usc of the abs(.) in Equation (15.1) preserves the 
sign of the original feedback quantity in the overall non-linear terms. Three limits 
are placed on the non-linear protocols investigated in this chapter: 
Maximum Infusion Rate The infusion rate is capped to a maximum limit of 
twice the maximum recorded infusion rate. This maximum infusion limit 
is set twice as high as the previous value to investigate the effects of higher 
peak infusion rates. Although this increased maximum infusion limit may 
have a negative impact on some patients, it is not expected to have negative 
attar>t<c on most patients, because the recorded infusion rate is typically a 
somewhat conservative, clinical indication [Shaw et al., 2003a]. 
Minimum Infusion Rate Negative infusion rates are not allowed. This limit 
results from the discussion in Section 9.1 regarding difficulty of removing 
drug from a patient once delivered. 
Zero Infusion Condition The infusion rate is set to zero if modelled agitation 
becomes negative. This condition explicitly prevents the delivery of drugs 
during periods of clearly low agitation, preventing the unnecessary delivery, 
and subsequent over-use, of sedative drugs. 
The specific control protocols investigated in this chapter are not selected for com-
pleteness or optimality but to sample the possibilities for analysis. The specific 
control laws are defined: 
GF6A2 This protocol employs parameter values: Kp=Kp, 'if 
0= O. 
o and 
(15.2) 
This protocol investigates the impact of the additional non-linear agitation 
term, A2, on agitation management. This term increases the continuous 
proportional control of sedation through a component of the infusion rate 
that increases with the square of agitation. 
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GF6A2 This protocol employs parameter values: Kp=O, 7r = 0, Kd = 1000Kd 
and 6 = 1. 
(15.3) 
This protocol investigates the impact of the additional non-linear agita-
tion derivative term, A2 , on agitation management. This term significantly 
enhances the derivative focus of the protocol through a component of the 
infusion rate that increases with the square of agitation derivative, where 
the last term ensures it has the proper sign. 
GF6A2 A2 This protocol employs parameter values: Kp=Kp, 7r 1, Kd 
1000Kd and 6 = 1. 
This protocol is a combination of the previous two protocols, and investi-
gates their combined impact. 
GF6A3 This protocol employs parameter values: Kp=Kp, 7r = 2, Kd = 0 and 
6 = O. 
(15.5) 
This protocol investigates the impact of increasing the power of the non-
linear agitation term, yielding the term A3 , significantly increasing the con-
tinuous proportional feedback of sedation. 
GF6A3 A2 This protocol employs parameter values: Kp=Kp, 7r 2, Kd 
1000Kd and 6 = 1. 
This protocol is a combination of the GF6A3 and GF6A2 protocols, and 
investigates their combined impact. 
Overall, these five control laws seek to examine non-linear enhancements that 
would enable more rapid automated, or semi-automated, response to patient 
agitation. In essence, they seek to add non-linearity to enhance the results seen 
with derivative-focused methods. 
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15.2 Results and Discussion 
Figures 15.1-15.2 present the results of the non-linear control protocols with in-
fusion limits for a typical patient using the extended physiologically-based model. 
Figure 15.1 presents the results for protocols GF6A2, GF6A2, and GF6A2 A2. The 
first three plots show the infusion profiles, and the lower plot shows the resulting 
agitation profiles. In these plots the GF6A2 protocol is represented by the lighter 
solid line, the GF6A2 protocol is represented by the dashed line, the GF6A2 A2 
protocol is represented by the dotted line, and the nurse control protocol is repre-
sented by the darker solid line as a benchmark for comparison. Similarly, Figure 
15.2 presents the results for protocols GF6A2, GF6A3, and GF6A3A2. The first 
three plots show the infusion profile, and the lower plot shows the resulting agita-
tion profiles. In these plots the GF6A2 protocol is represented by the lighter solid 
line, the GF6A3 protocol is represented by the dashed line, the GF6A3 A2 protocol 
is represented by the dotted line, and the nurse control protocol is represented 
by the darker solid line as a benchmark for comparison. 
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Figure 15.1 Example of the impact of non-linear control protocols GF6A2 (top), GF6A2 
(middle), and GF6A2 A2 (bottom) on agitation (lower plot). 
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(middle), and GF6A3.4,2 (bottom) on agitation (lower plot) 
The GF6A2 protocol produces an infusion profile with very high infusion rates 
during periods of high agitation, and very low infusion rates in periods of low 
agitation, as seen in the top plot of Figure 15.1, as expected. In many cases, this 
protocol is capped by the maximum infusion limit, and at the maximum 
infusion rate for long periods. The lighter solid line in the bottom plot of the 
same figure shows that this approach to sedation management reduces agitation 
considerably. The effect of the Zero Infusion Condition is seen after t =120 hours 
in these plots. However, in spite of zero infusion rate during this period, the 
agitation drops and continues to fall below zero. This is not the result of current 
sedative infusion, rather the effect of significant drug doses in the previous hours 
arriving at the effect site as the patient was effectively over-loaded and over-
sedated. These results occur despite an infusion profile that looks qUalitatively 
like a sedation-interruption algorithm was applied. 
In contrast, the GF6A2 protocol yields a strong bolus-oriented approach to 
sedation, as seen in the second plot of Figure 15.1. However, in contrast to the 
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earlier results of the linear derivative-focused protocols, this non-linear protocol 
has such a strong derivative focus that the infusion profile begins to look like 
that of a 'bang-bang' controller. This approach tends to employ a 'completely 
on or completely off' approach, by delivering either the maximum infusion rate, 
or none at all. The dashed line in the bottom plot shows that while the GF6A2 
protocol does not reduce agitation as low a.s the GF6A 2 protocol, it certainly pro-
vides considerably improved agitation management over current clinical practice 
represented by the nurse control protocol. An advantage of the GF6A2 protocol 
is the fact that it does not deliver excessive drugs resulting in agitation below 
zero, as observed in the GF6A2 results. 
The infusion protocol that combines these two approaches, GF6A2 A.2, results 
in an infusion profile with features from each of its constituent protocols. In 
particular, the profile in the third plot of Figure 15.1 again shows a heavy bolus-
oriented approach, but with more extended periods at maximum infusion rate. 
This profile looks even more like the output of a 'bang-bang' controller, and 
is almost always either at maximum or zero infusion. This protocol reduced 
agitation to levels between that of the two previous protocols, but closer to that 
of the GF6A2 protocol. Once again, the previously high infusion rates near the 
end of the profile cause agitation to fall below zero in spite of the Zero Infusion 
Condition. 
Although these three protocols (GF6A2, GF6A.2, and GF6A2 A.2) are seen 
to produce considerably reduced agitation, it is clear that the dose they employ 
to achieve that benefit is also considerable. Table 15.1, located at the end of 
this chapter, presents the summary statistics of the performance metrics across 
all 37 patients for the 5 control protocols analysed in this chapter. Note that 
imposing the upper limit on the infusion rate results in a maximum RPIR=2.0 
by definition. The GF6A2 protocol results in median reductions of over 80% 
and 45% in mean and peak agitation, respectively, while the GF6.42 protocol 
results reductions of 75% and 43%. The combined protocol, GF6A2 A.2, results 
in median reductions in mean and peak agitation of 87% and 48%, respectively. 
These improvements over current clinical practice are of great potential benefit, 
but come at the cost of increased dose. 
Although the infusion rates are capped, the total dose for these non-linear 
protocols is much larger than those of the linear protocols earlier investigated. 
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In particular, the median RTD for the GF6A2 protocol is 3.48, with a maxi-
mum RTD of 8.09. Although the median RTD values for the GF6A2 (1.96) and 
GF6A2 Ji.2 (2.54) protocols are lower, they all represent a considerable increase in 
the dosage and cost of reduced agitation. 
15.2 shows the impact of increasing the exponent of the non-linear 
agitation term from two to three. Comparing the top three infusion profile plots, 
it is seen that, for this patient, while there are some differences between them, 
they are all similar and dominated by large infusion rates capped by the maximum 
limit. More importantly, the bottom plot of this figure shows that, for this 
patient, these changes result in minimal reductions of agitation. However, the 
median RMA values for these protocols in Table 15.1 indicate that across all 
patients there is a significant reduction in mean agitation (97%) for the further 
increase in total drug (up to 284%). 
15.2.1 Summary 
These results have briefly explored the impact on non-linear control protocols 
on agitation management. results indicate that non-linear control offers 
potential benefits to agitation management' in the form of reduced mean agitation 
levels, but at the expense of considerable increases in total drug dose. Once again, 
these results show a trade-off between cost and benefit. Importantly, the results 
of this chapter highlight the relatively small improvement in benefits versus the 
linear control protocols for increased cost and complexity of the non-linear control 
protocols. Hence, they further emphasise the considerable benefits of the simple 
linear derivative-focused control protocols presented in Chapters 9-13. 
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Table 15.1 Performance metrics for all non-linear protocols using the extended 
physiologically-based model. 
RTD RPIR RMA RPA 
GF6A2 
UQ 4.26 2.00 0.31 0.62 
Med 3.48 2.00 0.19 0.54 
LQ 2.58 2.00 0.02 0.47 
Min 1.60 2.00 -0.68 0.39 
1.68 0.00 0.29 0.15 
GF6A2 
Max 3.26 2.00 0.63 0.82 
UQ 2.25 2.00 0.42 0.63 
Med 1.96 2.00 0.25 0.57 
LQ 1.61 2.00 -0.20 0.53 
Min 0.71 2.00 -1.39 0.09 
IQR 0.64 0.00 0.62 0.11 
GF6A2A 2 
Max 6.12 2.00 0.46 0.82 
UQ 3.21 2.00 0.32 0.59 
Med 2.54 2.00 0.13· 0.52 
LQ 2.04 2.00 -0.20 0.50 
Min 0.71 2.00 -1.41 0.09 
IQR 1.17 0.00 0.52 0.10 
GF6A3 
Max 10.65 2.00 0.44 0.82 
UQ 4.60 2.00 0.23 0.61 
Med 3.84 2.00 0.03 0.54 
LQ 2.97 2.00 -0.23 0.45 
Min 1.27 2.00 -1.44 0.13 
1.63 0.00 0.47 0.17 
GF6A3A2 
Max 10.01 2.00 0.44 0.82 
UQ 4.25 2.00 0.25 0.61 
Med 3.62 2.00 0.03 0.52 
LQ 2.44 2.00 -0.27 0.46 
Min 0.83 2.00 -1.40 0.09 
IQR 1.81 0.00 0.53 0.15 
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Conclusions and Future Work 

Chapter 16 
ConcI usions 
Agitation management via effective sedation management is an important and 
fundamental activity in the lCU. However, in clinical practice a lack of under-
standing of the underlying dynamics, combined with subjective assessment tools, 
makes effective and consistent clinical agitation management difficult. Quantita-
tive models and control protocol studies developed in this research provide the 
ability to gain insight into the underlying dynamics of the physiological system, 
and enable the development and evaluation of improved control strategies. Fur-
ther, these models and control studies, coupled with emerging quantified agita-
tion sensors, are a first step toward enabling the development of semi-automated 
sedative delivery methods for improved agitation management. 
The primary goal of lCU sedation is to control agitation, while preventing 
over-sedation and over-use of drugs. Current clinical practice employs subjective 
agitation/sedation assessment scales, combined with medical staff experience and 
intuition, to deliver appropriate sedation. This approach typically leads to largely 
continuous infusions that lack a bolus-focused approach, and commonly result in 
either over-sedation, or insufficient sedation and agitation. 
This thesis has developed quantitative models of the observed agitation-
sedation dynamics using compartmental PK and PD response surface modelling. 
The initial model creates a good platform for adding additional physiological dy-
namics and assessing the effect of no saturation limit. The physiologically-based 
model incorporates more advanced dynamics, such as separate compartmental 
modelling, effect saturation, drug effect synergism, and endogenous agitation 
reduction. These models are fundamentally based on observed dynamics and 
physiology, and are subsequently evaluated against recorded infusion data. 
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A fundamental conclusion of this thesis is that the essential dynamics of the 
agitation-sedation system are linear. This conclusion can be seen by the ability 
of the initial model to capture the fundamental dynamics of the system, and 
highlights that linear systems of differential equations are adequate representa-
tions of the basic dynamics. While the addition of saturation, and other more 
complex non-linear dynamics, adds significant improvements they do not alter 
the fact that the underlying dynamics of the agitation-sedation system are linear 
in nature. 
The models developed are employed as platforms for developing and evaluat-
ing several sedative control protocols for managing patient agitation. In partic-
ular, constant infusion rates, direct derivative-focused agitation feedback control 
protocols, and non-linear feedback protocols are investigated. Significant im-
provements over the current clinical practices are achieved through the use of 
very simple control protocols, indicating the potential for more automated ap-
proaches to sedation management. 
Constant infusion protocols are shown to provide poor agitation management 
across a range of ICU patients, because they fail to deliver sedation based on 
the current patient requirements. While the constant infusion protocol can be 
effective for some patients if the correct rate js selected, in general it results in 
poor performance and often results in over-sedation or insufficient sedation. More 
importantly, the correct infusion rate is difficult to select a priori, may change 
over time during a patients stay, and the consequences of an incorrect selection 
are potentially severe. 
The derivative-focused protocols represent simple approaches to agitation 
management, and are shown to be effective at reducing both mean and peak 
agitation, at the expense of increased total dose and peak infusion rate. Impos-
ing simple upper limits on the infusion rates of these protocols eliminates peak 
infusion rates, and helps prevent over-sedation. These protocols produce a bolus-
oriented approach to sedation that responds rapidly to increasing agitation with 
bolus drug delivery, and minimises over-sedation through minimal drug delivery 
during periods of low agitation. In particular, one protocol is shown to achieve 
median reductions of up to 63% and 28% for mean and peak agitation, respec-
tively. More importantly these benefits are achieved without exceeding conserva-
tive safety infusion limits, and at the expense of only 21 % more total drug dose. 
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Furthermore, this protocol is shown to be robust against unpredictable changes 
in patient parameters, which makes it suitable for clinical implementation. 
The physiological saturation effect observed in sedative drugs, and incorpo-
rated in the physiological model, restricts the capacity of sedative controllers to 
reduce agitation. A clinical implication of this feature is that it is not always 
possible to achieve a specific target level of agitation. It also means that in some 
cases more sedation will not be the solution for patient agitation. Hence, the 
ability to identify these situations using model estimation would alert clinical 
staff to consider other treatment options. 
A fundamental result is that agitation management represents a trade-off be-
tween the benefits of low patient agitation versus the cost of higher infusion rates 
and increased total dose requirements. However, in contrast to the 'stiff' nature 
of many engineering systems in which value can often be measured in dollars, the 
'soft' nature of biological systems precludes a formal cost/benefit analysis. As a 
result of the trade-off identified, this thesis suggests that the aim of a good proto-
col is to minimise patient agitation and over-sedation, seeking an optimal clinical 
balance. This clinical balance is, however, not a direct function of strict linear 
or non-linear cost per unit agitation controlled. Instead, it is trade-off in which 
the bounds are less rigorously defined and where smaller relative variations, for 
example in total drug dose, may have no effective cost compared to the improved 
agitation management achieved. The derivative-focused, bolus-based sedation 
approach is shown to be highly effective in achieving good clinical balance, and 
via Hoo analysis, is essentially optimal. Thus, more complex controllers may not 
be necessary, in the context of the models developed, to achieve good clinical 
outcomes. 
Overall, the research presented shows that it is possible to create and evaluate 
models of the agitation-sedation system and use them to develop and evaluate 
control protocols for improved agitation management. This thesis shows that a 
bolus-oriented approach works best, which matches anecdotal longer term experi-
ence. However, for a given dose of drug, agitation management is highly variable, 
and is dependant on the delivery strategy employed. This thesis clearly shows 
significant evidence to support the idea that it is not the drug class or drug dose 
that is important, but rather the drug administration strategy employed is the 
most important factor in agitation management. 

Chapter 17 
Future Work 
The models presented in this thesis represent the beginning of quantitative mod-
elling of agitation-sedation dynamics. While they incorporate many of the fun-
damental dynamics observed in critically ill patients, there remain many aspects 
that would benefit from additional research. Similarly, the simple control proto-
cols investigated in this thesis are only a small portion of the potentially applicable 
control protocols. This chapter presents areas of research which would benefit 
from future work. 
17.1 Model Development 
17.1.1 Drug Storage Dynamic 
The effect of adding a separate compartment representing the accumulation of 
drug in fatty tissue may enhance the clinically observed over-sedation effect. This 
effect is partially seen in Section 3.3 for the added PK compartments in the drug 
kinetics. An additional compartment would increase the number of differential 
equations and parameters, but may have an important impact on the resulting 
pharmacokinetics. In particular, slow transfer rates to and from the storage 
compartment may model the storage, and delayed release, of drugs. 
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17.1.2 Stimulus Profiles 
Fechner contributed to. the field of psychology through developing a quantitative 
relationship between a stimulus, such as source of light, or temperature, and the 
sensation a person feels [Mackay, 1963]. Perhaps, with additional experiments, 
a more robust form of stimulus profile can be obtained for use in the model. 
Another option that may be worth investigating is the generation of surrogate 
stimulus profiles from emerging agitation sensor recordings patients. 
17.1.3 Michaelis-Menton Dynamic 
The incorporation of the Michaelis-Menton dynamic is limited by the lack of 
published data from which parameters can be identified. Physiological estimates 
of the maximum physiological clearance rates would assist in determining the 
appropriate parameters. The Michaelis-Menton dynamics could then be added 
to the model, and the impact on drug accumulation and over-sedation analysed. 
17.1.4 Metabolite Compartments 
Although the pharmacological activity of many of the metabolites of Morphine 
and Midazolam is not yet fully quantified, there may be some benefit in 
tigating the impact of including metabolites into the agitation-sedation modeL 
This analysis would include the addition of compartments for the concentrations 
of the various metabolites, and additional effect compartments representing the 
pharmacodynamic activity of the metabolites. Incorporating the PD effect of the 
metabolites would require the creation of a PD response surface that is a function 
of more than two drugs. 
However, the complexity of the model would be greatly increased by the 
addition of metabolites, as will the number of parameters. This increased com-
plexity and additional parameters, may not provide significantly improved re-
sults. Therefore, a preliminary study to determine the impact of the inclusion of 
metabolites is suggested. If there is enough improvement from the increased com-
plexity, then these aspects should be retained. However, if the benefit is small, 
not including the effect of metabolites may represent an adequate model. 
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17.2 Model Applications, Clinical Trials, and Evaluation 
This research has proceeded with retrospective data and without the aid of quan-
titative agitation sensors. With ethical consent, clinical trials and experiments 
would further validate the models developed in this thesis, and further enhance 
control protocols. In particular, as quantitative agitation sensors become avail-
able, clinical trials become more feasible and should be undertaken. 
17.2.1 Agitation Verification 
The emergence of quantified agitation sensors enable direct verification of the 
agitation-sedation models developed in this thesis. Although agitation sensors 
are not yet commercially available, they may already provide some indication of 
agitation, which can be correlated to modelled agitation retrospectively. Agita-
tion verification trials would further validate the models in this thesis. 
17.2.2 Model Estimation of Saturation 
Estimating saturation has been identified as a major factor limiting the capac-
ity of control protocols to reduce agitation. Saturation points determined, or 
estimated in real-time, could be used in clinical practice to prevent additional 
infusions which may result in over-sedation. Although this task is difficult clini-
cally, model estimation of the saturation points could be used as an approximate 
indicator, and sedative delivery rates capped accordingly. 
17.2.3 Blood Concentration Study 
The pharmacokinetic portion of the models in this thesis can be verified indepen-
dently through simple clinical studies investigating the concentrations of drugs in 
critically ill patients over time. Drug concentrations recorded with drug infusion 
rates could be compared to modelled concentrations, and the PK parameters of 
the model adjusted accordingly. However, because the patient-specific parame-
ters in these models lie primarily in the PD components, the improved parameters 
resulting from such a study may not significantly change the results. 
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17.3 Control Systems Considerations 
17.3.1 Alternative Lyapunov Control Formulation 
The current Hoo methodology employs v xTpx as the general Lyapunov equa-
tion. However, other equations which satisfy the role of the Lyapunov equation 
exist. A common Lyapunov equation used in stable compartment systems is 
v = eTx, which is valid for positive systems. This could be used in the Hoo 
analysis to see what effect it has on the optimal gains obtained. 
17.3.2 Include A in Hoo Methodology 
The current Hoo methodology employs agitation, A, as the regulated feedback 
quantity. The addition of the rate of change of agitation, A, into the regulated 
output vector may produce control gains that reduce agitation as well as its rate 
of change. This approach may improve agitation management. 
17.3.3 Simulate Published Results 
The models developed may be used to simulate the results published by 
et al. [2000]. In this study the interruption of continuous sedative infusions lead 
to a reduction in over-sedation. By directly simulating the protocol employed in 
this study, similar results may be obtained. 
17.4 Summary 
In addition to the ideas mentioned in this chapter, there are many others that 
could improve or contribute to this research. However, some areas will have a 
greater impact than others. In all cases it is important to ensure that the future 
work is relevant to the advancement of the model and control protocols, and 
has clinical implications. The areas of greatest clinical and research potential 
identified in this chapter are: 
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1. Predator-Prey model investigation 
2. Clinical validation using quantified agitation sensors 
3. Clinical saturation determination using model estimation 

Appendix A 
Proof 1 
Proposition. Ex(J1t) and Var(J1t) can be estimated by: 
m 
Ex(J1t) = L Wt,i/lt+i (A.l) 
i=-rn 
i=-m i=-m i=-m 
(A.2) 
respectively, where a-l is defined: 
n->. a-~ = n ~ A L(Uk - tik)(Uk+>' - /lk+>') V A 0,1, ... , 2m (A.3) 
k=l 
Proof: 
and so, estimating f-lHi by /lHi, an estimate for Ex(J1t) is 
m 
(A.5) 
i=-m 
Next, 
(A.6) 
and 
m m 
J1t EX({it) = L WtAUHi - f-lHi) = L Wt,iCHi (A.7) 
i=-m i=-m 
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and so 
m m-l 
(/it EX(/it))2 = L W;,iE;+i + 2 L L Wt,iWt,jtt+iEt+j (A.8) 
i=-m i=-mi<j~m 
Therefore, 
m 
L W;'iEx(E;+i) 
i=-m 
m 
+2 L L Wt,iwt,jEx(EHiEHj) (A.9) 
i=-mi<j~m 
Let (T~ be the lag ,\ covariance for E. Then 
m m-l 
(T6 L W;,i + 2(Ti L Wt,iWt,i+l 
i=-m i=-m 
m-2 
+2(T~ L Wt,iWt,i+2 + ... + 2(T~mwt,-mWt,m (A.I0) 
i=-m 
and it remains to compute (T~ for ,\ = 0,1, ... , 2m. Using the observations, U1:n , 
and the estimates, fll:m let 
(A.ll) 
for t = 1, 2, ... , n. Then for A = 0,1, ... , 2m, estimate (T~ by 
(A.12) 
Finally, Var(flt) can be estimated by 
i=-rn i=-m i=-rn 
(A.13) 
where Equation (A.13) is the same as Equation (5.12). 
Appendix B 
Proof 2 
Theorem. Let Ex(it) and Var(it) be the mean and variance of it. Then 
and 
Proof: 
Ex(it) 
i=-m 
J {Lit ({L)d{L 
.f Wt,i J {L¢[{L I at{LHi + (1 - at)Ex({Lt) , a;s;]d{L 
'l..=-rn 
m L Wt,dat{LHi + (1 - at)Ex({Lt)] 
i=-m 
m 
at L Wt,i{LHi + (1 - at)Ex({Lt) 
i=-m 
(B.1) 
(B.2) 
(B.3) 
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and 
J p? h({L)d{L - EX(jt)2 
.f Wt,i J {L21>[{L I at{LHi + (1 at)Ex({Lt), a;s;]d{L - EX({Lt)2 
~=-m 
i=-111 
m 
at) ExUlt) L Wt,JtHi + 
i=-m i=-m 
m 
a;[s; + L Wt,dl;+i - Ex({Lt?] (B.4) 
i=-m 
The mean of It is automatically equal to Ex(jt). The next theorem shows that 
the variance of h can be made equal to V'arCh) through appropriate choice of 
at and St. a practical choice of the kernel bandwidth, atSt is selected. Let 
mt be the actual Il1lmber of points within the support of the regression kernel, so 
that mt s:; 2m + 1, and let Wt,(l) , ... , Wt,(mt) be the corresponding to those 
mt points. Define the effective number of points for It as [Liu and Chen, 1995] 
( 
mt ')-1 
fit = ~wi'(i) (B.5) 
The use of fit rather than mt for a weighted (dependent) collection of points 
is a simple way to account for dependence. Notice that fit mt if the points are 
actually independent. Therefore, a simple practical choice of bandwidth for the 
density kernel is [Scott, 1992] 
(B.6) 
II 
Theorem. Let 
(B.?) 
i=-m 
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If 
2 
2 2 VA (A) - -5 (B.8) atSt = ar Mt mt 
and 
2 _ (1 _ - -g) V~r(p,t) 
at - mt A l¥t 
(B.9) 
then 
VarCh) = V~r(p,t) (B.10) 
Proof: 
II 
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